"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03522545","Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression",,"Recruiting","No Results Available","Treatment-resistant Bipolar Depression","Biological: Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)|Biological: Placebo","Change in depression as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS)|Change in Functional impairment as assessed by the Functioning Assessment Short Test (FAST)|Change in Overall functioning in living as assessed by the Global Assessment of Functioning (GAF)|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity of mania subscale|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity of depression subscale|Change in Clinical Global Impression Scale for Bipolar illness (CGI-BP), severity overall subscale|Change in neurocognition as assessed by the California Verbal Learning Test|Change in problem-solving ability as assessed by the Wisconsin Card Sorting Test (WCST)|Number of participants with inflammatory markers as assessed by multiplex biomarker analysis|Change in brain-derived neurotrophic factor (BDNF) level as assessed by enzyme-linked immunosorbent assay (ELISA)|Change in C-reactive protein (CRP) level as assessed by enzyme-linked immunosorbent assay (ELISA)|Number of participants with a change in brain activity between baseline and week 26 as assessed by Magnetic Resonance Imaging (MRI)|Number of participants who withdrawal due to Adverse Events (AEs)|Number of participants with suicidal ideation based on clinical assessment|Number of participants with treatment emergent mania or hypomania as assessed by the Young Mania Rating Scale (YMRS) and clinical assessment","The University of Texas Health Science Center, Houston","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-16-0657","June 1, 2021","July 1, 2024","July 1, 2024","May 11, 2018",,"September 7, 2022","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03522545"
2,"NCT02213705","Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells","MSC","Active, not recruiting","No Results Available","SYSTEMIC SCLERODERMA|ALLOGENEIC MESENCHYMAL STEM CELLS|ADULT","Biological: INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS","toxicity|survival|progression free survival|Rodnan score|Clinical response","Assistance Publique - Hôpitaux de Paris","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC Severe Systemic Sclerosis","May 6, 2014","February 9, 2020","January 27, 2022","August 11, 2014",,"October 19, 2020","Saint-Louis Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT02213705"
3,"NCT01956903","Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.","CSM/EICH2010","Completed","No Results Available","Chronic Graft-Versus-Host Disease","Genetic: Allogenic Mesenchymal Stem Cell","Adverse effects|efficacy","Grupo Espanol de trasplantes hematopoyeticos y terapia celular","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSM/EICH2010|2010-020947-11","January 2010","September 2013","September 2013","October 8, 2013",,"October 8, 2013","Grupo Espanol de trasplantes hematopoyeticos y terapia celular, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01956903"
4,"NCT01775774","Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome","START","Completed","Has Results","Acute Respiratory Distress Syndrome","Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells","Incidence of Pre-specified Infusion Associated Adverse Events|Incidence of Severe Adverse Events (SAEs)|Ventilator Free Days at Study Day 28|Duration of Vasopressor Use (Days)|ICU Free Days to Day 28|Hospital Survival to Day 60|Mortality at Hospital Discharge","Michael A. Matthay|National Heart, Lung, and Blood Institute (NHLBI)|Massachusetts General Hospital|Stanford University|University of Pittsburgh|University of Minnesota|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARDS MSC 001|1U01HL108713-01","July 2013","February 2014","February 2015","January 25, 2013","August 14, 2017","August 14, 2017","University of California San Francisco Medical Center, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01775774"
5,"NCT01297413","A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke",,"Completed","No Results Available","Ischemic Stroke","Biological: Allogeneic adult mesenchymal bone marrow stem cells","The primary endpoint will be the safety of treatment with aMBMC during the twelve-month study period.|National Institutes of Health Stroke Scale Score.|Mini Mental Status Exam score.|Barthel Index Score.|The Geriatric Depression Scale Score.","Stemedica Cell Technologies, Inc.|University of California, San Diego|Mercy Gilbert Medical Center at AZ|Chandler Regional Medical Center at Chandler AZ|UCI Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","38","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STEM 101-M","February 2011","September 2017","November 15, 2018","February 16, 2011",,"December 3, 2018","Mercy Gilbert and Chandler Medical Center, Gilbert, Arizona, United States|University of California Irvine Department of Neurology, Orange, California, United States|University of California San Diego Division of Neurological Surgery, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT01297413"
6,"NCT04776239","Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)","ACESO-IHD","Recruiting","No Results Available","Diabetes Mellitus|Ischemic Heart Disease","Drug: 100 million Allogeneic Mesenchymal Human Stem Cells|Other: Placebo","Post-Percutaneous Coronary Intervention (PCI) coronary artery endothelial function as assessed via CFR|Post-PCI coronary artery endothelial function as assessed via FFR|Target lesion lumen loss|Flow Mediated Diameter Percentage (FMD%)|EPC-CFUs levels|Circulating angiogenic factors marker levels|Circulating inflammatory markers|Seattle Angina Questionnaire (SAQ) Angina Frequency|EuroQol(EQ)-5 Dimension (5D) Quality of Life Questionnaire|EQ-5D Quality of life Questionnaire Overall Health Status Question|Short Form (SF) 36 Questionnaire Quality of Life Questionnaire|International Index of Erectile Function (IIEF) Questionnaire|Sexual Quality of Life - Females (SQOL-F) Questionnaire|Incidence of Treatment-Emergent Serious Adverse Events (TE-SAE)|Incidence of Major Adverse Cardiac Events (MACE)|Rates of Adverse Events|Number of participants with abnormal lab values|Number of participants with Target Vessel Failure","Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|University of Miami","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20200874|1R01HL134558-01","August 16, 2021","July 16, 2024","July 16, 2024","March 1, 2021",,"July 11, 2022","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04776239"
7,"NCT02866721","Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis","CEASE-CF","Completed","No Results Available","Cystic Fibrosis","Biological: Mesenchymal Stem Cells","Dose limiting toxicity (DLT), triggered by occurrence in the first 24 hours after hMSC infusion of grade ≥3 infusion-related allergic toxicities|Incidence and severity of adverse events|Number of pulmonary exacerbations|Diary reports (Cystic Fibrosis Respiratory Symptom Diary (CFRSD))|Changes in subject reported symptoms as captured by the Respiratory Signs and Symptoms Questionnaire (RSSQ) from Baseline (Visit 2) Day 1 to Baseline (Visit 2) Day 2, Visits 3, 4, 5, 6 and 7 and at times when a pulmonary exacerbation is being considered|Changes in physical examination|Changes in vital signs including oxygen saturation checked throughout infusion|Changes in spirometry (FEV1 %, FEV1 (Liters), FEF25-75) determined 30 minutes, 4 hours, and 24 hours after completion of infusion and from Baseline (Visit 2) Day 1 to Visits 3, 4, 5, 6 and 7|Change in sputum quantitative microbiology (bacterial colony forming units between Baseline to Day 7 and Day 28)|Changes in hematology, comprehensive chemistry, ESR, hs-CRP, and urinalysis results|Change in blood inflammatory biomarkers from Baseline to Day 7 and Day 28|Change in sputum inflammatory biomarkers from Baseline to Day 7 and Day 28","Erica Roesch|Case Western Reserve University|Cystic Fibrosis Foundation|University Hospitals Cleveland Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Protocol CF-MSC-01|DASENB15A0","August 2016","August 2020","August 2020","August 15, 2016",,"December 22, 2020","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02866721"
8,"NCT02687646","Clinical Trial With MSC for Graft Versus Host Disease Treatment",,"Active, not recruiting","No Results Available","Acute Graft Versus Host Disease","Drug: Adult Allogeneic Mesenchymal cells from adipose tissue.","Safety measured by incidence of serious adverse events|Effectiveness measured by answer of refractory acute graft disease against host to first-line treatment","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Andalusian Initiative for Advanced Therapies|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-EICH-2014|2014-005533-32","May 2016","June 2022","June 2022","February 22, 2016",,"February 2, 2022","Clinica Universitaria de Navarra, Av Pio XII ,36, Pamplona, Navarra, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital clinico universitario de salamanca, Salamanca, Spain|Virgen del Rocio University Hospital, av. Manuel Siurot s/n, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT02687646"
9,"NCT02097641","Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)","START","Completed","Has Results","Respiratory Distress Syndrome, Adult","Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells|Biological: Plasma-Lyte A","Numbers of Patients Occurred Pre-specified Infusion Associated Events Occurring Within 6 Hours of Study Infusion|Numbers of Patients Occurred Any Cardiac Arrest or Death Within 24 Hours of Study Infusion|Numbers of Patients Occurred Any Unexpected Severe Adverse Events (Including All-cause Deaths)|PaO2:FiO2 Change From Baseline to Day 3|Lung Injury Score From Baseline to Day 3|Oxygenation Index Change From Baseline to Day 2|SOFA Score Change From Baseline to Day 3|Number of Patients Death to Day 28|Mortality to Day 60|Number of Ventilator-free Days to Day 28|Non-pulmonary Organ-failure-free Days to Day 28|Angiopoietin 2 Change From Baseline to 6 h|Angiopoietin 2 Change From Baseline to 24 h|Interleukin 6 Change From Baseline to 6 h|Interleukin 6 Change From Baseline to 24 h|Interleukin 8 Change From Baseline to 6 h|Interleukin 8 Change From Baseline to 24 h|RAGE Change From Baseline to 6 h|RAGE Change From Baseline to 24 h","Michael A. Matthay|National Heart, Lung, and Blood Institute (NHLBI)|Massachusetts General Hospital|Stanford University|University of Pittsburgh|University of Minnesota|Ohio State University|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UCSF-hMSC-ARDS-P2|1U01HL108713-01","March 15, 2014","March 9, 2017","February 9, 2018","March 27, 2014","April 10, 2019","April 10, 2019","University of California San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Minnesota Medical Center, Saint Paul, Minnesota, United States|Ohio State University, Columbus, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT02097641/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02097641"
10,"NCT02387151","Allogeneic Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients","Neptune","Completed","No Results Available","Rejection|Graft Loss","Drug: mesenchymal stromal cells","biopsy proven acute rejection / graft loss|Comparison of fibrosis by quantitative Sirius Red scoring|Serious adverse events|Renal function measured by cGFR (MDRD formula) and iohexol clearance|CMV, BK infection (viremia, disease and syndrome; and subtypes of BK viremia) and other opportunistic infections|Development of de novo donor specific antibodies (DSA) and immunological responses","Leiden University Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL4724400013|2013-005407-14","March 2015","November 2018","November 2018","March 12, 2015",,"July 2, 2019","Leiden University Medical Center, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT02387151"
11,"NCT02824653","Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD",,"Completed","No Results Available","Graft Versus Host Disease","Biological: Mesenchymal Stem Cells","Incidence of treatment-emergent adverse events and complications [Safety and Tolerability]|Acute GVHD-restaging [Efficacy]|Chronic GVHD-restaging [Efficacy]|Survival analysis at six months after MSC infusion|Incidence free survival at six months after MSC infusion","National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","All","1 Year to 65 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFBMTC-GVHD-2015","January 2015","July 2016","December 2016","July 7, 2016",,"January 25, 2017","Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Punjab, Pakistan",,"https://ClinicalTrials.gov/show/NCT02824653"
12,"NCT02150551","Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease",,"Completed","No Results Available","Inflammatory Bowel Diseases","Biological: Allogeneic bone marrow-derived mesenchymal stromal cells","Number of subjects who experience serious adverse events, adverse events, and/or early treatment discontinuations.|Proportion of patients with clinical response|Number of subjects demonstrating an improvement of laboratory tests reflecting systemic inflammation.|Number of subjects with endoscopic healing after treatment.","Catherine Bollard|Children's National Research Institute","All","12 Years to 22 Years   (Child, Adult)","Phase 1","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STOMP","September 2015","September 27, 2019","September 27, 2019","May 30, 2014",,"July 14, 2020","Children's National Medical Center, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT02150551"
13,"NCT04876326","Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy",,"Recruiting","No Results Available","Multiple System Atrophy|Parkinsonism|Multiple System Atrophy, Parkinson Variant","Biological: Autologous Adipose Mesenchymal Stem Cell Implantation|Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation|Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation","Changes of Clinical Evaluation from Baseline to 1,3,6,9 and 12 months after second implantation|Changes of structures improvement of the eyes from Baseline to 1,3,6,9 and 12 months after second implantation|Changes of the eyesight from Baseline to 1,3,6,9 and 12 months after second implantation|Imaging Evaluation from Baseline to 1,3,6,9 and 12 months after second implantation","Indonesia University","All","Child, Adult, Older Adult","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TGHISMMSCMSA","October 5, 2020","October 5, 2021","October 5, 2021","May 6, 2021",,"May 6, 2021","Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04876326"
14,"NCT03265808","Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.","Alaunus","Active, not recruiting","No Results Available","Major Depressive Disorder|Alcohol Use Disorder","Drug: allogeneic human mesenchymal stem cells (allo-hMSCs)|Drug: Placebo","Incident of treatment emergent-serious adverse events|Change in serum concentrations of high sensitivity C-reactive protein.|Change in serum concentrations of inflammatory biomarkers|Change in depressive symptoms as assessed by MADRS|Change in Depressive symptoms as assessed by CGI|Change in quantity of alcohol use as assessed by TLFB|Change in frequency of alcohol use as assessed by TLFB|Change in Anhedonia as measured by SHAPS|Change in cravings as assessed by AUQ|Change in cravings as assessed by OCDS|Change in cognition as assessed by BAC-A|Change in functioning as assessed by UPSA-B|Change in functioning as assessed by GAF|Change in quality of life as assessed by QOLI","Ihsan Salloum|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|University of Miami","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","28","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20170674|1R01AA024933-01A1","March 18, 2018","October 23, 2022","April 2025","August 29, 2017",,"February 28, 2022","University of Texas Rio Grande Valley School of Medicine, Harlingen, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03265808"
15,"NCT05286255","Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias","SAMPSON-1","Recruiting","No Results Available","COVID-19 Pneumonia|Viral Pneumonia","Biological: Allogeneic Mesenchymal Stromal Cells","Clinical deterioration|Serious Adverse Events|ICU transfer|Respiratory support|Hospital mortality and length of stay|Ventilator free days|28 day mortality","Medical University of South Carolina|Pandorum International, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","115966","May 4, 2022","May 4, 2023","May 4, 2023","March 18, 2022",,"May 10, 2022","Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT05286255"
16,"NCT04388761","Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI)",,"Recruiting","No Results Available","Ischemia Reperfusion Injury","Drug: Allogeneic adipose derived mesenchymal stem cells","Serious Adverse Events (SAEs)","Tambi Jarmi|Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-000264","September 28, 2020","February 1, 2024","February 1, 2024","May 14, 2020",,"October 14, 2021","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04388761"
17,"NCT02886884","Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects","ACESO","Completed","Has Results","Diabetes Mellitus, Type 2","Drug: 20 million Allogeneic Mesenchymal Human Stem Cells|Drug: 100 million Allogeneic Mesenchymal Human Stem Cells","Number of Treatment Emergent Serious Adverse Events (TE-SAEs)|EPC-CFU Levels|CRP Marker Levels|Circulating Angiogenic Factor Levels|Flow Mediated Diameter Percentage (FMD%)|Circulating Inflammatory Marker Levels|Tumor Necrosis Factor (TNF) Alpha Levels","Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|University of Miami","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","16","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20160686|1R01HL134558-01","October 20, 2017","August 26, 2019","September 3, 2020","September 1, 2016","May 11, 2022","May 11, 2022","University of Miami Miller School of Medicine, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02886884/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02886884"
18,"NCT02032004","Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.","DREAM HF-1","Completed","No Results Available","Chronic Heart Failure","Biological: Allogeneic Mesenchymal Precursor Cells (MPCs)|Other: Sham Comparator","Time to recurrent non-fatal decompensated heart failure major adverse cardiac events (HF-MACE) that occur prior to the first terminal cardiac event (TCE).|Time-to-first terminal cardiac event (TCE)|Time-to-hospital admissions for non-fatal decompensated HF events|Time-to-urgent care outpatient HF visits|Time-to-successfully resuscitated cardiac death (RCD) events|Total length of in-hospital stay in intensive care unit for non-fatal decompensated HF events|Time-to-first HF-MACE (composite of hospital admissions for decompensated HF, urgent care outpatient HF visit, and successfully RCD events)|Time-to-first HF-MACE (composite of hospital admissions for decompensated HF, urgent care outpatient HF visit, successfully RCD events or TCE)|Time-to-cardiac death|Time-to-all-cause death|Time-to-first non-fatal MI (myocardial infarction), non-fatal CVA (cerebrovascular attack) or coronary artery revascularization|Left Ventricular (LV) remodeling in LVESV determined by 2-D echocardiography|Correlations between baseline LVESV <=100 mL and LVESV >100 mL and clinical outcomes|Correlations between baseline LVESV <=100 mL and LVESV >100 mL and change in Month 6 to baseline LVESV and clinical outcomes|LV remodeling in LVEDV determined by 2-D echocardiography|Overall Left Ventricular systolic performance as assessed by left ventricular ejection fraction (LVEF [radionuclide ventriculography {RVG} or echocardiogram])|Functional exercise capacity as assessed by 6 Minute Walk Test|Functional status by New York Heart Association (NYHA) class|Quality of Life Measure - Minnesota Living With Heart Failure (MLHF) questionnaire|Quality of Life Measure - European Quality of Life (EuroQoL) 5-dimensional (EQ-5D) questionnaire|Safety as assessed by occurrence of adverse events related to the index cardiac catheterization on Day 0|Safety as assessed by occurrence of treatment-emergent adverse events|Safety as assessed by clinical laboratory tests (serum chemistry - ALT, AST, alkaline phosphate, GGT, LDH, BUN, creatinine, uric acid, total bilirubin - and hematology - hematocrit, hemoglobin, WBCs, eosinophils, ANC, platelet count)|Safety as assessed by urinalysis (blood, glucose, ketones, total protein)|Safety as assessed by vital signs (pulse, systolic blood pressure [BP], diastolic BP)|Safety as assessed by 12-lead electrocardiogram (ECG) findings - QT interval with Fridericia's correction (QTcF), heart rate-corrected QT interval (QTcB), QT, Q wave, R wave and S wave (QRS) complex, HR and T waves.|Safety as assessed by telemetry monitoring findings (clinically significant arrhythmias)|Safety as assessed by rhythm analysis (specifically, ventricular arrhythmias) by interrogation of any implanted device capable of defibrillation|Safety as assessed by 24-hr Holter monitoring (HR, rate & duration of arrhythmias, a-fib average rate, supra- & ventricular ectopy singles/couplets/runs/totals, sustained & non-sustained ventricular tachycardia, longest pauses RR duration, total pauses)|Safety as assessed by physical examination findings judged as clinically significant changes from baseline by the investigator or newly occurring abnormalities (including weight)|Safety as assessed by important cardiovascular events from adjudicated data","Mesoblast, Inc.|Mesoblast, Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","566","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSB-MPC-CHF001","February 14, 2014","May 29, 2020","May 29, 2020","January 9, 2014",,"January 10, 2022","Mesoblast Investigational Site 10757 - Cardiology, P.C., Birmingham, Alabama, United States|Mesoblast Investigational Site 13262 - University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States|Mesoblast Investigational Site 10779 - Mercy Gilbert Medical Center, Gilbert, Arizona, United States|Mesoblast Investigational Site 10786 - Cardiovascular Associates of Mesa, Mesa, Arizona, United States|Mesoblast Investigational Site 10756 - Mayo Clinic, Phoenix, Arizona, United States|Mesoblast Investigational Site 13023 - University of Arizona Medical Center, Tucson, Arizona, United States|Mesoblast Investigational Site 10754 - University of California, San Diego, La Jolla, California, United States|Mesoblast Investigational Site 10759 - Scripps Clinic, La Jolla, California, United States|Mesoblast Investigational Site 13265 - University of California, Los Angeles, Los Angeles, California, United States|Mesoblast Investigational Site 10775 - Cedars-Sinai Medical Care Foundation, Los Angeles, California, United States|Mesoblast Investigational Site 10778 - Orange County Cardiology, Orange, California, United States|Mesoblast Investigational Site 13031 - St. John's Regional Medical Center, Oxnard, California, United States|Mesoblast Investigational Site 13275 - Stanford University Hospital, Stanford, California, United States|Mesoblast Investigational Site 13267 - Bethesda Heart Hospital, Boynton Beach, Florida, United States|Mesoblast Investigational Site 10780 - Morton Plant Hospital, Clearwater, Florida, United States|Mesoblast Investigational Site 10760 - Shands Hospital, University of Florida, Gainesville, Florida, United States|Mesoblast Investigational Site 13273 - University of Florida Health, Jacksonville, Florida, United States|Mesoblast Investigational Site 10768 - University of Miami, Miami, Florida, United States|Mesoblast Investigational Site 13280, Orlando, Florida, United States|Mesoblast Investigational Site 13264 - Florida Hospital Pepin Heart Institute, Tampa, Florida, United States|Mesoblast Investigational Site 13027 - Emory University School of Medicine, Atlanta, Georgia, United States|Mesoblast Investigational Site 10765 - Georgia Regents University, Augusta, Georgia, United States|Mesoblast Investigational Site 10772 - University Cardiologist, Rush University Medical Center, Chicago, Illinois, United States|Mesoblast Investigational Site 13030 - University of Iowa, Iowa City, Iowa, United States|Mesoblast Investigational Site 10783 - Gill Heart Institute, University of Kentucky, Lexington, Kentucky, United States|Mesoblast Investigational Site 13022 - University of Louisville, Louisville, Kentucky, United States|Mesoblast Investigational Site 13266, New Orleans, Louisiana, United States|Mesoblast Investigational Site 10782, Boston, Massachusetts, United States|Mesoblast Investigational Site 10766 - Michigan Cardiovascular Institute, Saginaw, Michigan, United States|Mesoblast Investigational Site 10762 - Minneapolis Heart Institute, Minneapolis, Minnesota, United States|Mesoblast Investigational Site 10761 - Mayo Clinic, Rochester, Minnesota, United States|Mesoblast Investigational Site 13281, Las Vegas, Nevada, United States|Mesoblast Investigational Site 13263 - RWJ Barnabas Heart Center, Newark, New Jersey, United States|Mesoblast Investigational Site 10776 - Columbia University Medical Center, New York, New York, United States|Mesoblast Investigational Site 13026 - Sanger Heart and Vascular Institute, Carolinas Healthcare System, Charlotte, North Carolina, United States|Mesoblast Investigational Site 10781 - Duke University, Durham, North Carolina, United States|Mesoblast Investigational Site 10758 - The Christ Hospital, Cincinnati, Ohio, United States|Mesoblast Investigational Site 10770 - University of Cincinnati, Cincinnati, Ohio, United States|Mesoblast Investigational Site 10773, Cleveland, Ohio, United States|Mesoblast Investigational Site 13278 - OhioHealth Research Institute, Columbus, Ohio, United States|Mesoblast Investigational Site 10785 - Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Mesoblast Investigational Site 13261 - University of Pennsylvania, Philadelphia, Pennsylvania, United States|Mesoblast Investigational Site 10767 - Temple University Hospital, Philadelphia, Pennsylvania, United States|Mesoblast Investigational Site 13277, Philadelphia, Pennsylvania, United States|Mesoblast Investigational Site 10774 - University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Mesoblast Investigational Site 10777 - Stern Cardiovascular Foundation, Germantown, Tennessee, United States|Mesoblast Investigational Site 13024 - Austin Heart, PLLC, Austin, Texas, United States|Mesoblast Investigational Site 13274 - Soltero CV Research Center, Baylor Scott & White Research Institute, Dallas, Texas, United States|Mesoblast Investigational Site 10755 - Texas Heart Institute, Houston, Texas, United States|Mesoblast Investigational Site 13268 - Houston Methodist Hospital, Houston, Texas, United States|Mesoblast Investigational Site 10763 - University Hospital, Salt Lake City, Utah, United States|Mesoblast Investigational Site 10771 - Heart & Vascular Research, Swedish Medical Center, Seattle, Washington, United States|Mesoblast Investigational Site 10764 - University of Wisconsin, Madison, Wisconsin, United States|Mesoblast Investigational Site 10769 - Aurora Healthcare, Milwaukee, Wisconsin, United States|Mesoblast Investigational Site 13279, Milwaukee, Wisconsin, United States|Mesoblast Investigational Site 10789 - Aspirus Research Institute, Wausau, Wisconsin, United States|Mesoblast Investigational Site 11027, Edmonton, Alberta, Canada|Mesoblast Investigational Site 11024 - Victoria Heart Institute Foundation, Victoria, British Columbia, Canada|Mesoblast Investigational Site 11025 - St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02032004"
19,"NCT04626583","Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells",,"Recruiting","No Results Available","Mesenchymal Stromal Cells|Cornea|Safety|Corneal Defect","Biological: Allogeneic MSC","Primary Safety Outcome: Incidence of treatment emergent adverse events (TEAE) assessed at 28 days.|Primary Efficacy Outcome: Proportion of participants with improvement in epithelial defect or barrier integrity relative to baseline (based on fluorescein staining)|Secondary Efficacy Outcomes: Visual Acuity|Secondary Efficacy Outcomes: Time to Completion of Corneal Epithelialization|Secondary Efficacy Outcomes: Durability of the Corneal Epithelialization and Healing|Secondary Efficacy Outcomes: Corneal stromal haze|Secondary Efficacy Outcomes: Corneal epithelial thickness","University of Illinois at Chicago|United States Department of Defense","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-0334|W81XWH-18-1-0661","March 5, 2021","December 30, 2023","December 30, 2023","November 12, 2020",,"April 21, 2022","University of Illinois, Department of Ophthalmology and Visual Sciences, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04626583"
20,"NCT03929120","Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)",,"Completed","No Results Available","Interstitial Lung Disease|Connective Tissue Diseases","Biological: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)","Adverse Events","Mayo Clinic","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-007216","November 5, 2019","July 27, 2021","February 17, 2022","April 26, 2019",,"April 20, 2022","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03929120"
21,"NCT02421484","Cellular Immunotherapy for Septic Shock: A Phase I Trial","CISS","Completed","No Results Available","Septic Shock","Biological: Allogeneic mesenchymal stromal cells","Number of adverse events as a measure of safety and tolerability","Ottawa Hospital Research Institute|Canadian Institutes of Health Research (CIHR)","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014809","May 2015","June 2016","October 30, 2018","April 20, 2015",,"October 31, 2018","The Ottawa Hospital, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02421484"
22,"NCT02672267","A Study of Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells in Subjects With Myocardial Infarction",,"Completed","No Results Available","Myocardial Infarction","Biological: Stem cells|Other: Placebo","The safety and tolerability of aMBMC intravenous administration during the six month study period as determined by major adverse events MACE endpoint|The change from baseline on physical exam conducted at 1, 3 and 6 months post-administration|LV end diastolic volume|LV end systolic volume|Infarct size measured by MRI, with contrast|Global Left Ventricular Ejection Fraction","Altaco XXI, LLP|Duke University","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","CARDIO 1/2","July 2014","April 2016","April 2016","February 3, 2016",,"October 6, 2016","National Research Medical Center, Astana, Kazakhstan",,"https://ClinicalTrials.gov/show/NCT02672267"
23,"NCT01856140","Treatment of Tendon Injury Using Mesenchymal Stem Cells","ALLO-ASC","Completed","Has Results","Lateral Epicondylitis","Biological: ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection","Change From Baseline in Visual Analog Scale (VAS) at 6 and 12 Weeks|Modified Mayo Clinic Performance Index for the Elbow|Defect Area of Tendon by Ultrasonography in Long Axis|Defect Area of Tendon by Ultrasonography in Short Axis","Seoul National University Hospital|Medical Research Collaborating Center, Seoul, Korea","All","19 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SNUH-RM-SGChung-ASC-01","May 2013","July 2016","April 2018","May 17, 2013","February 18, 2022","March 18, 2022","Seoul National University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01856140"
24,"NCT04466007","Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stem Cells in Diabetic Patients With Critical Limb Ischemia",,"Recruiting","No Results Available","Limb Ischemia|Diabetic Foot","Drug: High dose allogeneic mesenchymal stromal cells|Drug: Low dose allogeneic mesenchymal stromal cells|Drug: Placebos","Complication rate after treatment administration|Evaluation of vascularization though RMN|Rutherford-Becker scale|Wifi scale|Ankle arm index|Temperature|Twin perimeter|Neuropathic symptoms (altered sensitivity)|% amputations","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Universitario La Paz|Gregorio Marañón Hospital|Hospital Clínico Universitario de Valladolid|Hospital Universitario Virgen de la Arrixaca|University of Salamanca|Hospital General Universitario de Alicante|Hospital Universitario La Fe|Hospital Victoria Eugenia Cruz Roja Española","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NOMA (No More Amputations)","January 11, 2021","September 2022","September 2022","July 10, 2020",,"August 30, 2022","Hospital General de Alicante, Alicante, Spain|Hospital Gregorio Marañon, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|La Paz University Hospital, Madrid, Spain|Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Victoria Eugenia Cruz Roja Española, Sevilla, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital de Valladolid, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT04466007"
25,"NCT04447833","Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome","ARDS-MSC-205","Active, not recruiting","No Results Available","ARDS, Human|COVID","Drug: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205","The incidence of pre-specified treatment related adverse events of interest (TRAEIs).|Safety; All-cause mortality|Changes in Leucocytes|Changes in Trombocytes|Changes in plasma concentration of C-reactive protein (CRP)|Changes in plasma concentration of Prothrombin complex (PK)|Changes in plasma concentration of Creatinine|Changes in plasma concentration of Aspartate amino transferase (ASAT)|Changes in plasma concentration of Alanine amino transferase (ALAT)|Changes in plasma concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP)|Changes in Blood pressure|Changes in Body temperature|Efficacy; Changes in pulmonary compliance|Efficacy; Changes in driving pressure (Plateau pressure- PEEP)|Efficacy; Changes in oxygenation (PaO2/FiO2)|Efficacy; Duration of ventilator support|Efficacy; Pulmonary bilateral infiltrates|Efficacy; Sequential Organ Failure Assessment (SOFA) score|Efficacy; Hospital stay|Lung function|Lung fibrosis|Six minutes walk test|Changes in Quality of life|Blood biomarkers|Sensitisation test","Uppsala University|Uppsala University Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-02238","June 17, 2020","January 30, 2021","June 30, 2025","June 25, 2020",,"March 4, 2021","Uppsala University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT04447833"
26,"NCT01649687","Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells",,"Completed","No Results Available","Cerebellar Ataxia","Biological: Allogeneic adult adipose-derived mesenchymal stem cells","Safety evaluation|Alterations in SARA score|Positron emission tomography|Magnetic resonance spectroscopy|Assessment of language and swallowing functions|Evaluation of syncope|Balance test","National Yang Ming University","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SB-VGH-201001","May 2012","January 2014","January 2014","July 25, 2012",,"September 12, 2014","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01649687"
27,"NCT01586312","Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells","MSV_allo","Completed","Has Results","Osteoarthritis, Knee|Arthritis of Knee|Knee Osteoarthritis","Other: Allogenic mesenchymal stromal cells injection|Drug: Hyaluronic Acid","Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Pain and Disability Evolution (WOMAC, Visual Analogue Scale, Lequesne Index and SF-12 Scores)|Evolution of Cartilage Degeneration by T2 Relaxation Measurements in MRI (Cartigram)","Red de Terapia Celular|University of Valladolid|Sanidad de Castilla y León|Centro Medico Teknon","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","TerCel004|2011-005321-51|EC11-309|MSV_allo","April 2012","December 2013","June 2014","April 26, 2012","November 6, 2014","October 16, 2015","Centro Medico Teknon, Barcelona, Spain|Hospital Clinico Universitario, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT01586312"
28,"NCT02140528","Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal Fractures",,"Completed","No Results Available","Tibial Fracture","Biological: Mesenchymal stem cell injection|Biological: Placebo","Number of patients with union after transplantation of mesenchymal stem cell in case group in comparison with control group","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Royan-Bone-012","August 2013","March 2016","April 2016","May 16, 2014",,"April 27, 2017","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02140528"
29,"NCT04366323","Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19",,"Completed","No Results Available","Sars-CoV2","Drug: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS","Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate|Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate","Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AdiQure/COVID-19","April 27, 2020","December 30, 2021","December 30, 2021","April 28, 2020",,"April 6, 2022","Hospital Universitario de Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Unversitario Virgen del Rocío, Sevilla, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT04366323"
30,"NCT02013674","The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)","Trident","Completed","Has Results","Chronic Ischemic Left Ventricular Dysfunction|Myocardial Infarction","Biological: Allogeneic hMSCs","Number of Participants With Treatment-emergent Serious Adverse Events (SAE).|Infarct Scar Size (ISS)|Number of Participant With Reported Tissue Perfusion|Peak Oxygen Consumption (VO2)|Six-minute Walk Test.|Changed in New York Heart Association (NYHA) Functional Classification Based on Patient's Self Reported Activity Level.|Number of Incidents of Major Adverse Cardiac Events (MACE).|Number of Participants With Treatment Emergent Adverse Event (AE)|Minnesota Living With Heart Failure (MLHF) Questionnaire Scores|Echocardiographic-derived Measures of Left Ventricular Function|Difference Between Regional Left Ventricular Function (at the Site of Allogeneic Cell Injections)|Difference Between the Regional Left Ventricular Wall Thickening|Difference Between Left Ventricular End Diastolic Wall Thickness|Difference Between the Left Ventricular Ejection Fraction (LVEF)|Difference in LVEF|Difference in Left Ventricular Volume|Difference in Left Ventricular Regional Myocardial Perfusion|Number of Participants With Abnormal Electrocardiogram (ECG) Reads.|Number of Clinically Significant of Abnormal Lab Values.|Serial Troponin I|Number of Participants With Abnormal ECHO Reading|Creatinine Kinase Muscle/Brain (CK-MB)","Joshua M Hare|The Emmes Company, LLC|University of Miami","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20120660","February 13, 2014","March 2, 2017","September 18, 2017","December 17, 2013","February 5, 2020","February 11, 2020","ISCI / University of Miami, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02013674/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02013674"
31,"NCT03874572","Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth","MESRIX-SAFETY","Active, not recruiting","No Results Available","Xerostomia Due to Radiotherapy|Hyposalivation|Xerostomia|Oropharynx Cancer|Salivary Gland Diseases|Dry Mouth|Mesenchymal Stem Cells|Mesenchymal Stromal Cells|Stem Cells","Biological: Allogeneic adipose derived stem/stromal cells","Safety: Number of patients with serious adverse events|Immune reponse :Development of donor specific antibodies|Efficacy: Change in Unstimulated Whole Salivary flow rate|Efficacy: Change in Stimulated Whole Salivary flow rate|Efficacy: Change in quality of life|Efficacy: Salivary gland function|Efficacy: Change in Saliva composition|Efficacy: Change in Saliva Proteomics|Efficacy: Change in RNA in Saliva|Immune reponse","Rigshospitalet, Denmark","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CVB2018-2|2018-003856-19","March 18, 2019","June 22, 2020","December 1, 2025","March 14, 2019",,"January 29, 2021","Department of Otolaryngology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark|Department of Otolaryngology, Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03874572"
32,"NCT01860417","Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)","Disc_allo","Completed","No Results Available","Degenerative Disc Disease|Intervertebral Disc Disease|Low Back Pain","Biological: Allogenic Mesenchymal Stromal Cells|Drug: Mepivacaine","Safety and tolerability|Pain and disability evolution|Evolution of affected disc(s) by quantitative Magnetic Resonance Imaging (RMI)|Llife quality evolution (Short Form (SF)-12 questionnaire)","Red de Terapia Celular|Citospin|University of Valladolid","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","25","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","TerCel005|2012-004444-30|Disc_allo_MSV","April 2013","April 2017","April 2017","May 22, 2013",,"April 26, 2017","Hospital Clinico Universitario, Valladolid, Spain|Instituto de Biologia y Genetica Molecular, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT01860417"
33,"NCT02065245","AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery","CRATUS","Completed","Has Results","Frailty","Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Biological: Placebo|Biological: Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)","Incidence of Any Treatment Emergent - Serious Adverse Events (TE-SAEs)|Change in Frailty as Assessed by CHAMPS Questionnaire|Change in Slowing of Mobility as Measured by 4 Meter Gait Speed Test|Change in Slowing of Mobility as Measured by SPPB|Change in Weight|Change in Diminished Hand Grip Strength|Change in Exhaustion as Measured by the MFI Questionnaire|Change in Quality of Life (QoL) as Measured by the ICECAP Questionnaire|Change in Quality of Life (QoL) as Measured by the SF-36 Questionnaire|Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Questionnaire|Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Overall Health Status Scale.|Change in Sense of Smell as Measured by UPSIT|Death|Change in Ejection Fraction (EF)|Change in Inflammatory Markers Levels|Change in Inflammatory Markers|Change in Inflammatory Marker D-dimer Levels","Longeveron Inc.|The Emmes Company, LLC","All","60 Years to 95 Years   (Adult, Older Adult)","Phase 1|Phase 2","65","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20130646","March 3, 2014","October 2, 2019","October 2, 2020","February 17, 2014","April 27, 2021","July 14, 2021","ISCI/University of Miami Miller School of Medicine, Miami, Florida, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT02065245/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02065245"
34,"NCT04382547","Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells",,"Completed","No Results Available","COVID|Covid-19|Coronavirus|Pneumonia|Pneumonia, Viral|Pneumonia, Interstitial|Sars-CoV2","Biological: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells|Other: Standard treatment according to the Clinical protocols","Number of cured patients|Number of patients with treatment-related adverse events","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_MSC2(Covid)","May 11, 2020","June 30, 2021","June 30, 2021","May 11, 2020",,"August 23, 2021","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04382547"
35,"NCT04357600","Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B",,"Recruiting","No Results Available","Liver Cirrhoses","Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell","Child Pugh Score|Examination of liver function|MELD Score","PT. Prodia Stem Cell Indonesia","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT/LC/01/2018","May 17, 2018","June 20, 2023","December 20, 2023","April 22, 2020",,"June 15, 2022","Cipto Mangunkusumo hospital, Jakarta, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04357600"
36,"NCT03562065","Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord","MSC-SLE","Recruiting","No Results Available","Lupus Erythematosus|Stem Cell Transplant","Biological: mesenchymal stem cells","Toxicity of allogeneic MSC injection according to CTCAE|Toxicity of allogeneic MSC injection according to CTCAE Month 1|Toxicity of allogeneic MSC injection according to CTCAE Month 3|Toxicity of allogeneic MSC injection according to CTCAE Month 6|Toxicity of allogeneic MSC injection according to CTCAE Month 12|Proportion of subjects with Clinical Response Month 3|Proportion of subjects with Clinical Response Month 6|Proportion of subjects with Clinical Response Month 9|Proportion of subjects with Clinical Response Month 12|Disease activity measured by the BILAG index Month 3|Disease activity measured by SELENA-SLEDAI Month 3|Disease activity measured by SELENA-SLEDAI Month 6|Disease activity measured by the BILAG index Month 6|Disease activity measured by the BILAG index Month 9|Disease activity measured by SELENA-SLEDAI Month 9|Disease activity measured by the BILAG index Month 12|Disease activity measured by SELENA-SLEDAI Month 12|SRI Month 3|SRI Month 6|SRI Month 9|SRI Month 12|comorbidities Month 3|comorbidities Month 6|comorbidities Month 9|comorbidities Month 12|Quality of life Month SF-36 Month 3|Quality of life EQ-5D Month 3|Quality of life Month SF-36 Month 6|Quality of life EQ-5D Month 6|Quality of life Month SF-36 Month 9|Quality of life EQ-5D Month 9|Quality of life Month SF-36 Month 12|Quality of life EQ-5D Month 12|Steroids Month 3|Steroids Month 6|Steroids Month 9|Steroids Month 12","Assistance Publique - Hôpitaux de Paris","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P150302","September 11, 2019","June 1, 2023","June 1, 2024","June 19, 2018",,"July 8, 2021","Saint-Louis Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT03562065"
37,"NCT01851070","A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: Allogeneic Mesenchymal Precursor Cells|Drug: Normal Saline","Evaluation of the safety of a single IV infusion of allogeneic MPCs compared to placebo at 12 weeks post-infusion|Evaluation of the efficacy of a single intravenous infusion of allogeneic MPCs compared with placebo at 12 weeks post-infusion with MPCs or placebo in the treatment of patients with active RA|Evaluation of long-term safety and efficacy of a singly IV infusion of allogeneic MPCs in patients with active RA","Mesoblast, Ltd.|PPD","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSB-RA001","July 2013","May 2016","March 2017","May 10, 2013",,"June 26, 2020","Pinnacle Research Group, Anniston, Alabama, United States|Arthrocare Arthritis Care and Research PC, Gilbert, Arizona, United States|Triwest Research Associates, El Cajon, California, United States|UCLA, Los Angeles, California, United States|Inland Rheumatology Clinical Trials Incorporated, Upland, California, United States|Ocala Rheumatology Research Center, Ocala, Florida, United States|Arthritis Center, Palm Harbor, Florida, United States|Sarasota Arthritis Research Center, Sarasota, Florida, United States|McIlwain Medical Group, Tampa, Florida, United States|JHU Arthritis Center Baltimore, Baltimore, Maryland, United States|Arthritis Treatment Center, Frederick, Maryland, United States|Reliant Medical Group, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Office of Ramesh C. Gupta, MD, Fair Lawn, New Jersey, United States|DJL Clinical Research, Charlotte, North Carolina, United States|Health Research of Oklahoma, Oklahoma City, Oklahoma, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|Accurate Clinical Research, Houston, Texas, United States|Texas Arthritis Research Center, San Antonio, Texas, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Southern Clinical Research Pty Ltd, Hobart, Tasmania, Australia|Emeritus Research, Malvern, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01851070"
38,"NCT01378182","Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis",,"Completed","No Results Available","Wilson's Disease","Genetic: allogeneic mesenchymal stem cell transplantation","differantiation of transplanted mesenchymal stem cells to hepatocytes in post treatment liver biopsies","Murat Kantarcioglu|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110S153","April 2011","March 2013","December 2014","June 22, 2011",,"December 31, 2014","Department of Gastroenterology; Gulhane Military Medical Academy, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT01378182"
39,"NCT02625246","Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis","CELEB","Completed","No Results Available","Bronchiectasis","Biological: hMSCs","Number of Participant with treatment emergent serious adverse events|Difference in Colony Forming Units (CFUs) in semiquantitative culture of sputum|rate of decline of lung function|frequency of acute exacerbations|reported dyspnea and quality of life assessment|death from any cause","Marilyn Glassberg|University of Miami","All","30 Years to 87 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20150627","February 4, 2016","May 15, 2019","May 15, 2019","December 9, 2015",,"August 28, 2019","University of Miami Hospitals & Clinics, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02625246"
40,"NCT05017298","Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells","AdMSCs","Not yet recruiting","No Results Available","Corona Virus Infection|Covid19","Biological: Allogeneic adipose-derived stem cells","Safety of AdMSC injection will be evaluated by assessment of the frequency and nature of adverse events occurring during the study based on the rate of all AdMSC-associated adverse events (AEs) in all subjects.|Safety for AdMSCs based upon incidence of all AEs|Compare the mortality rate|Recognized immune measurements evaluating patients' symptom changes and overall function|Organ functional tests including blood specific enzymes and proteins|Duration (days) of weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agent's usage|Duration of hospitalization (days)|Proportions of SARS-CoV-2 RT-PCR change to negative from respiratory tract specimens (oropharyngeal swabs) using CDC standard method|Proportions of quantifying viral RNA in stool change to negative in final follow-up using CDC standard method|Proportions of blood SARS-CoV-2 antibodies IgM/IgG show positive","Celltex Therapeutics Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CTX0020-004","November 1, 2022","November 1, 2023","November 15, 2025","August 23, 2021",,"April 29, 2022",,,"https://ClinicalTrials.gov/show/NCT05017298"
41,"NCT04869761","Stem Cell Therapy for Chronic Kidney Disease",,"Recruiting","No Results Available","Chronic Kidney Diseases|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1|Diabetes Mellitus|Diabetic Nephropathies","Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion|Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions","Adverse events and/or serious adverse events","LaTonya J. Hickson|Mayo Clinic","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","20-008380","October 7, 2021","December 2026","May 2027","May 3, 2021",,"November 4, 2021","Mayo Clinic Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04869761"
42,"NCT05039411","Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas Patients With Crohn's Disease",,"Recruiting","No Results Available","Perianal Fistula Due to Crohn's Disease|Fistula in Ano","Biological: Human umbilical cord mesenchymal stem cells (UC-MSCs)","Incidence of any treatment-emergent adverse events (TE-AEs)|Clinical healing","CryoCord Sdn Bhd|University of Malaya","All","18 Years and older   (Adult, Older Adult)","Phase 1","7","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCSB-CT-PF-01-2021 (Ver_01)","March 1, 2022","December 31, 2024","December 31, 2024","September 9, 2021",,"March 22, 2022","University of Malaya Medical Centre, Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT05039411"
43,"NCT02685098","A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation","CHAMP","Recruiting","No Results Available","Ischemia|Peripheral Arterial Disease|Peripheral Vascular Disease|Vascular Disease|Arterial Occlusive Disease|Arteriosclerosis|Atherosclerosis|Cardiovascular Disease|Pathologic Processes|Orthopedic Procedures|Amputation","Biological: Allogeneic bone marrow derived mesenchymal stem cells","Number of participants with treatment-related adverse events occurring during the enrollment period as assessed by the Investigator using the MeDRA scale.|Gene and protein arrays, IHC staining, and multiparametric flow cytometry will measure the time period of retention of allogeneic MSCs in harvested human skeletal muscle tissue post-MSC implantation.|Recruitment of proangiogenic hematopoietic cells into sites of ischemia will be measured and reported as assessed by the role of MSCs injected in human skeletal muscle at the time of amputation.","Indiana University","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1505714405","January 2017","September 2021","September 2025","February 18, 2016",,"February 12, 2020","Indiana University, Indianapolis, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02685098"
44,"NCT04615455","Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sjögren's Syndrome","AMASS","Active, not recruiting","No Results Available","Keratoconjunctivitis Sicca, in Sjogren's Syndrome","Drug: ASCs|Drug: Cryostor CS10","Ocular Surface Disease Index (OSDI)|Non-invasive keratography tear break-up time (NIKBUT)|Tear meniscus height (TMH)|Schirmer's I test|Tear osmolarity|Oxford scale|HLA anti-bodies","Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2020-002804-38","November 3, 2020","December 1, 2022","January 1, 2023","November 4, 2020",,"February 15, 2022","Rigshospitalet, Copenhagen, DK, Denmark",,"https://ClinicalTrials.gov/show/NCT04615455"
45,"NCT05532943","Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis","UMSC01","Not yet recruiting","No Results Available","Multiple Sclerosis","Biological: Allogeneic umbilical cord mesenchymal stem cells|Biological: Control group","Primary Endpoint for Phase I portion|Primary Endpoint for Phase IIa portion|Efficacy endpoint for phase I portion|Efficacy endpoints for phase IIa portion|The safety endpoints are listed below for both phase I and IIa portions","Ever Supreme Bio Technology Co., Ltd.","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ES-CMSC01-D1101","December 31, 2022","December 31, 2026","December 31, 2026","September 8, 2022",,"September 8, 2022","China Medical University Hospital, Taichung, Non-US, Taiwan",,"https://ClinicalTrials.gov/show/NCT05532943"
46,"NCT05501418","Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19","UMSC01","Active, not recruiting","No Results Available","COVID-19 Infection","Biological: Allogeneic umbilical cord mesenchymal stem cells|Biological: Controlled normal saline","Two Co-Primary Efficacy Endpoints|Secondary Efficacy Endpoints|Secondary Safety Endpoints","Ever Supreme Bio Technology Co., Ltd.","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ES-CMSC01-C1101","August 5, 2020","December 31, 2023","December 31, 2023","August 15, 2022",,"August 15, 2022","China Medical University Hospital, Taichung, Non-US, Taiwan",,"https://ClinicalTrials.gov/show/NCT05501418"
47,"NCT04791878","Study of Mesenchymal Stem Cells for Pediatric Perianal Fistulizing Crohn's Disease",,"Recruiting","No Results Available","Perianal Fistula Due to Crohn's Disease (Disorder)","Drug: Mesenchymal stem cells","Treatment related adverse events|Complete clinical healing|Partial clinical healing|Lack of response|Worsening of disease","Amy Lightner|The Cleveland Clinic","All","13 Years to 17 Years   (Child)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","21-134","April 1, 2021","April 1, 2023","April 1, 2023","March 10, 2021",,"April 5, 2022","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04791878"
48,"NCT02611167","Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease",,"Completed","No Results Available","Parkinson's Disease","Biological: Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)|Biological: Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)|Biological: Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)|Biological: Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)","Safety of allogeneic MSC therapy in patients with iPD as indicated by the presence of adverse events that are confirmed to be related to the therapy|Change in motor function as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) Total score|Change in motor function as assessed by the UPDRS Motor score|Change in motor function as assessed by Timed-Up-and-Go (TUG)|Change in disability as measured by the Modified Hoehn and Yahr Scale|functional connectivity between substantia nigra and dorsal striatum as assessed by resting state functional magnetic resonance imaging (fMRI)|perfusion as assessed by arterial spin-labeled (ASL) perfusion MRI|structural connectivity as assessed by diffusion-weighted MRI for diffusion tensor image (DTI) analysis|volume of subcortical structures as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|cortical thickness as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|Change in gross brain structure as assessed by T1- and T2- weighted MRI with Fluid Attenuated Inversion Recovery|Change in brain activity as assessed by task state fMRI|Change in quality of life as assessed by the modified Schwab and England activities of daily living (ADL) score|Change in quality of life as assessed by the Parkinson's Disease Questionnaire (PDQ-39)|Change in cognitive function as assessed by the Montreal Cognitive Assessment (MoCA)|Change in immunologic response as assessed by plasma concentrations of cytokines|Change in suicidal ideation or behaviors as assessed by and Columbia Suicide Severity Rating Scale (CSSRS)","The University of Texas Health Science Center, Houston","All","45 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-Schiess MSC PD","November 1, 2017","September 18, 2019","September 18, 2019","November 20, 2015",,"September 7, 2020","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02611167"
49,"NCT01678534","Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial","AMASCIS-01","Completed","No Results Available","Ischemic Stroke","Drug: Allogenic mesenchymal stem cells from adipose tissue|Drug: Placebo","Number of participants with Adverse events, complications.|Efficacy","Instituto de Investigación Hospital Universitario La Paz","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 2","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AMASCIS-01/2011|2011-003551-18","September 2014","December 2017","December 2017","September 5, 2012",,"February 28, 2018","University Hospital La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01678534"
50,"NCT01453738","Allogeneic Mesenchymal Stem Cells in Osteoarthritis",,"Completed","No Results Available","Osteoarthritis of Knee","Biological: Ex- vivo cultured adult allogeneic MSCs|Biological: Plasmalyte-A","Number and percentage of patients with adverse events as a measure of safety and tolerability|Change from baseline in the WOMAC OA (Western Ontario and McMaster Universities Osteoarthritis) Index -pain subscale score|Change from baseline in WOMAC OA stiffness index|Change from baseline in WOMAC OA composite index|Change from baseline in ICOAP (Intermittent and Constant Osteoarthritis Pain)|Change from baseline in radiographic (X-ray) findings of knee|Change from baseline in the WORMS score (Whole-Organ Magnetic Resonance Imaging Score) of knee using MRI|Change from baseline in arthritis pain scores on the visual analogue scale|Reduction in the intake of analgesic tablets from baseline","Stempeutics Research Pvt Ltd","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SRPL/OA/09-10/001","November 2011","November 2014","November 2014","October 18, 2011",,"May 12, 2016","Department of Orthopedics, M. S. Ramaiah Memorial Hospital, Bangalore, Karnataka, India|Department of Orthopedics, Kasturba Medical College, Manipal, Karnataka, India|Seth G. S. Medical College and KEM Hospital, Mumbai, Maharashtra, India|Jehangir Hospital, Pune, Maharashtra, India|Department of Immunology Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT01453738"
51,"NCT05362786","Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney Disease",,"Recruiting","No Results Available","Chronic Kidney Diseases","Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)","Adverse events and/or serious adverse events|Change in eGFR Value","LaTonya J. Hickson|Mayo Clinic","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","21-011822","July 1, 2022","December 2025","December 2025","May 5, 2022",,"July 22, 2022","Mayo Clinic Florida, Jacksonville, Florida, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05362786"
52,"NCT04255147","Cellular Therapy for Extreme Preterm Infants at Risk of Developing Bronchopulmonary Dysplasia",,"Not yet recruiting","No Results Available","Bronchopulmonary Dysplasia","Biological: Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells","Occurrence and rate of dose limiting toxicity|Rate of Death|Occurrence of Other Severe Complications of Prematurity|FiO2 and Oxygen Index|Need for Ventilatory Support|Need for Postnatal Steroids|Incidence and Severity of BPD|Rate of Survival Without (moderate or severe) BPD|Changes in Pulmonary Hemodynamics|Biological Measure of Clinical Improvement|Biological Measure of Lung Improvement|Feasibility: Cell Administration|Feasibility: Recruitment Efficiency|Feasibility: Recruitment Timing|Feasibility: Participant Retainment|Bayley Scale of Infant and Toddler Development|Long-term Safety Follow-Up|Animated Information Video","Ottawa Hospital Research Institute|Canadian Institutes of Health Research (CIHR)|Ontario Institute of Regenerative Medicine (OIRM)|Stem Cell Network","All","7 Days to 21 Days   (Child)","Phase 1","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HULC-1","June 2022","June 2023","December 2035","February 5, 2020",,"April 21, 2022","The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04255147"
53,"NCT02467387","A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure",,"Completed","Has Results","Non-Ischemic Heart Failure","Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Drug: Lactated Ringer's Solution","Safety Will be Evaluated by Number of AE|Change in LVEF From Baseline to Day 90 Post-initial Infusion.","CardioCell LLC|Stemedica Cell Technologies, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STEM-104-M-CHF","June 1, 2014","May 11, 2017","May 11, 2017","June 10, 2015","January 7, 2020","January 7, 2020","MedStar Washington Hospital Center, Washington, District of Columbia, United States|Emory University Hospital, Atlanta, Georgia, United States|Northwestern University Centers for Heart Failure Therapy, Chicago, Illinois, United States|Stony Brook Heart Institute, Stony Brook, New York, United States|Hospital of the University of Pennsylvania, Heart Failure and Transplant Program, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02467387/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02467387"
54,"NCT01484574","A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease",,"Completed","No Results Available","Critical Limb Ischemia|Buerger's Disease","Biological: Allogeneic Mesenchymal Stem Cells","Relief of the rest pain|Healing of ulcerations or reduction of ulcer area in the target limb|Pain free walking distance|Major amputation free survival|Ankle brachial pressure index (ABPI) - measured by Doppler|Increase in transcutaneous partial oxygen pressure (TcPO2)|Quality of life by King's College VascuQOL questionnaire|Angiogenesis - collateral blood vessels by Magnetic resonance angiogram (MRA)|The type of adverse events AE(s), number of AE(s) and proportion of patients with AE(s).|Assessment of clinical laboratory parameters|Physical examination findings and assessment of vital signs|Assessment of electrocardiogram (ECG) parameters","Stempeutics Research Pvt Ltd","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","90","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SRPL/CLI/10-11/001","January 2012","February 2014","March 2016","December 2, 2011",,"September 13, 2016","Department of Surgical Disciplines, All India Institute of Medical Sciences, New Delhi, Delhi, India|Division of Peripheral Vascular and Endovascular Sciences, Medanta - The Medicity, Gurgaon, Haryana, India|Department of Vascular and Endovascular Surgery, M. S. Ramaiah Medical College and Hospitals, Bangalore, Karnataka, India|Peripheral Vascular Surgery, Sri Jayadeva Institute of Cardiovascular Sciences & Research, Bangalore, Karnataka, India|Department of Surgery, KMC, Mangalore, Mangalore, Karnataka, India|Department of Vascular Surgery, Madras Medical College, Chennai, Tamil Nadu, India|Department of Vascular Surgery, Sri Ramchandra Medical College, Chennai, Tamil Nadu, India|Department of Vascular Surgery, Stanley Medical College, Chennai, Tamil Nadu, India|Department of Vascular Surgery, AMRI Hospital, Kolkata, West Bengal, India|Nightingale Hospital, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT01484574"
55,"NCT04056819","Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Myocardial Infarction",,"Completed","No Results Available","Acute Myocardial Infarction","Biological: Allogeneic umbilical cord mesenchymal stem cells","Incidence of Treatment emergent adverse event (TEAE) as presented by MedDRA coding system|Incidence of Serious adverse event (SAE) as presented by MedDRA coding system|Incidence of Suspected and unexpected serious adverse reaction (SUSAR) as presented by MedDRA coding system|New York Heart Association (NYHA) Classification|Incidence of major adverse cardiovascular events (MACE)|Serum level of amino-terminal pro-brain natriuretic peptide (NT pro-BNP)|Pulmonary function test|Echocardiogram|Cardiac MRI (cMRI) for baseline and efficacy evaluation","Ever Supreme Bio Technology Co., Ltd.","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ES-CMSC01-A1101","May 27, 2019","August 2, 2021","December 17, 2021","August 14, 2019",,"September 8, 2022","China Medical University Hospital, Taichung, Non-US, Taiwan",,"https://ClinicalTrials.gov/show/NCT04056819"
56,"NCT05086939","Multicenter Clinical Trial Comparing Treatment With Allogeneic Mesenchymal Cells Versus Autologous Mesenchymal Cells and Versus Active Control With Hyaluronic Acid in Patients With Knee Osteoarthritis.","ARTROCELL","Recruiting","No Results Available","Knee Osteoarthritis","Drug: Autologous MSCs|Drug: Allogenic MSCs|Drug: Hyaluronic Acid","Range of motion.|Pain self-assessment.|Knee Osteoarthritis.|Functional response.|X-ray changes of osteoarthritis.|Radiological response using nuclear magnetic resonance imaging.|Perceived general well-being.|Feasibility assessment of a multicentre strategy production of both cell types with several Cell Production Units|Evaluation of presence of adverse events related with investigational medical product (IMP).","Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León|Instituto de Investigación Biomédica de Salamanca|Spanish Clinical Research Network - SCReN|Institut d'Investigacions Biomèdiques August Pi i Sunyer|Hospital Universitari de Bellvitge","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARTROCELL|2019-002446-21","May 26, 2021","December 2025","December 2025","October 21, 2021",,"June 2, 2022","Hospital Clinic, Barcelona, Spain|Hospital Clínico Universitario San Carlos, Madrid, Spain|Hospital Fundación Jiménez Díaz, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Complejo Asistencial Universitario de Salamanca, Salamanca, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT05086939"
57,"NCT01222039","Multicenter Clinical Trial for the Evaluation of Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease.","CMM/EICH/2008","Completed","No Results Available","Graft Versus Host Disease|Chronic and Expanded Graft Versus Host Disease|Immune System Diseases","Other: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.","Number of adverse events|Percentage of patients in each group that may potentially reduce corticosteroids at week 7, 20 and 42, started immunosuppressive treatment and percentage of patients at week 56 have been suspended on full immunosuppressive treatment|Overall survival and disease-free survival.|Changes in lymphocyte subsets and levels of inflammatory and antiinflammatory cytokines in each of the groups.","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT: 2008-004014-27","June 2010","June 2014","June 2014","October 18, 2010",,"November 18, 2016","Hospital de Jerez de la Frontera., Jerez de la Frontera, Cádiz., Spain|Hospital Universitario Virgen de las Nieves, Granada., Spain|Hospital Universitario Virgen del Rocío de Sevilla, Sevilla, Spain|Hospital Clínico de Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01222039"
58,"NCT04318600","Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis",,"Completed","No Results Available","Lupus Nephritis|Mesenchymal Stem Cells","Drug: human amniotic mesenchymal stem cell","Incidence of Adverse Events|Changes in 24h urine protein quantification before and after treatment；|Changes in eGFR before and after treatment;|Changes in SLEDAI score before and after treatment；","Yan'an Affiliated Hospital of Kunming Medical University|The First People's Hospital of Yunnan","All","14 Years to 60 Years   (Child, Adult)","Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2014001","January 1, 2014","March 1, 2017","January 1, 2019","March 24, 2020",,"March 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04318600"
59,"NCT01591200","Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis",,"Completed","No Results Available","Alcoholic Liver Cirrhosis","Biological: Allogeneic Mesenchymal Stem Cells","Safety|Liver function tests.|CT scan of abdomen.|Change in MELD score|Improvement in quality of life as assessed by SF 36 questionnaire|Histological evaluation of liver biopsy by immunohistochemical staining for AFP, PCNA, SMA|Change in Child-Pugh score","Stempeutics Research Pvt Ltd","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SRPL/LC/09-10/001","June 2012","April 2016","April 2016","May 3, 2012",,"September 15, 2016","Centre for Liver Research & Diagnostics, Hyderabad, Andhra Pradesh, India|Mediciti Hospital, Hyderabad, Andhra Pradesh, India|Manipal Hospital, Bangalore, Karnataka, India|KMC Hospital, Mangalore, Karnataka, India|Institute of liver disease, HPB surgery and transplant Global Hospitals, Mumbai, Maharashtra, India|Bombay Hospital & Medical Research Center, Mumbai, Maharashtra, India|Ruby Hall clinic, Pune, Maharashtra, India|Sahyadri Speciality Hospital, Pune, Maharashtra, India|SMS Medical college and Hospital, Jaipur, Rajasthan, India|SGPGI Lucknow, Lucknow, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT01591200"
60,"NCT02298023","Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells (Rotator Cuff Tear)",,"Completed","Has Results","Rotator Cuff Tear","Biological: allogenic adipose stem cell injection|Biological: fibrin glue/normal saline injection|Biological: normal saline injection","Change of Pain During Activity From Baseline to 3 Months After Intervention|Pain During Rest|Pain During Activity|American Shoulder and Elbow Surgeons (ASES) Shoulder Score|Disability of Arm, Shoulder and Hand (DASH) Score|University of California, Los Angeles(UCLA) Shoulder Score|Tear Size at 3 Months After Injection|Tear Size at 12 Months After Injection","Seoul National University Hospital","All","19 Years to 90 Years   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALLO-ASC_TR","September 2014","July 19, 2016","April 10, 2018","November 21, 2014","June 30, 2021","October 19, 2021","Seoul National University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02298023"
61,"NCT04519697","Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease","RVF","Recruiting","No Results Available","Rectovaginal Fistula|Crohn Disease|Crohn Disease of Vulva|Rectolabial; Fistula","Drug: Mesenchymal Stem Cells|Other: Placebo","Treatment related adverse events|Complete clinical healing|Partial healing|Lack of response|Worsening disease","Amy Lightner|The Cleveland Clinic","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20-936","October 28, 2020","October 2022","October 2022","August 20, 2020",,"April 5, 2022","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04519697"
62,"NCT02235844","Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (DMD)",,"Completed","No Results Available","Duchenne's Muscular Dystrophy","Biological: Umbilical Cord Mesenchymal Stem Cells","Adverse Events|Change from baseline of weight|Change of muscle diameter (circumferential measurements) from baseline|Change from baseline of Pulmonary Maximum Expiratory Pressure|Change from baseline of Pulmonary Forced Vital Capacity|Maximum Change from baseline of Predicted Inspiratory Pressure %|Change from baseline of Predicted Maximum Expiratory Pressure %|Change from baseline of Predicted Forced Vital Capacity %","Allergy and Asthma Consultants, Wichita, Kansas|Aidan Foundation|Neil H. Riordan PhD","Male","28 Years to 31 Years   (Adult)","Phase 1","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IND 16026 DMD Single Patient","September 2014","September 30, 2017","September 30, 2017","September 10, 2014",,"September 16, 2019","Asthma and Allergy Consultants, Wichita, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT02235844"
63,"NCT04519671","Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease","PFCD","Recruiting","No Results Available","Perianal Crohn Disease|Perianal Fistula|Crohn Disease","Drug: Mesenchymal Stem Cells|Other: Placebo","Treatment related adverse events|Complete clinical healing","Amy Lightner|The Cleveland Clinic","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20-1020","November 19, 2020","November 2022","November 2022","August 20, 2020",,"April 5, 2022","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04519671"
64,"NCT03356821","Perinatal Arterial Stroke Treated With Stromal Cells Intranasally","PASSIoN","Completed","No Results Available","Perinatal Arterial Ischemic Stroke|Neonatal Stroke","Biological: Mesenchymal Stem Cells","Incidence of adverse events related to intranasal MSC treatment (safety and tolerability) in the acute setting.|Incidence of adverse events related to intranasal MSC treatment (safety and tolerability) in the subacute/long-term setting","UMC Utrecht|ZonMw: The Netherlands Organisation for Health Research and Development|M.D. Anderson Cancer Center|The University of Texas Health Science Center at San Antonio","All","up to 10 Days   (Child)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL59265.000.16","February 11, 2020","July 27, 2021","July 27, 2021","November 29, 2017",,"October 7, 2021","Wilhelmina Childrens Hostpital/University Medical Center Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT03356821"
65,"NCT04519684","Study of Mesenchymal Stem Cells for the Treatment of Ileal Pouch Fistula's in Participants With Crohn's Disease","IPAAF","Recruiting","No Results Available","Ileal Pouch|Crohn Disease","Drug: Mesenchymal stem cells|Other: Placebo","Treatment related adverse events|Complete clinical healing|Partial healing|Lack of response|Worsening disease","Amy Lightner|The Cleveland Clinic","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20-818","October 28, 2020","October 2022","October 2022","August 20, 2020",,"April 5, 2022","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04519684"
66,"NCT03878628","Treatment With Allogeneic Adipose-derived Mesenchymal Stem Cells in Patients With Aqueous Deficient Dry Eye Disease","MESADDE","Active, not recruiting","No Results Available","Dry Eye|Kerato Conjunctivitis Sicca|Aqueous Tear Deficiency","Drug: Adipose tissue-derived mesenchymal stem cells","Pain at injection site: grade|Infection at injection site|Bleeding at injection site|Eyelid function disorder|Periorbital edema|Ocular discomfort|Flu-like symptoms|Fever|OSDI questionnaire|Schirmer's I test|Tear osmolarity|Ocular SICCA Grading Score|HLA anti-bodies","Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","001-2018","October 16, 2019","June 30, 2020","June 30, 2022","March 18, 2019",,"February 15, 2022","Rigshospitalet, Copenhagen, DK, Denmark",,"https://ClinicalTrials.gov/show/NCT03878628"
67,"NCT04476901","Transendocardial Injection of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy","DCMII","Recruiting","No Results Available","Non-ischemic Dilated Cardiomyopathy","Biological: allogeneic human mesenchymal stem cells (hMSCs)|Other: Placebo","Change in LVEF|Change in global ventricular strain|Change in left regional strain|Left ventricular function concordance|Change in LVEDVI|Change in LVESVI|Change in Maximal oxygen consumption (peak VO2)|Change in Exercise tolerance|Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) Score|Change in New York Heart Association (NYHA) Class|Percent change in flow mediated diameter|Change in EPC-CFU|Change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)|Change in cytokines|Incidence of MACE|Incidence of TE-SAEs","Joshua M Hare|United States Department of Defense|The University of Texas Health Science Center, Houston|University of Miami","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","136","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20200566|CDMRP-PR191597|20-02-134","May 7, 2021","December 2024","December 2024","July 20, 2020",,"September 29, 2022","Stanford University, Stanford, California, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|University of Louisville, Louisville, Kentucky, United States|Texas Heart Institute, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04476901"
68,"NCT04939077","Treatment of Heart Failure Using Human Umbilical Cord Mesenchymal Stem Cells(hUC-MSC)",,"Recruiting","No Results Available","Myocardial Ischemia|Ventricular Dysfunction, Left","Biological: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells","Left ventricular ejection fraction|Left ventricular end diastolic volume|Left ventricular end systolic volume|Stroke volume|Left ventricular apex four-chamber end systolic diameter|6 minutes walking distance|THE WORLD HEALTH ORGANIZATION QUALITY OF LIFE (WHOQOL) -BREF","Shanghai East Hospital","All","up to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MR-31-20-000323","November 27, 2019","July 31, 2022","November 30, 2022","June 25, 2021",,"June 25, 2021","Shanghai East Hospital, Shanghai Tongji University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04939077"
69,"NCT01448434","Allogeneic Mesenchymal Stem Cells for Osteoarthritis",,"Completed","No Results Available","Osteoarthritis of Knee Joint","Biological: Ex- vivo cultured adult allogeneic MSCs|Biological: Plasmalyte-A","Number and percentage of patients with adverse events as a measure of safety and tolerability|Change from baseline in the WOMAC OA (Western Ontario and McMaster Universities Osteoarthritis) Index -pain subscale score|Change from baseline in WOMAC OA stiffness index|Change from baseline in WOMAC OA composite index|Change from baseline in ICOAP (Intermittent and Constant Osteoarthritis Pain)|Change from baseline in radiographic (X-ray) findings of knee|Change from baseline in the WORMS score of knee using MRI|Change from baseline in arthritis pain scores on the visual analogue scale|Reduction in the intake of analgesic tablets from baseline","Stempeutics Research Pvt Ltd|Stempeutics Research Malaysia SDN BHD","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 2","72","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SRM/OA/10-11/001","September 2011","September 2013","September 2013","October 7, 2011",,"May 12, 2016","Pantai Cheras Medical Centre, Kuala Lumpur, Federal territory, Malaysia|Serdang Hospital, Kuala Lumpur, Selangor, Malaysia|KPJ Ampang Puteri Specialist Hospital, Kuala Lumpur, Selangor, Malaysia|Selayang Hospital, Kuala Lumpur, Selangor, Malaysia",,"https://ClinicalTrials.gov/show/NCT01448434"
70,"NCT02641860","Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis",,"Completed","No Results Available","Osteoarthritis","Biological: Mesenchymal progenitor cells","Safety, recording of Adverse Events and Serious Adverse Events|WOMAC Score|VAS Score|SF-36|The volume of articular cartilage|WORMS Score","Cellular Biomedicine Group Ltd.|RenJi Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","22","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CBMG-Allo-KOA-1.1","December 2015","March 2018","March 2018","December 30, 2015",,"September 13, 2018","Department of Rheumatology,Ren Ji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,China, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02641860"
71,"NCT04208646","Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis",,"Recruiting","No Results Available","Knee Osteoarthritis","Biological: Mesenchymal progenitor cells|Biological: No mesenchymal progenitor cells","WOMAC Score|MRI quantitative analysis of articular cartilage|VAS Score|SF-36|Adverse Events and Serious Adverse Events|Changes of laboratory test indexes and vital signs","Cellular Biomedicine Group Ltd.|RenJi Hospital|Shanghai 6th People's Hospital|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Second Affiliated Hospital, School of Medicine, Zhejiang University|China-Japan Friendship Hospital|Huashan Hospital|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 2","108","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CBM-ALAM.1-01","May 16, 2020","December 2021","January 2022","December 23, 2019",,"November 4, 2020","China-Japan Friendship Hospital, Beijing, China|The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, China|Huashan Hospital Affiliated to Fudan University, Shanghai, China|Shanghai General Hospital, Shanghai, China|Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai, China|Shanghai Sixth People's Hospital, Shanghai, China|Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04208646"
72,"NCT03673748","Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells","MSV_LE","Not yet recruiting","No Results Available","Lupus Nephritis|Lupus Erythematosus","Drug: Mesenchymal stromal cells (MSC)|Drug: Placebo","Frequency of severe adverse events|Evolution of Complete Renal Response defined as decrease of urine protein:creatinine ratio (UPCR; Normal value<50mg/mmol)|Change in disease activity measured by change of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K)|Change in prednisone dose measured as percent of the baseline value|Cellular markers of inflammation and autoimmunity|Serum markers of inflammation and autoimmunity","Red de Terapia Celular|Hospital del Río Hortega|Hospital Clínico Universitario de Valladolid|University of Valladolid","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","36","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TerCel_006|2017-000391-28","December 2022","December 2023","June 2024","September 17, 2018",,"June 7, 2022","University Hospital Río Hortega, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT03673748"
73,"NCT03406585","Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes",,"Completed","No Results Available","Type1 Diabetes Mellitus","Drug: ProTrans: Allogeneic transplantation with WJMSCs|Drug: Placebos","Safety; measured through set safety parameters|Efficacy; comparison of the intervention versus placebo at day 372 versus start of treatment|Number of patients insulin independent (ADA criteria) at days 187 and 372|Number of patients with daily insulin needs <0.25U/kg at days 187 and 372|Insulin requirement/kg BW at days 187 and 372|HbA1c at days 187 and 372.|Glucose variability at day 372|Delta change of levels of fasting C-peptide at day 372|Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372","NextCell Pharma Ab","All","18 Years to 40 Years   (Adult)","Phase 1|Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ProTrans-T1D|2017-002766-50","November 28, 2017","July 1, 2020","September 4, 2020","January 23, 2018",,"January 11, 2022","Karolinska Trial Alliance, Fas 1 enheten, Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03406585"
74,"NCT04328714","Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease",,"Recruiting","No Results Available","Acute Leukemia|Myelodysplastic Syndromes","Drug: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells","Number of successful preparations and deliveries of investigational product|Number of adverse events attributed to the investigational product|Maximal Tolerated Dose|Primary graft failure|Secondary graft failure|Platelet engraftment|Non-relapse mortality (NRM)|Change in Acute graft-versus-host disease (aGvHD) Incidence|Change in Chronic graft-versus-host disease (cGvHD) Incidence|Disease-free survival (DFS)|Primary cause of death|Relapse|Early discontinuation|Viral activation","Edwin Horwitz|Ossium Health, Inc.|Emory University","All","1 Year and older   (Child, Adult, Older Adult)","Phase 1","45","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00105305","December 2, 2021","August 2023","August 2023","March 31, 2020",,"July 19, 2022","Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04328714"
75,"NCT04184258","Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells",,"Completed","No Results Available","Systemic Lupus Erythematosus","Biological: Pooled mesenchymal stem cell|Other: Standard treatment according to the Clinical protocols","Efficacy evaluation|Safety eveluation","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","7","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_MSC1(SLE)","July 1, 2019","December 31, 2020","December 31, 2020","December 3, 2019",,"January 22, 2021","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04184258"
76,"NCT02104440","Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro",,"Completed","No Results Available","Cytopenia","Biological: Sequential infusion of allogeneic mesenchymal stem cells expanded ""in vitro""","Adverse effects at the time of infusion and infections after infusion of MSC|Mesenchymal cell efficiency in recovering cytopenia","Red de Terapia Celular|University of Navarrra Hospital (Clinica Universitaria)|Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán|Hospitales Universitarios Virgen del Rocío|Spanish National Health System","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","15","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSM/CIT|2013-000534-35","October 2013","March 2017","March 2017","April 4, 2014",,"March 30, 2017","University Clinical Hospital of Salamanca, Salamanca, Salamanca/Castilla León, Spain",,"https://ClinicalTrials.gov/show/NCT02104440"
77,"NCT04520022","Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB",,"Completed","No Results Available","Recessive Dystrophic Epidermolysis Bullosa","Drug: Human Umbilical Cord Blood-derived Mesenchymal Stem Cells","Adverse events related to the intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell|Change in type VII collagen and anchoring fibril expression at dermoepidermal junction|Change in Birmingham Epidermolysis Bullosa Severity Score (BEBSS)|Change in Global severity score|Change in total body surface area affected by RDEB|Change in Quality of Life in Epidermolysis Bullosa (QOLEB) questionnaire|Change in blister count|Change in pruritus visual analogue scale (VAS)|Change in pain visual analogue scale (VAS)","Gangnam Severance Hospital|Daewoong Pharmaceutical Co. LTD.","All","10 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","5","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3-2015-0285","October 13, 2016","January 10, 2020","January 10, 2020","August 20, 2020",,"August 20, 2020","GangnamSeverance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04520022"
78,"NCT05016011","Efficacy of Allogeneic UCMSCs for Treating Large Defects Knee Injury",,"Recruiting","No Results Available","Osteoarthritis, Knee","Biological: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|Procedure: Marrow cellution","Recording of Adverse Events and Serious Adverse Events|International Knee Documentation Committee (IKDC) score|Knee Injury and Osteoarthritis Outcome Score (KOOS)|Visual Analog Score (VAS)|Magnetic resonance imaging (MRI)|Immunohistochemistry (IHC)","Cytopeutics Sdn. Bhd.|Universiti Kebangsaan Malaysia Medical Centre","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","POD0032/CP/R","July 1, 2020","June 1, 2022","June 1, 2023","August 23, 2021",,"August 23, 2021","Hospital Canselor Tuanku Muhriz Universiti Kebangsaan Malaysia (HCTM-UKM), Bandar Tun Razak, Wilayah Persekutuan Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT05016011"
79,"NCT04314687","Stem Cell and Conditioned Medium for Cerebral Palsy",,"Recruiting","No Results Available","Cerebral Palsy","Biological: Umbilical Cord Mesenchymal Stem Cells|Biological: Conditioned Medium|Other: Standard Therapy","Gross Motor Function|Cognitive Function|Chemical Marker","PT. Prodia Stem Cell Indonesia","All","6 Months to 3 Years   (Child)","Phase 1|Phase 2","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","CT/CP/02/2020","October 13, 2021","September 25, 2023","December 25, 2023","March 19, 2020",,"June 14, 2022","Indonesian National Brain Center, Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04314687"
80,"NCT03265613","Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis","ADMSP","Active, not recruiting","No Results Available","Mesenchymal Stromal Cells|Psoriasis|Drug Toxicity|Drug Effect","Biological: adipose-derived multipotent mesenchymal stem cells","Incidence of adverse events (AEs) related to intervention|Incidence of serious adverse events (SAEs) related to intervention|Improvement rate of PASI(Psoriasis Area and Severity Index)|PASI(Psoriasis Area and Severity Index)|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI（Dermatology Life Quality Index）","Guangdong Provincial Hospital of Traditional Chinese Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S2017-01","September 24, 2017","August 20, 2019","December 28, 2021","August 29, 2017",,"March 1, 2021","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03265613"
81,"NCT03905824","The Effectiveness of Adding Allogenic Stem Cells After Traditional Treatment of Osteochondral Lesions of the Talus","OLT","Recruiting","No Results Available","Osteochondral Fracture of Talus","Biological: Allogenic stromal mesenchymal cells derived from the umbilical cord|Procedure: Debridement and microfracture","Change on tissue reparation quality|Change over time of general health status|Change over time of functional limitations of foot and ankle.|Change over time of functionality of musculoskeletal ankle and foot pathology|Change on declared pain|Surgical time|Complication rate|Cost-effective comparative analysis","University of Chile","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","OLT Protocol","January 15, 2019","December 31, 2020","December 31, 2024","April 5, 2019",,"April 9, 2019","Universidad de Chile Clinical Hospital, Santiago, Independencia, Chile",,"https://ClinicalTrials.gov/show/NCT03905824"
82,"NCT04995081","Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)",,"Recruiting","No Results Available","Parkinson Disease","Biological: Biological/Vaccine: Allogeneic HB-adMSCs|Other: Placebo","1. Changes in the total score MDS-UPDRS Part II.|2. Incidence of treatment-emergent Adverse Event (TEAEs).|3. Incidence of treatment-emergent Serious Adverse Events (SAEs).|4. AEs of special interest (serious or non-serious) - thromboembolic events.|5. AEs of special interest (serious or non-serious) - thromboembolism of the extremities|6. AEs of special interest (serious or non-serious) - infections|7. AEs of special interest (serious or non-serious) - hypersensitivities.|8. Laboratory value Complete Blood Count (CBC)|9. Laboratory values Chemistry Metabolic Panel (CMP)|10. Laboratory values Coagulation Panel; Prothrombin time, Partial Prothrombin time, and INtern|11. Vital signs. - Respiratory Rate (breaths per minute)|12. Vital signs. - Heart Rate (beats per minute)|13. Vital signs. - Body Temperature (Fahrenheit )|14. Vital signs. - Blood Pressure (mmHg)|15. Weight in lb.|16. Physical examination results. General|17. Physical examination results. Body Systems.|18. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale -UPDRS Part I.|19. Changes in the total score Movement Disorder Society Unified Parkinson's Disease Rating Scale -UPDRS Part II and Part III.|20. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale MDS-UPDRS Part III.|21. Changes in Movement Disorder Society Unified Parkinson's Disease Rating Scale MDS-UPDRS Part IV.|22. Changes in Short Form 36 Health Survey Questionnaire (SF-36).|23. Changes in Parkinson's disease fatigue scale (PFS-16)|24. Changes in Parkinson's disease Questionnaire (PDQ-39).|25. Changes in Visual Analog Scale for Pain.|26. Changes in Visual Analog Scale for Muscle spasms.|27. Changes in Dosage of medications taken to treat Parkinson's disease.","Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","45 Years to 80 Years   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HBPD04","July 16, 2021","July 20, 2023","July 20, 2023","August 6, 2021",,"September 22, 2022","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04995081"
83,"NCT05147675","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for OA",,"Recruiting","No Results Available","Osteoarthritis|Spinal Arthritis","Biological: AlloRx","Safety (adverse events)|Efficacy: Single Assessment Numeric Evaluation Score (SANE)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-011","December 2021","December 2025","December 2025","December 7, 2021",,"December 7, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05147675"
84,"NCT05152290","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for SCI",,"Recruiting","No Results Available","Spinal Cord Injuries","Biological: AlloRx","Safety (adverse events)|Efficacy: American Spinal Injury Association Impairment Scale (ASIA)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-012","January 2022","January 2026","January 2026","December 9, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05152290"
85,"NCT05158127","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Skin Ulcer",,"Recruiting","No Results Available","Skin Ulcer","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-2-MSC-015","January 2022","January 2026","January 2026","December 15, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05158127"
86,"NCT05147701","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Eye Diseases",,"Recruiting","No Results Available","Eye Diseases|Retinitis Pigmentosa|Glaucoma|Diabetic Retinopathy|Macular Degeneration|Traumatic Optic Neuropathy|Optic Atrophy","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-014","January 2022","January 2026","January 2026","December 7, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05147701"
87,"NCT05147766","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Heart Disease",,"Recruiting","No Results Available","Congestive Heart Failure|Angina","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-017","February 2022","February 2026","February 2026","December 7, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05147766"
88,"NCT05158933","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Ovarian Failure",,"Recruiting","No Results Available","Ovarian Failure","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-2-MSC-012","January 2022","January 2026","January 2026","December 15, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05158933"
89,"NCT05158101","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Stroke",,"Recruiting","No Results Available","Stroke","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-2-MSC-011","February 2022","February 2026","February 2026","December 15, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05158101"
90,"NCT05147688","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Pulmonary Diseases",,"Recruiting","No Results Available","Pulmonary Disease|Asthma|Chronic Obstructive Pulmonary Disease","Biological: AlloRx","Safety (adverse events)|Efficacy: Forced vital capacity (FVC)|Efficacy: Pulmonary function test","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-013","December 2021","December 2025","December 2025","December 7, 2021",,"December 7, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05147688"
91,"NCT05018858","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Lupus",,"Recruiting","No Results Available","Lupus","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-20-ATG-4","February 2022","October 2025","October 2025","August 24, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05018858"
92,"NCT05152394","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Parkinson's Disease",,"Not yet recruiting","No Results Available","Parkinson Disease","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-016","January 2022","January 2026","January 2026","December 9, 2021",,"January 28, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05152394"
93,"NCT05003960","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Autism",,"Recruiting","No Results Available","Autism","Biological: AlloRx","Safety (adverse events)|Efficacy: Autism Treatment Evaluation Checklist (ATEC)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-8-ATG-8-02","February 2022","September 2025","September 2025","August 13, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003960"
94,"NCT05018819","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CP",,"Recruiting","No Results Available","Cerebral Palsy","Biological: AlloRx","Safety (adverse events)|Efficacy: Gross Motor Function Measure (GMFM)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-11-ATG-11-02","February 2022","November 2025","November 2025","August 24, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05018819"
95,"NCT05003908","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Diabetes",,"Recruiting","No Results Available","Diabetes","Biological: AlloRx","Safety (adverse events)|Efficacy: the level of A1C|Efficacy: the level of C-Peptide|Efficacy: Insulin dose reduction","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-10-ATG-11-01","February 2022","November 2025","November 2025","August 13, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003908"
96,"NCT05003388","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS",,"Recruiting","No Results Available","Multiple Sclerosis","Biological: AlloRx","Safety (adverse events)|Efficacy: Kurtzke Expanded Disability Status Scale (EDSS)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-8-ATG-9-03","February 2022","October 2025","October 2025","August 12, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003388"
97,"NCT05003934","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for RA",,"Recruiting","No Results Available","Rheumatoid Arthritis","Biological: AlloRx","Safety (adverse events)|Efficacy: the 28-joint disease activity score (DAS 28)|Efficacy: visual analog scale (VAS)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-8-ATG-10-03","February 2022","September 2025","September 2025","August 13, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003934"
98,"NCT05152381","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Osteoporosis",,"Recruiting","No Results Available","Osteoporosis","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-018","January 2022","January 2026","January 2026","December 9, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05152381"
99,"NCT05018832","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for TBI",,"Not yet recruiting","No Results Available","Traumatic Brain Injury","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-20-ATG-12-4","December 2022","November 2025","November 2025","August 24, 2021",,"July 22, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05018832"
100,"NCT05018845","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CKD",,"Recruiting","No Results Available","Chronic Kidney Diseases","Biological: AlloRx","Safety (adverse events)|Efficacy: creatinine levels|Efficacy: changes in eGFR","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-20-ATG-22","February 2022","November 2025","November 2025","August 24, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05018845"
101,"NCT05003947","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IBD",,"Recruiting","No Results Available","Inflammatory Bowel Diseases","Biological: AlloRx","Safety (adverse events)|Efficacy: The Short Inflammatory Bowel Disease Questionnaire (SIBDQ)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-8-ATG-11-04","February 2022","October 2025","October 2025","August 13, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003947"
102,"NCT05016804","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis",,"Recruiting","No Results Available","Systemic Sclerosis","Biological: AlloRx","Safety (adverse events)|Efficacy: skin score|Efficacy: Forced vital capacity (FVC)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-10-ATG-12-04","February 2022","November 2025","November 2025","August 23, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05016804"
103,"NCT05018767","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Aging Frailty",,"Recruiting","No Results Available","Frailty","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-11-ATG-12-01","February 2022","November 2025","November 2025","August 24, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05018767"
104,"NCT05016817","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF",,"Recruiting","No Results Available","Idiopathic Pulmonary Fibrosis","Biological: AlloRx","Safety (adverse events)|Efficacy: Forced vital capacity (FVC)|Efficacy: Oxygen saturation test","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-10-ATG-13-08","February 2022","September 2025","September 2025","August 23, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05016817"
105,"NCT05003921","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for ALS",,"Recruiting","No Results Available","Amyotrophic Lateral Sclerosis","Biological: AlloRx","Safety (adverse events)|Efficacy: revised ALS functional rating scale (ALSFRS-R)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-7-ATG-7-01","February 2022","September 2025","September 2025","August 13, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003921"
106,"NCT05158114","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Testicular Injury and Oligospermia",,"Recruiting","No Results Available","Testicular Injury|Oligospermia","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-2-MSC-013","January 2022","January 2026","January 2026","December 15, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05158114"
107,"NCT04506073","Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for iPD",,"Active, not recruiting","No Results Available","Parkinson's Disease","Drug: MSC+placebo|Drug: MSC|Drug: Placebo","Safest number of effective doses of MSC as measured by the Part III of the Movement Disorder Society Unified Parkinson's disease Rating Scale (MDS-UPDRS) scale|Safety and tolerability as measured by serious adverse reactions.|Safety and tolerability as measured by immunologic responses.|Motor function as measured by the Timed-Up-and-Go (TUG) scale|Global measurement of disability as measured by the change in the screening ""Off"" modified Hoehn and Yahr (H&Y)|Quality of life as measured by the modified Schwab and England activities of daily living scale (ADL)|Quality of life as measured by the Parkinson's Disease Questionnaire 39 (PDQ-39)|Quality of life as measured by the EuroQol- 5 Dimension (EQ-5D)|Non-motor symtoms as measured by the The University of Pennsylvania Smell Identification Test (UPSIT- 40 odor test booklet).|Cognitive function as measured by the the change in Montreal Cognitive Assessment (MoCA)|Behavioral changes as measured by the Columbia Suicide Severity Rating Scale (C-SSRS)|Behavioral changes as measured by the Geriatric Depression Scale-Short Form (GDS-SF)|Behavioral changes as measured by the Parkinson Anxiety Scale (PAS)|Measurement of putative paracrine mechanism of MSCs using neuroimaging|Measurement of putative paracrine mechanism of MSCs as measured by concentration of cytokines in patient blood sample.|Measurement of putative paracrine mechanism of MSCs as measured by concentration of chemokines in patient blood sample.|Measurement of putative paracrine mechanism of MSCs as measured by concentration of growth factors|Measurement of putative paracrine mechanism of MSCs as measured by concentration of neurotransmitters|Measurement of putative paracrine mechanism of MSCs as measured by alpha-synuclein oligomers in the blood (serum or plasma)|Measurement of putative paracrine mechanism of MSCs as measured by alpha-synuclein oligomers in the cerebral spinal fluid","The University of Texas Health Science Center, Houston|Michael J. Fox Foundation for Parkinson's Research","All","50 Years to 79 Years   (Adult, Older Adult)","Phase 2","45","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HSC-MS-20-0150","November 9, 2020","July 26, 2023","December 22, 2023","August 10, 2020",,"February 10, 2022","The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04506073"
108,"NCT05042206","Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease",,"Recruiting","No Results Available","Chronic Kidney Disease Stage 3B|Chronic Kidney Disease stage4","Biological: Cellgram-CKD","Incidence of adverse event, and the level of the adverse event (AE) analyzed according to the Common Terminology Criteria for Adverse Event (CTCAE) (version 5.0)|Changes in eGFR|Changes in BUN|Changes in Creatinine","Pharmicell Co., Ltd.","All","19 Years to 79 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PMC-P-12","October 2021","April 2023","April 2023","September 13, 2021",,"October 21, 2021","Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05042206"
109,"NCT02833792","Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Dementia","Drug: Human Mesenchymal Stem Cells and Lactated Riunger's Solution|Other: Placebo","Safety of aMBMC administration|Efficacy of aMBMC administration","Stemedica Cell Technologies, Inc.|Stemedica International SA","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 2","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","STEM105-M-AD","June 2016","December 2022","June 2023","July 14, 2016",,"October 29, 2020","John Wayne Cancer Institute @ Providence St. John's Health Center, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT02833792"
110,"NCT04918706","Allogeneic MSC Treatment for Pulmonary Emphysema",,"Recruiting","No Results Available","Pulmonary Emphysema|Mesenchymal Stromal Cells","Genetic: Allogeneic MSC|Drug: Placebo","Difference in expression of CD31|The difference between MSC and placebo treatment in change in CO diffusion capacity|The differences in expression of Surfactant Protein-C expression by alveolar type II cells in lung tissue obtained from study patients treated with placebo or MSC.|The difference in immunostaining of various leukocytes in resected lung tissue, including T lymphocytes, B lymphocytes, macrophages and neutrophils obtained from study patients treated with placebo or MSC.|The difference in shear stress responses, expressed as % elongation of 100 cells, of isolated pMVECs ex vivo obtained from study patients treated with placebo or MSC.|The difference in endothelial microparticles concentration and concentration of immunological markers in blood samples from study patients treated with placebo or MSC.|The correlation between arterial pO2 or gas transfer value TLCO (measured as standard of care) and the outcome of the primary objective of the study for patients treated with MSC or placebo.","Leiden University Medical Center|Erasmus Medical Center|Amsterdam UMC, location VUmc","All","45 Years to 65 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HEP study","June 25, 2019","September 1, 2021","June 1, 2022","June 9, 2021",,"June 9, 2021","Department of Pulmonology, Leiden University Medical Center, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT04918706"
111,"NCT04385056","Evaluate Umbilical Cord-derived Allogeneic Mesenchymal Stem Cells for the Treatment of Bradykinesia",,"Recruiting","No Results Available","Bradykinesia","Biological: MSCTC-0010","Incidence of Serious Adverse Events and Adverse Events","IMAC Holdings, Inc.","All","55 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMAC-001","December 15, 2020","July 1, 2022","July 1, 2022","May 12, 2020",,"January 6, 2021","IMAC Regeneration Center, Paducah, Kentucky, United States|Ozzie Smith IMAC Regeneration Center, Chesterfield, Missouri, United States|David Price IMAC Regeneration Center, Brentwood, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04385056"
112,"NCT04336254","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients",,"Recruiting","No Results Available","COVID-19","Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Other: Intravenous saline injection (Placebo)","TTCI|Lung lesion|Immune function|Time of SARS-CoV-2 clearance|Blood test|SPO2|RR|Body temperature|Side effects in the treatment group|C-reactive protein (mg/L)","Renmin Hospital of Wuhan University|Beijing SH Bio-Tech Corporation, Beijing (CN)|Utooth Biological Technology Co., Ltd. Hubei (CN)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020K-G005|hDPSC-CoVID-2019-02-2020","May 6, 2020","November 30, 2021","December 31, 2021","April 7, 2020",,"March 10, 2021","Renmin Hospital of Wuhan University (East Campus), Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04336254"
113,"NCT02336646","Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease",,"Completed","No Results Available","Critical Limb Ischemia","Drug: Allogenic MSC|Drug: Normal saline","Adverse events|Efficacy-The Wong Baker FACES® pain rating scale|Efficacy-Transcutaneous oxygen pressure(TcPO2)|Efficacy-walking distance (TWD)|Efficacy-Ankle Brachial Pressure Index (ABPI)","Taiwan Bio Therapeutics Co., Ltd.","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2012-02-070B","May 1, 2015","April 27, 2018","December 20, 2018","January 13, 2015",,"August 25, 2021","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02336646"
114,"NCT03384433","Allogenic Mesenchymal Stem Cell Derived Exosome in Patients With Acute Ischemic Stroke",,"Recruiting","No Results Available","Cerebrovascular Disorders","Biological: exosome","Incidence of Treatment-Emergent Adverse Events|measurement of Modified Ranking Scale","Isfahan University of Medical Sciences|Tarbiat Modarres University","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","med shahid beheshti university","April 17, 2019","June 17, 2021","December 17, 2021","December 27, 2017",,"January 25, 2021","Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT03384433"
115,"NCT04361942","Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)","COVID_MSV","Completed","No Results Available","COVID-19 Pneumonia","Biological: Mesenchymal Stromal Cells|Other: Placebo","Proportion of patients who have achieved withdrawal of invasive mechanical ventilation|Rate of mortality|Proportion of patients who have achieved clinical response|Proportion of patients who have achieved radiological responses","Red de Terapia Celular|Citospin|University of Valladolid|Castilla-León Health Service|Hospital del Río Hortega|Instituto de Salud Carlos III","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","TerCel_007|2020-001682-36","May 1, 2020","October 28, 2021","October 28, 2021","April 24, 2020",,"June 7, 2022","Hospital Universitario Rio Hortega, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT04361942"
116,"NCT02594839","Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease",,"Completed","No Results Available","Idiopathic Interstitial Pneumonia|Interstitial Lung Disease|Idiopathic Pulmonary Fibrosis","Drug: Bone marrow mesenchymal stem cells|Drug: Placebo","Safety: Number of serious adverse events|DLCO changes from baseline|FVC changes from baseline|exercise capacity changes","Federal Research Clinical Center of Federal Medical & Biological Agency, Russia","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ILD-01","February 2013","January 2018","January 2018","November 3, 2015",,"January 9, 2018","Federal Research Clinical Center FMBA of Russia, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02594839"
117,"NCT01753440","Allogeneic Stem Cells Implantation Combined With Coronary Bypass Grafting in Patients With Ischemic Cardiomyopathy",,"Completed","No Results Available","Coronary Artery Disease|Ischemic Cardiomyopathy","Procedure: Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP).","iMP-related adverse events|Hypersensitivity|Scar reduction|LVEF|Change in quality of life","AHEPA University Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","11","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AHEPA_CTL_01","November 2012","September 2014","December 2014","December 20, 2012",,"May 7, 2019","AHEPA University Hospital, Thessaloniki, Greece",,"https://ClinicalTrials.gov/show/NCT01753440"
118,"NCT04535856","Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients","DW-MSC","Completed","No Results Available","Covid19|Corona Virus Infection|SAR","Drug: allogeneic mesenchymal stem cell|Other: Placebo","Incidence of TEAE* in Treatment group|Survival rate|Duration of hospitalization|Clinical improvement Ordinal scale|Clinical improvement National EWS|Clinical improvement Oxygenation index|Clinical improvement Lung involvement change|Clinical improvement Inflammation markers change","Ina-Respond|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia|Daewoong Pharmaceutical Co. LTD.","All","19 Years and older   (Adult, Older Adult)","Phase 1","9","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DW_DWP710101|U1111-1263-1723","November 14, 2020","January 14, 2021","January 14, 2021","September 2, 2020",,"January 27, 2021","Site 550: University of Hassanudin/ Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia",,"https://ClinicalTrials.gov/show/NCT04535856"
119,"NCT03798353","Pericardial Matrix With Mesenchymal Stem Cells for the Treatment of Patients With Infarcted Myocardial Tissue","PERISCOPE","Active, not recruiting","No Results Available","Myocardial Infarction","Combination Product: PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.|Procedure: Surgery by sternotomy","Rate of death or rehospitalization due to any cause and / or adverse reactions related to the procedure / product under investigation.|Death rate or rehospitalization due to cardiovascular causes|Rate of relevant arrhythmias in Holter of 24 hours|Relevant changes in N-terminal B-type natriuretic peptide (NT-proBNP) and High sensitivity troponin I (hsTnI) levels|Changes in the necrotic myocardial mass ratio|Changes of regional contractility|Changes in ejection fraction of the left ventricle|changes in left and right ventricular geometric remodeling|Changes in the score on the quality of life test Short Form 36 Healthy Survey (SF-36).|Changes in the score on the quality of life Kansas City Cardiomyopathy Questionnaire (KCCQ) test in cases of participants with heart failure will be used.","Fundació Institut Germans Trias i Pujol|Germans Trias i Pujol Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ICOR-2016-02|2018-001964-49","May 13, 2019","September 2022","September 2022","January 9, 2019",,"October 5, 2021","Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03798353"
120,"NCT04992247","Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 ""Long Haul"" Pulmonary Compromise","BR","Not yet recruiting","No Results Available","Covid19","Biological: COVI-MSC|Biological: Placebo","Change in 6-Minute Walk Distance (6MWD) at Day 60|Change in 6MWD at Day 30|Relief of symptoms on Day 30 and Day 60|Change in Pulmonary Function|Change in oxygenation|Change in biomarker levels","Sorrento Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSC-PLH-201BR","November 2022","July 2023","September 2023","August 5, 2021",,"August 8, 2022",,,"https://ClinicalTrials.gov/show/NCT04992247"
121,"NCT04905836","Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress",,"Recruiting","No Results Available","Covid19","Biological: COVI-MSC|Drug: Placebo","All-cause mortality rate at Day 28|Incidence of all adverse events (AEs) (safety)|Incidence of treatment-emergent adverse events (safety)|Incidence of severe adverse events (safety)|Incidence of infusion-related adverse events (safety)|All-cause mortality rate at Day 60 and 90|Number of ventilator-free days through Day 28|Number of ICU days through Day 28|Change in clinical status|Change in oxygenation","Sorrento Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSC-COV-202","November 16, 2021","December 2022","March 2023","May 28, 2021",,"April 11, 2022","Teradan Clinical Trials LLC, Brandon, Florida, United States|Sarasota Memorial Health Care System (SMH), Sarasota, Florida, United States|St Luke's Research, Boise, Idaho, United States|St. Luke's Boise, Boise, Idaho, United States|Ascension St. John, Tulsa, Oklahoma, United States|PRX Research/Dallas Regional Medical Center, Mesquite, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04905836"
122,"NCT02384499","Treatment of Fecal Incontinence Using Allogenic-Adipose-derived Mesenchymal Stem Cells: A Prospective, Dose Escalation, Randomized, Placebo-controlled, Parallel-group, Single-blind, Single-center Pilot Study",,"Completed","No Results Available","Fecal Incontinence","Biological: ALLO-ASC injection|Drug: Placebo","Clinically measured abnormality of laboratory tests and adverse events|Satisfaction as measured by Wexner Score","Yonsei University","All","19 Years and older   (Adult, Older Adult)","Phase 1","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","3-2014-0271","December 2014","June 30, 2017","June 30, 2017","March 10, 2015",,"August 13, 2018","Section of Colon and Rectal Surger, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02384499"
123,"NCT04780685","A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19",,"Recruiting","No Results Available","Covid19","Biological: hMSC","Survival|Number of patients with treatment-related adverse events as assessed by CTCAE v4.0","Stemedica Cell Technologies, Inc.|bioRASI, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STEM-107-COVID-19","March 20, 2021","September 30, 2022","December 31, 2022","March 3, 2021",,"July 8, 2022","Providence Medical Foundation, Fullerton, California, United States|Providence Saint John's Health Center - Saint John's Cancer Institute, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT04780685"
124,"NCT03818854","Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome","STAT","Recruiting","No Results Available","Respiratory Distress Syndrome, Adult","Biological: Human Mesenchymal Stromal Cells|Biological: Cell Reconstitution Media","Change in oxygenation index (OI)|Acute Lung Injury Score (LIS)|Pulmonary Dead Space Fraction|Chest radiograph assessment of pulmonary edema (RALE score)|Ventilator free-days|Duration of assisted ventilation over 28 days|Percentage of patients achieving pressure support ventilation for 2 hours|Occurrence of Infection|Sequential Organ Failure Assessment (SOFA) over 7 days|All-cause hospital mortality|Glasgow Outcome Score (GCS)|Percentage of patients occurred any thromboembolic events|Plasma angiopoietin-2|Plasma Receptor for Advanced Glycation Endproducts (RAGE)|Plasma interleukin-6|Plasma interleukin-8|Plasma Soluble tumor necrosis factor 1 (sTNF-1)|Plasma protein C|Plasma lipoxin A4|Plasma Resolvin D1|Plasma angiopoietin-1|Plasma keratinocyte growth factor (KGF)|Urine microalbumin|Total protein in min-bronchoalveolar lavage (mBAL)|Tolerability of the hMSCs - incidence of pre-specified infusion-associated events and unexpected severe adverse events","Michael A. Matthay|United States Department of Defense|Harborview Injury Prevention and Research Center|Oregon Health and Science University|Vanderbilt University Medical Center|The University of Texas Health Science Center, Houston|University of Minnesota|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UCSF-hMSC-ARDS-P1P2-12","November 26, 2019","July 1, 2023","July 1, 2024","January 28, 2019",,"September 14, 2022","University of California Davis Medical Center, Sacramento, California, United States|Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California, United States|University of California San Francisco, San Francisco, California, United States|Oregon Health & Science University, Portland, Oregon, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Memorial Hermann Hospital - Texas Medical Center, Houston, Texas, United States|Harborview Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03818854"
125,"NCT03174587","Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis",,"Completed","No Results Available","Lupus Nephritis","Biological: allogenic bone marrow derived mesenchymal stem cells","Safety assessment(evaluation)","Corestem, Inc.|Hanyang University","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 1","7","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CS20AT04-LN101","May 30, 2017","March 12, 2019","August 19, 2019","June 2, 2017",,"November 20, 2019","Hanyang university hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03174587"
126,"NCT00721045","A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure",,"Completed","No Results Available","Heart Failure","Biological: Mesenchymal Precursor Cells (MPCs)|Procedure: standard-of-care treatment with mock mapping and injection procedures.","The primary objective of this study is to evaluate the feasibility and safety of transendocardial injection using mapping Catheter with the Left Ventricular Injection Catheter of 25 M, 75 M, and 150 M allogeneic MPCs in subjects with heart failure.|The secondary objectives are to explore functional efficacy for subsequent study design.","Mesoblast, Ltd.","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HF-AB002","August 2008","June 2011","July 2013","July 23, 2008",,"March 11, 2020","Mercy Gilbert Medical Center, Gilbert, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Minneapolis Heart Institute 920 East 28th St, Suite 300, Minneapolis, Minnesota, United States|UPMC, Pittsburgh, Pennsylvania, United States|Texas Heart Institue, Houston, Texas, United States|Swedish Heart and Vascular Institute, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00721045"
127,"NCT04889963","Regeneration of Posterior Cruciate Ligament Injury Using Hypoxic Conditioned Allogenic Adipose Mesenchymal Stem Cell and Condition Medium",,"Recruiting","No Results Available","Adypose Mesenchimal Stem Cell|Ligament Rupture|Ligament Derived Conditined Medium","Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium","tensile strength of posterior cruciate ligament|Thrombosite of Growth Factor - beta 1|basic fibroblast of growth factor","Gadjah Mada University","Male","2 Months to 12 Months   (Child)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","STEMCELL-LIGAMENTREGENERATION","January 1, 2021","June 30, 2021","June 30, 2021","May 17, 2021",,"May 17, 2021","Sholahuddin Rhatomy, Sleman, Yogyakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04889963"
128,"NCT04835883","Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients",,"Recruiting","No Results Available","Systemic Lupus Erythematosus","Biological: CS20AT04 (allogenic bone marrow derived mesenchymal stem cell)","Reduction of corticosteroid dose to ≤ 7.5 mg/day of prednisone or equivalent|Hematologic improvement without ongoing SLE treatment|Renal response improvement|Proportion of subjects who achieve a prednisone dose of ≤ 7.5mg/day or equivalent|Proportion of subjects achieving Low Level Disease Activity State|Proportion of subjects with ≥ 4 point reduction from baseline in Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score|Proportion of subjects with baseline Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) ≥ 4 having SLE responder index 4 (SRI5)|Proportion of subjects with baseline Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) ≥ 5 having SLE responder index 5 (SRI5)|Proportion of subjects with baseline Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) ≥ 6 having SLE responder index 6 (SRI6)|Time to first severe modified SLE Flare Index (SFI) flare|Change from baseline of hematologic parameters|Time to first hematologic flare|Change in baseline of renal function parameters|Time to event for each of the individual components of treatment failure|Time to complete remission|Time to first renal flare","Hanyang University Seoul Hospital|Corestem, Inc.|Ministry of Health & Welfare, Korea","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CS20AT04-SLE101","September 26, 2019","November 5, 2021","January 20, 2026","April 8, 2021",,"April 8, 2021","Hanyang University Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04835883"
129,"NCT04497805","Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers",,"Recruiting","No Results Available","Diabetic Foot Ulcer","Biological: ALLO-ASC-SHEET","Proportions of subjects who achieved complete wound closure.|Time to initial complete wound closure between the 2 groups.|Changes in wound size compared to baseline between the 2 groups.|Proportions of subjects who achieved complete wound closure between the 2 groups by the classification of wound size.|Proportions of subjects who achieved complete wound closure between the 2 groups by the classification of location of diabetic foot ulcer.|Durability of complete wound closure for the additional 24 weeks.","Anterogen Co., Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALLO-ASC-SHEET","August 1, 2020","June 2022","December 2022","August 4, 2020",,"January 22, 2021","University of Southern California, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04497805"
130,"NCT05521672","Clinical Trial to Evaluate if the Laparoscopic Administration of Cells Derived From the Fatty Tissue Can Improve the Inflammatory Stenosis in Patient With Crohn's Disease","MEIC","Not yet recruiting","No Results Available","Stenosis; Bowel|Crohn Disease","Drug: Adipose derived allogenic mesenchymal stem cells (adAMSC)","Percentage of complications|Change from baseline length and diameter of the stenosis|Crohn's disease activity index (CDAI) questionnaire score|inflammatory bowel disease questionnaire (IBDQ32 )|patients with an obstructive episode who required resection surgery","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Effice Servicios Para la Investigacion S.L.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FJD-MEIC-21-01|2021-006068-26","September 2022","June 1, 2025","June 1, 2025","August 30, 2022",,"August 30, 2022","Hospital Universitario Valle de Hebrón, Barcelona, Spain|Hospital Universitario Fundación Jiménez Diaz, Madrid, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT05521672"
131,"NCT05553132","A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects",,"Recruiting","No Results Available","Cartilage Defect","Combination Product: Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier","Incidence of Adverse Events|Incidence of serious adverse events (SAEs)|Change in pain|Change in physical function|Change in hip function","Daniel B. F. Saris|Mayo Clinic","All","18 Years to 50 Years   (Adult)","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","22-004639","October 2022","December 2023","December 2025","September 23, 2022",,"September 23, 2022","Mayo Clinic Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05553132"
132,"NCT04348435","A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19",,"Completed","No Results Available","COVID-19","Biological: HB-adMSCs|Other: Placebos","Incidence of hospitalization for COVID-19|Incidence of symptoms associated with COVID-19|Absence of upper/lower respiratory infection|Leukocyte differential|C Reactive protein|TNF alpha|IL-6|IL-10|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|white blood cells|red blood cells|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|SF-36|PHQ-9","Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","Child, Adult, Older Adult","Phase 2","55","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HBCOV02","May 14, 2020","July 9, 2021","July 30, 2021","April 16, 2020",,"August 20, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04348435"
133,"NCT03589287","Allogeneic Bone Marrow MSC Therapy for Knee Osteoarthritis",,"Completed","No Results Available","Knee Osteoarthritis","Biological: Chondrochymal®","Number of participants with adverse events as measure of safety and tolerability|Efficacy - Radiographic evidence|Efficacy - WOMAC assessment|Efficacy - Visual Analogue Scale(VAS) assessment|Efficacy - Lequesne Index assessment|Efficacy - Keen Society Score(KSS) assessment|Efficacy - QOL assessment","Taipei Veterans General Hospital, Taiwan|Virginia Contract Research Organization Co., Ltd.","All","40 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-11-006C","May 2, 2018","May 3, 2019","April 30, 2020","July 17, 2018",,"August 19, 2021","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03589287"
134,"NCT04869397","Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells","ProTrans19+","Recruiting","No Results Available","Covid19","Biological: Allogeneic Wharton's jelly-MSCs (WJ-MSC)|Other: Placebo","Composite endpoint|Clinical status evaluation assessed by the 9-point ordinal scale|Survival|Time to clinical improvement assessed by the 9-point ordinal scale|Duration of hospitalization and ICU stay","McGill University Health Centre/Research Institute of the McGill University Health Centre","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2021-6954","June 14, 2021","June 30, 2022","July 30, 2022","May 3, 2021",,"June 15, 2021","McGill University Health Centre, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04869397"
135,"NCT03865394","Treatment of Chronic Wounds in Diabetic Foot Syndrome With Allogeneic Adipose Derived Mesenchymal Stem Cells","1ABC","Completed","No Results Available","Diabetic Foot Ulcer","Biological: Application of allogeneic ADSC stem cells in fibrin gel|Procedure: Standard care in diabetic foot ulcer","Changes in wound size|Changes in wound morphology|Changes in pro-angiogenic factors expression|Changes in wound-associated pain|Changes in the quality of life|Record of adverse events","Medical University of Warsaw|Polish Stem Cells Bank S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","46","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1ABC Therapy|267976/13/NCBR/2015|2016-004109-15|PL008125|Z4217","July 1, 2019","March 31, 2021","September 30, 2021","March 6, 2019",,"October 14, 2021","Medical University of Warsaw, Department of Diabetology and Internal Diseases, Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT03865394"
136,"NCT03473301","A Study of UCB and MSCs in Children With CP: ACCeNT-CP","ACCeNT-CP","Completed","Has Results","Cerebral Palsy","Biological: Infusion of allogeneic umbilical cord blood|Biological: Infusion of MSCs","Change in Gross Motor Function Measure (GMFM-66) in Excess of Expected Change|Number of Adverse Events","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University","All","24 Months to 60 Months   (Child)","Phase 1|Phase 2","91","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Pro00089362","April 10, 2018","February 26, 2020","May 31, 2021","March 22, 2018","February 17, 2021","August 19, 2021","Duke University Medical Center, Durham, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03473301/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03473301"
137,"NCT02509156","Stem Cell Injection in Cancer Survivors","SENECA","Completed","Has Results","Cardiomyopathy Due to Anthracyclines","Biological: Allo-MSCs|Biological: Placebo","Proportion of Major Adverse Cardiac Events (MACE)|Proportion of Other Significant Clinical Events|Subjects With Events Precluding Their Receipt of Product|Subjects Who Receive Less Than 20 Injections During SPI|Subjects Who Did Not Receive the Study Product (Either 100 Million Cells or Placebo)|Subjects Who Have at Least One Cardiac MRI Endpoint Measure That is Uninterpretable|Subjects Who Fail to Complete Follow-up|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)-Trajectory|Change From Baseline in Global Strain (HARP MRI)|Change From Baseline in Global Strain (HARP MRI)-Trajectory|Change From Baseline in Regional Strain (HARP MRI)|Change From Baseline in Regional Strain (HARP MRI)-Trajectory|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)-Trajectory|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)-Trajectory|Change From Baseline in Left Ventricular Sphericity Index|Change From Baseline in Left Ventricular Sphericity Index-Trajectory|Change From Baseline in Area of Injury|Change From Baseline in Area of Injury-Trajectory|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)-Trajectory|Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score|Change From Baseline in Minnesota Living With Heart Failure Questionnaire Score-Trajectory|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)-Trajectory|Cumulative Days Alive and Out of Hospital for Heart Failure","The University of Texas Health Science Center, Houston|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 1","46","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC-SPH-15-0443|5UM1HL087318","August 2016","November 2019","April 20, 2020","July 27, 2015","November 5, 2020","November 5, 2020","Stanford University School of Medicine, Stanford, California, United States|University of Florida-Department of Medicine, Gainesville, Florida, United States|University of Miami-Interdiciplinary Stem Cell Institute, Miami, Florida, United States|Indiana Center for Vascular Biology and Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|Texas Heart Institute, Houston, Texas, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02509156/ICF_001.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02509156/Prot_SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02509156"
138,"NCT05132972","Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients","UCMSC","Recruiting","No Results Available","Covid 19","Biological: Normoxic Allogenic UCMSC|Other: Normal saline solution","Duration of hospital stay|Post-administration clinical and radiological improvement|Adverse Event and Serious Adverse Event Evaluation","Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia|Dr. Moewardi General Hospital, Surakarta, Indonesia|Dr. Sardjito General Hospital, Yogyakarta, Indonesia|Dr. Hasan Sadikin General Hospital, Bandung, Indonesia|PT Bifarma Adiluhung","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","42","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BRIN20211118a","January 17, 2021","November 2021","November 2021","November 24, 2021",,"November 24, 2021","Dr. Moewardi General Hospital, Surakarta, Central Java, Indonesia|Dr. Hasan Sadikin, Bandung, West Java, Indonesia|Dr. Sardjito General Hospital, Yogyakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT05132972"
139,"NCT00186914","Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation",,"Completed","No Results Available","Osteodysplasia","Biological: Marrow stromal cell infusion","To evaluate the safety of the stromal cell infusion","St. Jude Children's Research Hospital|Drexel University|Wayne State University","All","Child, Adult, Older Adult","Phase 1","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STOD","July 1999","November 2001","January 2008","September 16, 2005",,"March 4, 2015","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00186914"
140,"NCT03967275","Subconjunctival Injection of Allogeneic Mesenchymal Stem Cells in Severe Ocular Chemical Burn","SYMBOLpreclini","Completed","No Results Available","Bone Marrow Donor","Other: bone marrow harvest","The number of donors needed to obtain 3 BM harvest.","Fondation Ophtalmologique Adolphe de Rothschild","All","18 Years and older   (Adult, Older Adult)",,"7","Other","Observational","Observational Model: Other|Time Perspective: Prospective","EGN_2018_11","September 9, 2020","June 1, 2022","June 1, 2022","May 30, 2019",,"July 5, 2022","Saint Louis Hospital, APHP, Paris, France",,"https://ClinicalTrials.gov/show/NCT03967275"
141,"NCT05333029","Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD",,"Not yet recruiting","No Results Available","Graft Versus Host Disease","Biological: Allogeneic mesenchymal stromal cells (MSCs)|Biological: Extracorporeal photopheresis (ECP)","Percent of participants with response to therapy|aGVHD severity per Blood and Marrow Transplant Clinical Trials Network Manual of Operations (BMT MOP).|aGVHD incidence|Safety as measured by number of adverse events attributed to MSC and ECP therapy|Safety as measured by severity of adverse events attributed to MSC and ECP therapy|Number of participants with non-relapse mortality (NRM)|Number of participants with relapse-related mortality|Average time to relapse|Chronic GVHD incidence|Overall Survival (OS)|Steroid dose decrease|Steroid discontinuation rate|Change in FACT-BMT (Functional Assesment of Cancer Therapy-Bone Marrow Transplant) survey score|Percent regulatory T cells (% Tregs)|CD4:CD8 ratio","Molly Gallogly|Case Comprehensive Cancer Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE1Z20","October 2022","June 2023","December 2023","April 18, 2022",,"July 26, 2022","University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05333029"
142,"NCT02192749","Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism",,"Completed","No Results Available","Autism","Biological: Umbilical cord mesenchymal stem cells","Number of participants with adverse events|Number of participants with a change in disability as measured by the Autism Treatment Evaluation Checklist (ATEC)|Number of participants with a change in disability as measured by the Childhood Autism Rating Scale (CARS)|Change from baseline macrophage-derived chemokine (MDC)|Change from baseline thymus and activation-regulated chemokine (TARC)","Translational Biosciences","All","6 Years to 16 Years   (Child)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TBS-UCMSC-ASD001","July 2014","August 2017","August 2017","July 17, 2014",,"October 13, 2017","Stem Cell Institute, Panama City, Panama",,"https://ClinicalTrials.gov/show/NCT02192749"
143,"NCT04785027","Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis",,"Recruiting","No Results Available","Traditional Chinese Medicine|Drug Effect|Drug Safety|Psoriasis|Mesenchymal Stromal Cells","Drug: PSORI-CM01 formula|Drug: Gu Ben Hua Yu formula|Biological: adipose-derived multipotent mesenchymal stem cells","PASI score improvement rate|PASI (Psoriasis Area and Severity Index)|Relapse rate in treatment period / follow-up period|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI (Dermatology Life Quality Index)","Guangdong Provincial Hospital of Traditional Chinese Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S2020-01-01","March 17, 2021","September 30, 2022","September 30, 2022","March 5, 2021",,"May 25, 2021","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04785027"
144,"NCT02619877","Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers",,"Completed","No Results Available","Diabetic Foot Ulcer","Biological: ALLO-ASC-DFU|Other: Standard therapy","Proportion of re-epithelialization|Time to re-epithelialization|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Anterogen Co., Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ALLO-ASC-DFU-201","October 2015","September 2016","October 2016","December 2, 2015",,"September 1, 2017","Korea University Guro Hospital, Guro-gu, Seoul, Korea, Republic of|Eulji General Hospital, Nowon-Gu, Seoul, Korea, Republic of|Severance Hospital, Seodaemun-Gu, Seoul, Korea, Republic of|Asan medical center, Songpa-Gu, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02619877"
145,"NCT02619851","A Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury Subjects",,"Active, not recruiting","No Results Available","Burn Injury","Biological: ALLO-ASC-DFU|Device: Conventional Therapy","Time of re-epithelialization|Safety (laboratory tests and adverse events)|Burn Scar Index|healing status of the wound evidenced by photography","Anterogen Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALLO-ASC-BI-201","December 2015","December 2022","June 2023","December 2, 2015",,"July 21, 2021","Hallym university Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02619851"
146,"NCT04340609","Stem Cell in Acute Myocardial Infarction","AMI","Completed","No Results Available","Acute Myocardial Infarction","Biological: Mesenchymal Stem Cells","Major adverse cardiac events (MACE) endpoints of mortality|Re-infarction|Target vessel revascularization (TVR)|Heart failure hospitalization|Cardiac MRI|Echocardiography|Electrocardiography (ECG)|Wellness Parameter|Laboratory Assessment","PT. Prodia Stem Cell Indonesia","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","4","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT/AMI/01/2019","March 11, 2019","April 8, 2021","April 8, 2022","April 9, 2020",,"June 14, 2022","PT Prodia StemCell Indonesia, Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04340609"
147,"NCT02408432","Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines",,"Completed","No Results Available","Cardiomyopathy|Heart Failure","Other: Laboratory Biomarker Analysis|Other: Standard of Care|Drug: Mesenchymal Stem Cell Transplantation","Incidence of adverse events of intravenous injection of human mesenchymal stem cells (hMSCs) in patients with recent onset left ventricular systolic dysfunction from anthracyclines|Change in improvement in left ventricular systolic function by 7 points|Development of acute heart failure decompensation|Emergency center visits for heart failure|Need for new pacemaker/automatic implantable cardioverter defibrillator|New onset arrhythmias|Sudden cardiac death|Acute pulmonary edema|Asymptomatic decrease in left ventricular ejection fraction (LVEF) of > 10%|Heart failure admission|Progression free survival","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","7","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-0519|NCI-2015-00969","January 11, 2016","December 8, 2021","December 8, 2021","April 3, 2015",,"May 17, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02408432"
148,"NCT03529877","Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa",,"Active, not recruiting","No Results Available","Recessive Dystrophic Epidermolysis Bullosa","Biological: allo-APZ2-EB","Overall improvement of EB symptoms after 12 weeks (measured by percentage change of a patient's EBDASI score), score), or last available post-baseline measurement if the Week 12 measurement is missing|Assessment of adverse event (AE) occurrence|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB), or last available post-baseline measurement if the Week 12 measurement is missing|Overall improvement of EB symptoms after 12 weeks (measured by percentage change of patient's iscorEB)|Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms at Day 17 (measured by percentage change of a patient's iscorEB)|Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's EBDASI score)|Overall improvement of EB symptoms at Day 35 (measured by percentage change of a patient's iscorEB)|Inflammation (measured by panel of inflammation markers)|Pain assessment as per NRS|Itch assessment as per NRS|Differences in patient's quality of life in EB|Physical examination until Week 12;|Vital signs: Body temperature until Week 12;|Vital signs: Blood pressure until Week 12;|Vital signs: Heart rate until Week 12;|Overall survival at month 24","RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Granzer Regulatory Consulting & Services|Ticeba GmbH","All","0 Years to 55 Years   (Child, Adult)","Phase 1|Phase 2","16","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","allo-APZ2-EB-II-01","January 16, 2019","December 2021","December 2021","May 18, 2018",,"October 14, 2020","University of Minnesota, Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States|EB-Haus Austria; Salzburger Landeskliniken (SALK); Paracelsus Medizinische Privatuniversität Salzburg (PMU), Salzburg, Austria|Hôpital Saint-Louis; Département de dermatologie, Paris, France|Department of Dermatology, Medical Center-University of Freiburg, Freiburg, Germany|King's College London; St John's Institute of Dermatology;, London, United Kingdom|Great Ormond Street Hospital; Dermatology Department, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03529877"
149,"NCT02290041","Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response",,"Completed","No Results Available","Discordant Immunological Response in HIV Infected Subjects","Drug: Infusion of MSC|Drug: Infusion of placebo","Incidence of adverse reactions|Incidence of opportunist diseases|Changes in CD4+ cell count and CD4+/CD8+ ratio|T CD4 +/µl count evolution and CD4 +/CD8 + ratio throughout 48 weeks","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","5","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CeTMAd-VIH-2014","February 8, 2017","July 30, 2019","July 30, 2019","November 13, 2014",,"March 4, 2020","Virgen del Rocío University Hospital, Seville, Spain",,"https://ClinicalTrials.gov/show/NCT02290041"
150,"NCT04289194","Clinical Study to Assess the Safety and Preliminary Efficacy of HCR040 in Acute Respiratory Distress Syndrome",,"Recruiting","No Results Available","Acute Respiratory Distress Syndrome","Drug: HCR040 (Phase 1)|Drug: Placebo (Phase 2)|Drug: HCR040 (Phase 2)","Number of adverse events as a measure of safety and tolerability of a single dose of HCR040 when administered by intravenous injection|Average stay in the Intensive Care Unit (ICU) 28 days after the administration of HCR040|Sequential Organ Failure Assessment (SOFA) index at 3, 7, 14, 21, and 28 days after the administration of HCR040|Mechanical ventilation-free days 28 days after the administration of HCR040|Percent mortality 28 days after the administration of HCR040|Daily pulmonary mechanics values (Ppl, DP, CRS)|Determination of lung damage using the Murray scale at day 3, 7, 14 and 28 after the administration of HCR040|Vasopressor-free days 28 days after the administration of HCR040|ICU-free days 28 days after the administration of HCR040","Histocell, S.L.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALICELL-CT-01|2019-002688-89","December 10, 2019","August 15, 2021","April 16, 2022","February 28, 2020",,"May 14, 2021","Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain|Fundación Jiménez Díaz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04289194"
151,"NCT01144962","Dose-escalating Therapeutic Study of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With Refractory Perianal Crohn's Disease",,"Completed","No Results Available","Crohn's Disease|Fistula","Procedure: Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.|Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.","Safety and efficacy (fistula closure)|Clinical scores|Endoscopic scores|Quality of life|C-reactive protein (CRP)|Safety","Leiden University Medical Center|DigestScience","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","21","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P10.102","June 2010","September 2014","December 2014","June 16, 2010",,"December 30, 2014","Leiden University Medical Center (LUMC), Leiden, Zuid Holland, Netherlands",,"https://ClinicalTrials.gov/show/NCT01144962"
152,"NCT03449082","Treatment of Intractable Common Extensor Tendon Injury Using Mesenchymal Stem Cells (Allo-ASC)",,"Active, not recruiting","No Results Available","Lateral Epicondylitis","Biological: High concentration of Allo-ASC|Biological: Low concentration of Allo-ASC|Drug: Fibrin glue|Drug: Normal saline","Change of pain visual analogue scale (VAS) during activity|Change of pain visual analogue scale (VAS) at rest|Change of Mayo elbow performance index (MEPI)|Ultrasonographic assessment|Shear wave elastography|Magnetic resonance image (MRI) assessment","Seoul National University Hospital|Korea Health Industry Development Institute","All","19 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SNUH-RM-SGChung-ASC-02","May 4, 2018","April 3, 2019","December 30, 2021","February 28, 2018",,"March 26, 2021","Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03449082"
153,"NCT02230514","Mesenchymal Stromal Cells for the Treatment of Non-union Fractures of Long Bones",,"Completed","No Results Available","Atrophic Nonunion of Fracture","Drug: XCEL-MT-OSTEO-ALPHA|Other: autologous iliac crest|Procedure: Surgery","Efficacy assessment of XCEL-MT-OSTEO-ALPHA in non-union fractures by imaging procedures|Safety assessment of XCEL-MT-OSTEO-ALPHA in non-union fractures|Efficacy assessment by quality of life test","Banc de Sang i Teixits|Hospital ASEPEYO Sant Cugat","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","XCEL-PSART-01|2013-005025-23","November 20, 2014","March 5, 2019","December 20, 2019","September 3, 2014",,"April 12, 2021","Hospital ASEPEYO Sant Cugat, Sant Cugat, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02230514"
154,"NCT03326505","Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment",,"Completed","No Results Available","Multiple Sclerosis","Biological: Umbilical cord derived Mesenchymal Stem Cells|Other: Supervised physical therapy","Isolation and Expansion of Mesenchymal Stem Cells|Safety and Efficacy Assessment Pre and Post Treatment|Motor Functions Assessments|Measuring Non-motor outcomes to assess treatment efficacy.|Biological Assessments","University of Jordan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","ALLOMSUJCTC","September 25, 2017","January 25, 2020","February 20, 2020","October 31, 2017",,"March 4, 2020","Cell Therapy Center, University of Jordan, Amman, Jordan|Cell Therapy Center, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT03326505"
155,"NCT05126563","Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome","HBPCOVID02","Recruiting","No Results Available","Post COVID-19 Syndrome","Biological: HB-adMSCs (allogeneic)|Other: Placebo","Changes in Visual Analog Scale of Neurological Symptoms. - Extreme fatigue|Changes in Visual Analog Scale of Neurological Symptoms. - Brain fog|Changes in Visual Analog Scale of Neurological Symptoms. - Headache|Changes in Visual Analog Scale of Neurological Symptoms. - Sleep disturbances|Changes in Visual Analog Scale of Neurological Symptoms. - Loss of taste|Changes in Visual Analog Scale of Neurological Symptoms. - Loss of smell|Incidence of treatment-emergent Adverse Event (TEAEs).|Incidence of treatment-emergent Serious Adverse Events (SAEs).|AEs of special interest (serious or non-serious) - thromboembolic events.|AEs of special interest (serious or non-serious) - thromboembolism of the extremities.|AEs of special interest (serious or non-serious) - infections.|AEs of special interest (serious or non-serious) - hypersensitivities.|Changes in Laboratory values. - CBC.|Changes in Laboratory values. - CMP.|Changes in Laboratory values. - Coagulation Panel.|Changes in Vital Signs. - Respiratory Rate (breaths per minute)|Changes in Vital Signs. - Heart Rate (beats per minute)|Changes in Vital Signs. - Body Temperature (Fahrenheit )|Changes in Vital Signs. - Blood Pressure (mmHg)|Changes in Weight in lb.|Changes in Physical examination results. - General|Changes in Physical examination results. - Body Systems|Changes in Subject's energy - Fatigue Assessment form.|Changes in Visual Analog Scale of non -Neurological Symptoms. - Dyspnea a rest|Changes in Visual Analog Scale of non -Neurological Symptoms. - Dyspnea with activity|Changes in Visual Analog Scale of non -Neurological Symptoms. - Cough|Changes in Visual Analog Scale of non -Neurological Symptoms. - Body aches|Changes in Visual Analog Scale of non -Neurological Symptoms. - Joint pain|Changes in Subject's quality of life - Short Form 36 Health Survey Questionnaire|Changes in Subject's level of depression - PHQ 9 scale.","Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HBPCOVID02","January 6, 2022","December 20, 2023","December 20, 2025","November 19, 2021",,"February 3, 2022","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05126563"
156,"NCT05152368","Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Trigeminal Neuralgia and Peripheral Neuropathy",,"Recruiting","No Results Available","Peripheral Neuropathy|Trigeminal Neuralgia","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-019","January 2022","January 2026","January 2026","December 9, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05152368"
157,"NCT05147779","Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis",,"Recruiting","No Results Available","Erectile Dysfunction|Peyronie's Disease|Interstitial Cystitis","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-015","December 2021","December 2025","December 2025","December 7, 2021",,"December 7, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05147779"
158,"NCT05464381","Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)",,"Not yet recruiting","No Results Available","Epidermolysis Bullosa","Drug: allo-APZ2-OTS|Drug: Placebo","Proportion of subjects with complete target wound closure","RHEACELL GmbH & Co. KG","All","Child, Adult, Older Adult","Phase 3","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","allo-APZ2-EB-III","December 2022","December 2024","December 2025","July 19, 2022",,"July 19, 2022",,,"https://ClinicalTrials.gov/show/NCT05464381"
159,"NCT04280003","Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells in Ischemic Stroke","AMASCIS-02","Recruiting","No Results Available","Ischemic Stroke|Adipose Tissue-derived Stem Cell|Functional Status","Other: Alogenic adipose tissue-derived stem cells|Drug: Placebo solution","Safety of administration of adipose tissue-derived mesenchymal stem cells measured as reported adverse events|Safety of administration of adipose tissue-derived mesenchymal stem cells measured as neurological o systemic complications|Efficacy of administration of adipose tissue-derived mesenchymal stem cells measured by the Modified Rankin Scale|Efficacy of administration of adipose tissue-derived mesenchymal stem cells measured by the NIHSS|Efficacy of administration of adipose tissue-derived mesenchymal stem cells measuring blood brain repair biomarkers","Instituto de Investigación Hospital Universitario La Paz","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AMASCIS - 02","January 20, 2021","July 15, 2023","July 15, 2023","February 21, 2020",,"June 14, 2022","Hospital Universitario La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04280003"
160,"NCT04236479","Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)",,"Recruiting","No Results Available","Congenital Heart Disease (CHD)","Biological: BM-MSC","Number of subjects who experience serious adverse events, adverse events, and/or early treatment discontinuations.|Actual magnitude of differences in neuroimaging and neurodevelopmental variables will be measured after MSC delivery.","Catherine Bollard|Children's National Research Institute","All","up to 6 Months   (Child)","Phase 1","36","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00011914","July 29, 2020","September 2024","April 2025","January 22, 2020",,"May 13, 2022","Children's National Health System, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT04236479"
161,"NCT01781390","Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction","AMICI","Completed","Has Results","Acute Myocardial Infarction","Other: Placebo|Biological: Mesenchymal Precursor Cells (MPC) 12.5 M|Biological: Mesenchymal Precursor Cells (MPC) 25 M","Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","Mesoblast, Inc.|Mesoblast, Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","106","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ANG.AMI-IC001|2010-020497-41","March 11, 2013","April 6, 2021","April 6, 2021","February 1, 2013","January 18, 2022","June 23, 2022",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT01781390/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01781390"
162,"NCT01552707","Safety Study of Mesenchymal Stem Cells and Spinal Fusion",,"Completed","No Results Available","Lumbar Spondylolisthesis Involving L4-L5, and/or|Degenerative Discopathy Involving L4-L5","Biological: XCEL-MT-OSTEO-ALPHA|Procedure: Standard treatment","safety of XCEL-MT-OSTEO-ALPHA (tissue engineering product composed by ""ex-vivo"" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)|Feasibility of XCEL-MT-OSTEO-ALPHA (composed by ""ex-vivo"" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)|Efficacy spinal fusion by imaging procedures (X-Ray).|Efficacy spinal fusion by imaging procedures (computerized helicoidal tomography)|Clinical outcomes (VAS)|Clinical outcomes (SF-36)|Clinical outcome (Oswestry Disability Index)","Banc de Sang i Teixits|TFS Trial Form Support|Ministerio de Sanidad, Servicios Sociales e Igualdad|Ministerio de Ciencia e Innovación, Spain","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","69","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XCEL-MT-10-02","July 19, 2012","May 3, 2018","October 21, 2019","March 13, 2012",,"January 21, 2020","Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Parc de Salut Mar, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Institut Universitari Dexeus (ICATME), Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01552707"
163,"NCT04971161","Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)",,"Recruiting","No Results Available","Skin Ulcer Venous Stasis Chronic","Biological: allo-APZ2-CVU|Drug: Placebo","Complete wound closure at Week 18 already persisting for at least two weeks|Assessment of adverse event (AE) occurrence|Wound size change in percent at each post-baseline follow-up visit|Time to complete wound closure|Complete wound closures at each post-baseline follow-up visit|Duration of wound closure|Recurrence of the wound|Quality of wound healing (wound exudate) at each post-baseline follow-up visit|Quality of wound healing (granulation tissue together with epithelialization) at each post-baseline follow-up visit|Quality of wound healing (scar formation) at each post-baseline follow-up visit|Assessment of Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14|Pain assessment as per numerical rating scale on each post-baseline efficacy follow-up visit|Physical examination and vital signs at V14","RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Ticeba GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","allo-APZ2-CVU-IIb","August 18, 2021","August 2023","August 2023","July 21, 2021",,"September 21, 2022","Universitätsklinikum Augsburg, Klinik für Dermatologie und Allergologie, Campus Süd, Augsburg, Germany|Fachklinik Bad Bentheim, Dermatologische Ambulanz, Bad Bentheim, Germany|Franziskus-Krankenhaus Berlin, Klinik für Innere Medizin, Angiologie und Diabetologie, Berlin, Germany|Helios Klinikum Berlin-Buch, Klinik für Plastische und Ästhetische Chirurgie, Berlin, Germany|Helios Klinikum Emil von Behring, Klinik für Plastische und Ästhetische Chirurgie, Berlin, Germany|Hautarztpraxis Dr. Niesmann & Dr. Othlinghaus, Hautzentrum im Jahrhunderthaus, Bochum, Germany|Katholisches Klinikum Bochum gGmbH, Venenzentrum der Kliniken für Dermatologie und Gefäßchirurgie der Ruhr-Universität Bochum, Bochum, Germany|Hautärzte Braunschweig am Altstadtmarkt, Hautärztliche Gemeinschaftspraxis, Braunschweig, Germany|Klinikum Bremerhaven Reinkenheide gGmbH, Klinik für Dermatologie, Allergologie und Phlebologie, Wundzentrum, Bremerhaven, Germany|Klinische Forschung Dresden GmbH, Dresden, Germany|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Medizinische Klinik und Poliklinik III Angiologie und Gefäßzentrum, Dresden, Germany|Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Klinik für Dermatologie, Düsseldorf, Germany|Universitätsklinikum Erlangen, Hautklinik - Wundzentrum Dermatologie, Erlangen, Germany|Universitätsklinikum Essen, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Essen, Germany|Universitätsklinikum Freiburg, Klinik für Dermatologie und Venerologie, Freiburg, Germany|Marienhospital Gelsenkirchen GmbH, Klinik für Chirurgie (Allgemein-, Viszeral- und Endokrine Chirurgie, Thorax-, Gefäß- und Endovaskuläre Chirurgie und Kinderchirurgie), Gelsenkirchen, Germany|SRH Wald-Klinikum Gera GmbH, Zentrum für Klinische Studien, Gera, Germany|Praxis Dr. med. Abdou Zarzour, Halle, Germany|Universitätsklinikum Hamburg- Eppendorf, Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP), Hamburg, Germany|MVZ Prof. Dr. Ockenfels, Haut und Allergie-Praxisklinik GmbH, Hanau, Germany|SRH Klinikum Karlsbad- Langensteinbach GmbH, Interdisziplinäres Gefäßzentrum Innere Medizin, Karlsbad, Germany|Medizinisches Versorgungszentrum DermaKiel GmbH, Kiel, Germany|Helios Klinikum Krefeld, Klinik für Dermatologie und Venerologie, Krefeld, Germany|Hautarztpraxis Langenau, Studienzentrum, Langenau, Germany|Universitätsklinikum Leipzig AöR, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Leipzig, Germany|Studienambulanz Dr. Schubert Leipzig, Leipzig, Germany|Diabetologikum Ludwigshafen, die Praxis am Ludwigsplatz, Ludwigshafen, Germany|Beldio Research GmbH, Memmingen, Germany|Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Dermatologie und Allergologie, München, Germany|Dermazentrum München, Standort Neuhausen, Studienzentrum, München, Germany|Universitätsklinikum Münster, Klinik für Hautkrankheiten, Allgemeine Dermatologie und Venerologie, Münster, Germany|Klinikum Nürnberg Nord, Klinik für Dermatologie, Nürnberg, Germany|Hautarztpraxis Prof. Dr. med. Khusru Asadullah, Potsdam, Germany|Caritas-Krankenhaus St. Josef, Klinik für Plastische und Ästhetische, Hand- und Wiederherstellungschirurgie, Regensburg, Germany|Universitätsmedizin Rostock, Klinik und Poliklinik für Dermatologie und Venerologie, Rostock, Germany|Helios Kliniken Schwerin, Plastische, Rekonstruktive und Ästhetische Chirurgie, Schwerin, Germany|Hautärztliche Gemeinschaftspraxis Dr. Leitz und Kollegen, Stuttgart, Germany|Universitätsklinikum Tübingen, Universitäts-Hautklinik Tübingen, Tübingen, Germany|Helios Universitätsklinikum Wuppertal, Zentrums für Dermatologie, Allergologie und Dermatochirurgie, Wuppertal, Germany|Universitätsklinikum Würzburg, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT04971161"
164,"NCT02587572","Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial","SIRONA","Not yet recruiting","No Results Available","Metabolic Disease|Endothelial Dysfunction","Biological: Peripheral Intravenous (IV) infusion of LMSCs","Endothelial function: Changes in endothelial function as assessed by the following:|Difference in rate of change in the metabolic syndrome as defined by the following:","Longeveron Inc.","All","45 Years to 85 Years   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00-0000-02","December 2022","December 2023","December 2023","October 27, 2015",,"March 7, 2022",,,"https://ClinicalTrials.gov/show/NCT02587572"
165,"NCT00504803","Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease",,"Completed","No Results Available","Hematological Malignancies","Procedure: Mesenchymal stem cell infusion","Day-100 incidence of non-relapse mortality|1. Hematopoietic engraftment and graft rejection. 2. Incidence of grade II-IV and III-IV acute GVHD. 3. Immunologic reconstitution","University of Liege","All","up to 75 Years   (Child, Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TJB0601","December 2006","December 2010","December 2010","July 20, 2007",,"September 2, 2011","CHU Sart Tilman, Liege, Belgium",,"https://ClinicalTrials.gov/show/NCT00504803"
166,"NCT03171194","Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus",,"Completed","No Results Available","System; Lupus Erythematosus","Drug: Low Dose Mesenchymal Stem Cells (MSCs)","Frequency of Grade 3 or higher adverse events|Frequency of All Adverse Events|Change in Disease Activity|Change in Patient Reported Outcomes - Life|Change in Patient Reported Outcomes - Fatigue|Change in Patient Reported Outcomes - Pain|Change in Patient Reported Outcomes - Depression|Change in Disease Biomarkers - Cellular|Change in Disease Biomarkers - Serum","Medical University of South Carolina","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00061632","April 27, 2017","April 30, 2018","October 25, 2018","May 31, 2017",,"May 2, 2019","Emory University, Atlanta, Georgia, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03171194"
167,"NCT05491681","AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial","ACE_CARD","Not yet recruiting","No Results Available","ARDS, Human","Biological: intravenous delivery of allogeneic bone marrow-derived MSCs","Number of product related adverse events through the duration of the study.|Secondary Endpoint","BioCardia, Inc.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05539-A","September 15, 2022","December 31, 2023","March 31, 2024","August 8, 2022",,"August 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05491681"
168,"NCT04654286","Human Amniotic Membrane and Mesenchymal Stem Cells Composite","BPI+MSC","Recruiting","No Results Available","Brachial Plexus Neuropathies","Procedure: Nerve transfer procedure|Procedure: Nerve transfer with HAM-AdMSC composite wrapping","Active range of motion (AROM) pre-surgery|Active range of motion (AROM) at 12 months follow-up|Functional motor power outcome pre-surgery|Functional motor power outcome at 12 months follow-up|Initial elbow flexion MRC grade 1 (in months)|Initial elbow flexion MRC grade 3 (in months)|Pain outcome pre-surgery|Pain outcome at 12 months follow-up|Disabilities of the Arm, Shoulder, and Hand (DASH) score pre-surgery|Disabilities of the Arm, Shoulder, and Hand (DASH) score at 12 months follow-up|Short Form-36 (SF-36) score pre-surgery|Short Form-36 (SF-36) score at 12 months follow-up","Dr. Soetomo General Hospital","All","15 Years to 55 Years   (Child, Adult)","Not Applicable","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","647 / Panke.KKE/ XI / 2016","November 17, 2016","July 30, 2021","July 30, 2022","December 4, 2020",,"December 7, 2020","Cell and Tissue Bank - Regenerative Medicine, Dr. Soetomo General Academic Hospital/ Faculty of Medicine Universitas Airlangga, Surabaya, East Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT04654286"
169,"NCT05130983","A Phase I Study of ExoFlo, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Crohn's Disease",,"Not yet recruiting","No Results Available","Crohn Disease|IBD - Irritable Bowel Disease","Drug: Bone Marrow MSC Derived Extracellular Vesicle Isolate","• To evaluate the feasibility of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the safety of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in inducing clinical remission in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in inducing clinical response in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.|• To evaluate the efficacy of intravenous ExoFlo in improving disease-specific health-related quality of life.|• To evaluate the pharmacokinetics and pharmacodynamics of ExoFlo therapy, including changes in C-reactive protein (CRP), fecal calprotectin, fecal lactoferrin, and other pharmacodynamic biomarkers.","Direct Biologics, LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DB-EF-CROHNS-0004","September 1, 2022","January 1, 2024","March 1, 2024","November 23, 2021",,"September 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05130983"
170,"NCT01087996","The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)",,"Completed","Has Results","Stem Cell Transplantation","Biological: Auto-hMSCs|Biological: Allo-hMSCs","Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation|CT Infarct Size From Early Enhanced Defect: - Difference Between the Baseline and 13-month|CT Measure of Left Ventricular Ejection Fraction|CT Measure of End Diastolic Volume|CT Measure of End Systolic Volume|CT Measure of Scar Size as % of LV Mass|Change in Distance Walked in 6-minutes From Baseline.|Change in Minnesota Living With Heart Failure Total Score|Change in New York Heart Association Class at 12-months","University of Miami|National Heart, Lung, and Blood Institute (NHLBI)|The Emmes Company, LLC","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","31","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090352|R01HL110737|R01HL107110|R01HL084275|P20HL101443|R01HL094849","March 2010","April 2011","October 2012","March 16, 2010","May 27, 2015","May 27, 2015","University of Miami Miller School of Medicine, Miami, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01087996"
171,"NCT04410731","Allogeneic BM-MSCs in Patients With Lumbar Facet Arthropathy","Cellkine","Active, not recruiting","No Results Available","Facet-Mediated Low Back Pain","Drug: Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy","Clinical assessment of nature, incidence, and severity of adverse events (AEs)|Self-reported assessment of nature, incidence, and severity of AEs|Study personnel assessment of nature, incidence, and severity of AEs|Global Health Scale (GHS)|Visual Analog Scale (VAS) - back and leg pain|Oswestry Disability Index (ODI)|Patient Health Questionnaire-4 (PHQ-4)|Narcotic Use Questionnaire|Work Status Questionnaire|PROMIS-CAT|Changes from Baseline evaluated by MRI|Change in number of red blood cells following treatment|Change in white blood cells with differential following treatment|Change in number of platelets following treatment|Change in Serum C-Reactive Protein (CRP)|Change in Erythrocyte Sedimentation Rate (ESR)|Change in Blood Urea Nitrogen (BUN)|Change in Creatinine|Change in Sodium|Change in Potassium|Change in Chloride|Change in Aspartate Aminotransferase (AST)|Change in Glucose|Change in Carbon Dioxide","Mayo Clinic","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-000330","April 28, 2020","April 2024","April 2024","June 1, 2020",,"May 12, 2022","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04410731"
172,"NCT03973827","Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed With Type I Diabetes",,"Active, not recruiting","No Results Available","Type1diabetes","Drug: ProTrans","The primary safety endpoint in this study is; safety parameters include adverse events, hypoglycemia and allergic reactions|Delta-change of C-peptide AreaUnder the Curve (AUC) (0-120 min) for Mixed Meal Tolerance Test (MMTT) at day 372 following WJMSC infusion when compared to test performed before start of treatment.|Number of patients insulin independent (ADA criteria) at day 372.|Number of patients with daily insulin needs <0.25U/kg at day 372.|HbA1c at day 372|Glucose variability (mean amplitude of glycaemic excursions and glycaemic lability index) duration derived from the continuous glucose monitoring system® at day 372|Delta change of levels of fasting C-peptide at day 372 when compared to test before start of treatment|Numbers of patients with peak C-peptide >0.20 nmol/l, in response to the MMTT, at day 372.","NextCell Pharma Ab","Male","18 Years to 41 Years   (Adult)","Phase 1|Phase 2","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ProTrans-Repeat|2018-004158-11","May 17, 2019","December 10, 2020","October 30, 2024","June 4, 2019",,"January 11, 2022","Karolinska Trial Alliance, Fas 1 enheten, Karolinska Universitetssjukhuset Huddinge, Huddinge, Sweden",,"https://ClinicalTrials.gov/show/NCT03973827"
173,"NCT02328612","Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Lipopolysaccharyde in Human Volunteers","CELLULA","Completed","No Results Available","Sepsis","Other: Intravenous infusion of cells","Inflammatory response as measured by laboratory measurements and functional assays of innate immunology","Tigenix S.A.U.|Cellerix","Male","18 Years to 35 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cx611-0102","October 2014","March 2015","March 2015","December 31, 2014",,"April 3, 2015","Academic Medical Center, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02328612"
174,"NCT02585622","NEPHSTROM for Diabetic Kidney Disease","NEPHSTROM","Recruiting","No Results Available","Diabetic Kidney Disease","Biological: Mesenchymal Stromal Cells|Other: Placebo","Number and severity of all pre-specified infusion-associated events and the overall number and frequency of adverse events.|Glomerular filtration rate (GFR)|Urinary Albumin/Creatinine Ratio (ACR)|Urinary albumin excretion (UAE).|Fasting blood glucose (target <126mg/dL)|HbA1c (target <75mmol/mol or <9%)|Total cholesterol (target <200 mg/dl)|LDL cholesterol (target <100 mg/dl)|Triglycerides (target <170 mg/dl)|Arterial blood pressure (the target value <130/80 mmHg)|Quality of life|Anti-HLA antibody development|Inflammation and fibrosis related soluble mediators|Serum/plasma concentrations (pg/ml) of biomarkers of inflammation.|Serum/plasma concentrations (ng/ml) of biomarkers of CKD progression.|Urine concentrations (pg/ml adjusted to urine creatinine concentration) of biomarkers of inflammation.|Proportion/total number of circulating T cells, B cells, NK cells, monocytes, dendritic cells|Cost-effectiveness of cell therapy","Mario Negri Institute for Pharmacological Research|Leiden University Medical Center|ASST Papa Giovanni XXIII, Bergamo, Italy|IRCCS - Istituto di Ricerche Farmacologiche Mario Negri - Bergamo, Italy|Belfast Health and Social Care Trust|National University of Ireland, Galway, Ireland|University Hospital Birmingham, NHS Foundation Trust, Hospital, Birmingham, UK|NHS Blood and Transplant","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","NEPHSTROM|2016-000661-23","December 11, 2017","December 2021","July 2022","October 23, 2015",,"July 14, 2021","National University of ireland - Galway University Hospital -Regenerative Medicine Institute, Galway, Ireland|ASST - Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/ Mario Negri Institute for Pharmacological Research - Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Bergamo, BG, Italy|Belfast Health and Social Care Trust - Belfast City Hospital, Belfast, United Kingdom|University Hospital Birmingham NHS Foundation Trust - Queen Elizabeth Medical Centre, Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02585622"
175,"NCT04615429","Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19",,"Recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID-19 Pneumonia","Biological: Mesenchymal stromal cells|Other: Placebo","Change in the PaO2/FiO2* ratio from baseline to day 7 of treatment administration|All-cause mortality|Time to PaO2/FiO2 ratio greater than 200 mmHg|Clinical status on the World Health Organization ordinal scale|PaO2/FiO2 ratio|SOFA score|Oxygen therapy-free days|Duration of hospitalization|Duration of ICU admission|Incidence of non-invasive ventilation|Incidence of invasive mechanical ventilation|Duration of non-invasive ventilation|Duration of invasive mechanical ventilation|Mechanical ventilation-free days|Survival rate|Cumulative incidence SAEs, Grade 3 and 4 AEs, ADR and AEs of special interest.","Cristina Avendaño Solá|Puerta de Hierro University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","COVID-AT|2020-002193-27","September 15, 2020","January 2022","February 2022","November 4, 2020",,"November 10, 2021","Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04615429"
176,"NCT02633163","Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)",,"Recruiting","No Results Available","Systemic Lupus Erythematosus","Drug: Low Dose Mesenchymal Stem Cells (MSCs)|Drug: High Dose Mesenchymal Stem Cells (MSCs)|Drug: Placebo Infusion","Clinical response at Week 24 as defined by the SLE Responder Index (SRI):|Change in SLEDAI score between groups|Renal and non-renal organ system flares|Changes in SLICC-DI|Changes in HR-QOL|Changes in Fatigue|Changes in Pain|Changes in Depression|Changes in patient-reported lupus-specific disease status|Steroid-sparing effect|Cumulative systemic steroid dose|Changes in the presence of serum and urine biomarkers of SLE activity:","Medical University of South Carolina","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MUSC-UCMSC-001","October 26, 2018","December 2022","June 2023","December 17, 2015",,"September 7, 2022","Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California - San Diego, San Diego, California, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|The Feinstein Institute for Medical Research, Manhasset, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02633163"
177,"NCT04433104","Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Chronic Obstructive Pulmonary Disease",,"Recruiting","No Results Available","COPD","Biological: Umbilical Cord Mesenchymal Stem Cells transplantation|Drug: drug therapy according to Vietnamese MOHS procedure","Adverse events and serious adverse events|Quality of Life using Georges Respiratory Questionnaire|Chest CT|arterial blood gas analysis (pH)|arterial blood gas analysis (PaO2)|arterial blood gas analysis (PaCO2)|arterial blood gas analysis (BE)|arterial blood gas analysis (HCO3-)|Respiratory functions (FEV1)|Respiratory functions (FEV1/FVC)|Respiratory functions (VC)|Respiratory functions (TLC)|Respiratory functions (RV)|Respiratory functions (DLCO)|Respiratory functions (DLNO/DLCO)|inflammatory response (CRP)|inflammatory response (Pro-BNP)|inflammatory response (Troponin-T)|cytokine analysis from patients' plasma|modified medical research council","Vinmec Research Institute of Stem Cell and Gene Technology","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","VinmecISC1916","June 9, 2020","July 30, 2021","December 25, 2021","June 16, 2020",,"April 21, 2021","Vinmec International Hospital Times City, Hà Nội, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT04433104"
178,"NCT04548583","Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis",,"Recruiting","No Results Available","Crohn Colitis","Drug: Remestemcel-L|Other: Placebo","Treatment related adverse events|Complete clinical healing|Clinical response|Partial clinical response|Lack of response|Crohn's disease activity index|Inflammatory bowel disease questionnaire|EuroQol 5 Dimensions survey|Inflammatory bowel disease patient reported treatment impact survey|Short Form 36 health survey","The Cleveland Clinic|Mesoblast, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20-845","November 4, 2020","October 2023","October 2023","September 14, 2020",,"April 5, 2022","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04548583"
179,"NCT02104713","Stem Cell Therapy to Improve Burn Wound Healing",,"Completed","No Results Available","Skin Burn Degree Second","Biological: Allogeneic (MSC's) Application to the Burn Wounds","Monitoring for adverse events as Assessed by CTCAE v4.0 following administration of allogeneic MSCs to 2nd degree burn wounds.","E.Badiavas|United States Department of Defense|University of Miami","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","20120925","June 4, 2014","March 18, 2019","March 18, 2019","April 4, 2014",,"April 30, 2020","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02104713"
180,"NCT04543994","Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)","UC","Recruiting","No Results Available","Ulcerative Colitis","Drug: Remestemcel-L|Other: Placebo","Treatment related adverse events|Clinical and endoscopic remission|Clinical and endoscopic response|Partial clinical and endoscopic response|Lack of response|Mayo clinic score","The Cleveland Clinic|Mesoblast, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20-1005","November 10, 2020","November 2023","November 2023","September 10, 2020",,"April 5, 2022","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04543994"
181,"NCT04545307","Transplantation of Allogeneic MSC in Patients With Pulp Necrosis and Chronic Apical Periodontitis","MSC","Completed","No Results Available","Pulp Necroses|Apical Periodontitis","Biological: Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis","Sings and Symptoms Absence|Root canal Narrowing|Elongation of the root|Sensitivity tests perception|Repair of the bone lesion produced by the apical periodontitis|Stability of bio ceramic cements used in the obturation of the access cavity|Evaluate blood circulation within the root canal","Universidad Central de Venezuela|Instituto Venezolano de Investigaciones Cientificas","All","6 Years to 16 Years   (Child)","Phase 2|Phase 3","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSCYPPNAP001","November 27, 2019","December 27, 2019","January 27, 2020","September 11, 2020",,"September 16, 2020","Unidad de Terapia Celular del Instituto de Investigaciones Científicas, San Antonio de los Altos, Miranda, Venezuela",,"https://ClinicalTrials.gov/show/NCT04545307"
182,"NCT03684122","Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson's (PD).",,"Active, not recruiting","No Results Available","Parkinson Disease","Biological: Injection of Umbilical cord derived MSCs","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the injection|Drug Reduction Rate test|Tractography|Blood-based biomarkers|Cerebrospinal Fluid (CSF) based biomarkers","University of Jordan","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PKUJCTC","June 1, 2018","July 30, 2020","September 20, 2021","September 25, 2018",,"August 25, 2021","Cell Therapy Center, University of Jordan, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT03684122"
183,"NCT03370874","Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.",,"Active, not recruiting","No Results Available","Diabetic Foot Ulcer","Biological: ALLO-ASC-DFU|Procedure: Vehicle sheet","Proportions of subjects who achieved complete wound closure|Time taken to complete wound closure between the two groups|Proportions of subjects who achieved complete wound closure by the classification of Wagner Grade between the two groups|Change rates in wound size and depth compared to baseline between the two groups|Proportions of subjects who achieved complete wound closure at every visit by the classification of ulcer locations","Anterogen Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ALLO-ASC-DFU-301","July 4, 2018","June 30, 2021","June 30, 2021","December 13, 2017",,"January 22, 2021","Korea University Kuro Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03370874"
184,"NCT04392206","AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses",,"Recruiting","No Results Available","End Stage Renal Disease","Drug: Adipose Derived Mesenchymal Stem Cells","Number of participants with treatment-related adverse events","Albert Hakaim|Mayo Clinic","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-007203","May 15, 2020","June 2025","June 2025","May 18, 2020",,"July 28, 2022","Mayo Clinic in Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04392206"
185,"NCT03754465","Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Foot Ulcers",,"Recruiting","No Results Available","Diabetic Foot Ulcer","Biological: ALLO-ASC-DFU|Procedure: Hydrogel SHEET(Vehicle control)","Proportions of subjects who achieved complete wound closure|Time to initial complete wound closure between the two groups|Changes in wound size compared to baseline between the two groups|Proportions of subjects who achieved complete wound closure by the classification of location of diabetic foot ulcer, Plantar and the other location between the two groups|Durability of complete wound closure","Anterogen Co., Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ALLO-ASC-SHEET-102","January 2, 2019","December 30, 2022","December 30, 2022","November 27, 2018",,"May 3, 2022","University of Southern California, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT03754465"
186,"NCT01843387","Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy",,"Completed","No Results Available","Diabetic Nephropathy|Type 2 Diabetes","Biological: Mesenchymal Precursor Cells (MPCs)","The primary objective of the study is to assess the safety and tolerability of MPC therapy|Exploratory assessment of the efficacy of MPC therapy","Mesoblast, Ltd.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSB-DN001","July 2013","September 2014","September 2015","April 30, 2013",,"October 14, 2016","Monash Universtiy, Clayton, Australia|Melbourne Renal Research Group, Melbourne, Australia",,"https://ClinicalTrials.gov/show/NCT01843387"
187,"NCT01562002","Safety Study of Stem Cell Transplant to Treat Limbus Insufficiency Syndrome",,"Completed","No Results Available","Limbus Corneae Insufficiency Syndrome","Procedure: Stem Cell with Amniotic Membrane Transplant","Viability and safety of mesenchymal stem cell transplant|Absence of complications in pre and peri surgical implantation|Improvement of 2 lines in Best Corrected Visual Acuity","Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA|University of Valladolid|Centro en Red de Medicina Regenerativa de Castilla y Leon|Red de Terapia Celular","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","27","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IOBA-05-2010","March 2012","December 2014","December 2014","March 23, 2012",,"January 8, 2015","IOBA, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT01562002"
188,"NCT04714801","Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation",,"Recruiting","No Results Available","Lung Transplant Rejection","Drug: adipose derived mesenchymal stromal cells|Drug: Saline","Pulmonary graft dysfunction (PDG)|Kidney glomerular Filtration Rate|Inflammatory markers","Rigshospitalet, Denmark","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ASC Lungtransplantation","October 1, 2020","November 30, 2023","November 30, 2024","January 19, 2021",,"July 16, 2021","2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04714801"
189,"NCT03183726","A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-101 Clinical Trial",,"Completed","No Results Available","Diabetic Foot Ulcer","Biological: ALLO-ASC-DFU","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Wound size and depth measurement","Anterogen Co., Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)",,"4","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ALLO-ASC-DFU-102","January 11, 2016","June 30, 2017","July 31, 2017","June 12, 2017",,"January 10, 2018",,,"https://ClinicalTrials.gov/show/NCT03183726"
190,"NCT01392625","PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)","PoseidonDCM","Completed","Has Results","Non-ischemic Dilated Cardiomyopathy","Biological: Autologous hMSCs|Biological: Allogeneic hMSCs","Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)|Measurement of Changes in Peak VO2|Measurement of Changes in 6 Minute Walk|Measurement of Changes in Global Ejection Fraction|Measurement of Changes in New York Heart Association (NYHA)|Measurement of Changes in Minnesota Living With Heart Failure (MLHF) Questionnaire","Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|University of Miami","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 1|Phase 2","37","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20100968|1R01HL110737-01","May 19, 2011","August 28, 2016","August 28, 2017","July 12, 2011","February 15, 2018","February 15, 2018","University of Miami School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01392625"
191,"NCT05520086","Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis.","CELOPHIN","Not yet recruiting","No Results Available","Chronic Conjunctivitis|Stevens-Johnson Syndrome|Lyell Syndrome|Pemphigoid","Drug: Single Dose|Drug: Double Dose","Percentage of complications|Signs improvement|Symptom improvement|Visual acuity improvement|changes in quality of life|evolution of the conjunctival flora","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Effice Servicios Para la Investigacion S.L.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CELOPHIN","September 2022","February 2024","February 2024","August 29, 2022",,"August 29, 2022","Instituto Oftalmológico Fernández - Vega, Oviedo, Asturias, Spain|Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain|Hospital General La Mancha Centro, Alcázar De San Juan, Ciudad Real, Spain|Hospital La Arruzafa, Córdoba, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Fundación Jiménez Diaz, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT05520086"
192,"NCT04040348","Alzheimer's Disease Stem Cells Multiple Infusions",,"Active, not recruiting","No Results Available","Alzheimer Disease","Biological: Approximately 100 million cells allogeneic hMSC","Number of Incidence of any Treatment-Emergent Serious Adverse Events (TE-SAEs)|Cognitive function over time as assessed by the Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog 11)|Cognitive function over time as assessed by the Mini Mental State Examination (MMSE) of Folstein test|Depressive symptoms over time as assessed by the Geriatric Depression Scale (GDS) Short Version|Participant quality of life over time assessed via Alzheimer's Disease Related Quality of Life (ADRQL-40) Questionnaire as completed by the caregiver|Participant quality of life over time as assessed via the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Questionnaire as completed by the caregiver|Neuropsychiatric Inventory-Q (NPI-Q) Scores over time|Caregiver's Quality of life over time as assessed by the Caregiver Self-Assessment Questionnaire scores|Biomarker levels over time|Serum ApoE level over time|Serum PRA level over time|Serum Tau protein level over time|Cerebrospinal Fluid (CSF) Biomarker levels over time|CSF ApoE level over time|CSF PRA level over time|CSF Tau protein level over time|Change in hippocampal volume","Bernard (Barry) Baumel|University of Miami","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20190438","October 8, 2019","May 1, 2023","May 1, 2023","July 31, 2019",,"August 16, 2022","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04040348"
193,"NCT03337243","Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis",,"Completed","No Results Available","Knee Osteoarthritis|Knee Pain Chronic|Joint Disease|Arthritis|Osteo Arthritis Knee|Musculoskeletal Disease","Procedure: HAM and HUMCWJ Injections","Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) over 3 months|Change in pain during sit-to-stand over 3 months|Change in pain during supine to upright over 3 months|Change in pain during ascent/decent stairs over 3 months","Sport and Spine Rehab Clinical Research Foundation","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","StemCell","November 9, 2017","April 26, 2019","April 26, 2019","November 8, 2017",,"May 6, 2020","Scott Medical Health Center, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03337243"
194,"NCT05061030","Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents",,"Recruiting","No Results Available","Type1diabetes","Biological: the ATMP Protrans","Safety at one year evaluated as adverse events|Safety at five years evaluated as adverse events|Efficacy measured as change in C-peptide Area under the curve to a mixed mealtolerance test.|Insulin independency|Low insulin needs|Insulin needs|HbA1c|Time in target|Time in range|C-peptide|Change in peak C-peptide","Uppsala University Hospital","All","7 Years to 21 Years   (Child, Adult)","Phase 1|Phase 2","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WJMSC-P01","January 14, 2022","September 2028","December 2028","September 29, 2021",,"May 23, 2022","Uppsala University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT05061030"
195,"NCT03392311","Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis",,"Enrolling by invitation","No Results Available","Mesenchymal Stromal Cells|Psoriasis|Drug Effect|Drug Toxicity","Drug: Calcipotriol ointment|Biological: adipose-derived multipotent mesenchymal stem cells","Improvement rate of PASI(Psoriasis Area and Severity Index)|PASI(Psoriasis Area and Severity Index)|Relapse rate in treatment period / follow-up period|PASI-50|PASI-75|Pruritus Scores on the Visual Analogue Scale|BSA|DLQI（Dermatology Life Quality Index）","Guangdong Provincial Hospital of Traditional Chinese Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S2016-04-02","August 17, 2019","December 15, 2019","April 30, 2021","January 5, 2018",,"March 4, 2021","Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03392311"
196,"NCT01576328","Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes",,"Completed","No Results Available","Type 2 Diabetes","Drug: Mesenchymal Precursor Cells (MPCs)","Primary objective of the study is to assess the safety and tolerability of MPC therapy","Mesoblast, Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","MSB-DM003","April 2012","October 2013","October 2015","April 12, 2012",,"June 2, 2020","SC Clinical Research, Garden Grove, California, United States|Diabetes Research Institute, Miami, Florida, United States|Compass Research, Orlando, Florida, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Tulane University Medical Center, New Orleans, Louisiana, United States|Big Sky Clinical Research, Butte, Montana, United States|Desert Endocrinology Clinical Research Center-Henderson, Henderson, Nevada, United States|Alliance Against Diabetes/AAD Clinical Research, Las Vegas, Nevada, United States|Active Practices and Research, Newington, New Hampshire, United States|The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, United States|Providence Health Partners - Center for Clinical Reseach, Dayton, Ohio, United States|Dallas Diabetes and Endocrine Center, Dallas, Texas, United States|West Houston Clinical Research Services, Houston, Texas, United States|Paragon Research Center, San Antonio, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|National Clinical Research - Norfolk, Inc, Norfolk, Virginia, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States|Capital Clinical Research Center, Olympia, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01576328"
197,"NCT04494386","Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS","ULSC","Active, not recruiting","No Results Available","Covid19|Corona Virus Infection|SARS-CoV Infection|ARDS|Coronavirus","Biological: Umbilical Cord Lining Stem Cells (ULSC)|Other: Placebo (carrier control)","Incidence of Dose Limiting Toxicity (DLT)|Incidence of Dose Limiting Toxicity (DLT), suspected adverse reaction (SAR), or serious adverse event (SAE)|Treatment-emergent adverse events (AE) and serious adverse events (SAE)|Levels of COVID-19 related ARDS as defined by the Berlin Definition of ARDS|Changes from baseline pulse oximetric saturation SpO2/FiO2 ratio or arterial oxygen pressure pAO2/FiO2 ratio|Number of ventilator-free days (VFD)|Changes in Complete Blood Count (CBC) with differential from baseline|Changes in levels of blood glucose (mg/dL) from baseline|Changes in levels of sodium (mEq/L) from baseline|Changes in levels of potassium (mEq/L) from baseline|Changes in levels of blood urea nitrogen (BUN; mg/dL) from baseline|Changes in levels of alanine transaminase (ALT; U/L) from baseline|Change in Urinalysis (UA) from baseline","Restem, LLC.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","17","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ULSC-CV-01","July 23, 2020","September 30, 2022","December 30, 2022","July 31, 2020",,"September 22, 2022","Miami Baptist Hospital, Miami, Florida, United States|Sanford Research, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT04494386"
198,"NCT02709343","Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction","ASSIST-CLAD","Active, not recruiting","No Results Available","Chronic Lung Allograft Dysfunction (CLAD)","Drug: Bone-marrow derived MSCs|Drug: Placebo","Progression-free survival|Time to fall in FEV1 > 10%|Freedom from Bronchiolitis Obliterans Syndrome (BOS) grade 3|All cause mortality|CLAD-specific mortality|Freedom from acute rejection|Freedom from the development of new donor specific anti-HLA antibodies|Freedom from CLAD progression|Rate of FEV1 decline|Rate of FVC decline|Change in 6-minute walk distance (6MWD)|Change in St George's Respiratory Questionnaire (SGRQ) Score|Inpatient bed-days","The University of Queensland|Isopogen|Cell and Tissue Therapies","All","18 Years and older   (Adult, Older Adult)","Phase 2","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ASSIST-CLAD","April 21, 2017","July 2023","July 2023","March 16, 2016",,"August 24, 2022","St Vincents Hospital, Sydney, New South Wales, Australia|The Prince Charles Hospital, Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT02709343"
199,"NCT04034316","Reduce Immunosuppression With Atmp in NS ChildrEn","RACE","Enrolling by invitation","No Results Available","Nephrotic Syndrome in Children|Steroid-Dependent Nephrotic Syndrome|Idiopathic Nephrotic Syndrome","Other: Cord-blood mesenchymal stromal cells","The percentage of patients without nephrotic syndrome recurrence after complete withdrawal of immunosuppressive treatment for at least 6 months|The percentage of adverse events|The time to recurrence of nephrotic syndrome|The percentage of participants achieving a reduction in the immunosuppressive therapy|The dose of immunosuppressive therapy to prevent further NS relapses|Reported Quality of Life","Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Cell Factory Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico|Laboratorio Sperimentale di Immunologia e Trapianti, Oncoematologia Pediatrica, Fondazione IRCCS Policlinico S. Matteo, Pavia","All","3 Years to 18 Years   (Child, Adult)","Phase 2","11","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIFA-2016-02364896|2018-001162-42","November 2, 2018","June 30, 2022","December 2022","July 26, 2019",,"August 26, 2021","Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan, Milan, MI, Italy",,"https://ClinicalTrials.gov/show/NCT04034316"
200,"NCT01605383","Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head",,"Completed","No Results Available","Avascular Necrosis of Femur Head","Biological: XCEL-MT-OSTEO-ALPHA|Procedure: Standard treatment","Safety of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head|Feasibility of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head|Bone regeneration by measuring the necrotic angle using the modified Kerboul method|Dynamic changes of signal intensity|Clinical outcomes (pain) by Visual Analogue Scale (VAS)|Clinical outcomes (SF-36)|Clinical outcome (WOMAC)","Banc de Sang i Teixits|Ministerio de Sanidad, Servicios Sociales e Igualdad|Ministerio de Ciencia e Innovación, Spain|European Regional Development Fund","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XCEL-MT-10-01|2010-023998-18","May 5, 2015","April 11, 2018","June 27, 2019","May 24, 2012",,"January 21, 2020","Hospital Universitari Vall d'Hebron, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01605383"
201,"NCT03079401","Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle",,"Active, not recruiting","No Results Available","Hypoplastic Left Heart Syndrome|Atrioventricular Canal","Biological: MPC; rexlemestrocel-L","Safety- Incidence of severe adverse events|Safety- Absence of PRA status change or local inflammation|Efficacy- rate of biventricular conversion|Efficacy- improvement of LV end diastolic pressure|Efficacy- improvement of LV mass/volume ratio","Boston Children's Hospital","All","up to 5 Years   (Child)","Phase 1|Phase 2","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRB-P00020575","November 27, 2017","January 2023","January 2024","March 14, 2017",,"January 5, 2022","Boston Children's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03079401"
202,"NCT04939337","A Study of TH-SC01 for Treating Complex Perianal Fistula in Perianal Crohn's Disease.",,"Enrolling by invitation","No Results Available","Crohn's Disease","Drug: TH-SC01","Percentage of Participants who Achieve Combined Remission|Percentage of Participants who Achieve Clinical Remission|Percentage of Participants who Achieve Clinical Response|Percentage of Participants who decrease in PDAI|Percentage of Participants who decrease in IBDQ|Percentage of Participants who decrease in VAS scale|Percentage of Participants who decrease in Wexner incontinence score","Jinling Hospital, China|Jiangsu Topcel-KH Pharmaceutical Co., Ltd","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20181231","November 12, 2020","January 2024","August 2024","June 25, 2021",,"June 25, 2021","Jinling hospital, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04939337"
203,"NCT04314661","Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for Osteoartrithis","OA","Recruiting","No Results Available","Osteoarthritis, Knee","Biological: Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|Biological: Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome|Biological: Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome|Biological: Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome","Visual Analog Scale (VAS)|Western Ontario and McMaster Universities Osteoarthritis Index|Laboratory Asessment|Magnetic Resonance Imaging (MRI) T2 mapping","PT. Prodia Stem Cell Indonesia","All","55 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT/OA/02/2022","August 3, 2020","July 8, 2024","December 8, 2024","March 19, 2020",,"September 28, 2022","Gatot Soebroto Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04314661"
204,"NCT05204329","Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease","MSC Secretome","Not yet recruiting","No Results Available","Mesenchymal Stromal Cells|Cornea|Corneal Defect|Corneal Epithelium Defect","Biological: MSC Secretome Eye Drops","Epithelial Status Assessment|Visual Acuity|Corneal Epithelial thickness|Corneal Scarring / Haze|Tolerability of MSC secretome drops|Durability of Corneal Epithelial Status Improvement|Time to Improvement of Corneal Epithelial Barrier","University of Illinois at Chicago|National Institutes of Health (NIH)|National Eye Institute (NEI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","18","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021-0754|1UG3EY031809-01","December 1, 2022","January 1, 2025","January 1, 2025","January 24, 2022",,"January 24, 2022",,,"https://ClinicalTrials.gov/show/NCT05204329"
205,"NCT04661644","Efficacy and Safety of Mesenchymal Stem Cell Clusters in Patients With Critical Limb Ischemia",,"Recruiting","No Results Available","Critical Limb Ischemia","Biological: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial)|Biological: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial)","Changes in ischemic pain|Changes in pain-free walking distance|Changes in TBI (Toe Brachial Index)|Changes in ABI (Ankle Brachial Index)|Change in size of the Ulcer|Determination of maximum tolerable dose according to DLT occurrence|Incidence of abnormal laboratory tests results|Incidence of abnormal blood pressure|Incidence of abnormal temperature|Incidence of abnormal physical condition","S.Biomedics Co., Ltd.|Dt&Sanomedics","All","19 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SB-AC-001","November 4, 2020","June 2022","June 2022","December 10, 2020",,"May 5, 2022","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04661644"
206,"NCT04602104","A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS",,"Recruiting","No Results Available","Acute Respiratory Distress Syndrome","Biological: low dose hMSC-Exos|Biological: medium dose hMSC-Exos|Biological: high dose hMSC-Exos|Biological: Dosage 1of hMSC-Exos|Biological: Dosage 2 of hMSC-Exos|Biological: No hMSC-derived exosomes","Incidence of adverse reaction|TTCI|28-day mortality|Murray lung injury score|PaO2/FiO2|SOFA score|ApachⅡ score|The number of days the survivor was in ICU","Ruijin Hospital|Cellular Biomedicine Group Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","169","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MEXARDS","November 30, 2020","June 2022","September 2022","October 26, 2020",,"November 2, 2021","Ruijin Hospital, Medical School of Shanghai Jiaotong University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04602104"
207,"NCT05559801","Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)",,"Not yet recruiting","No Results Available","Osteogenesis Imperfecta|Osteogenesis Imperfecta Type III","Drug: Bone marrow-derived mesenchymal stromal cells (MSCs)","Recruitment rate of participants|Number of participants with correctly collected data for the study outcomes|Total number of visits with protocol deviation|Visit attendance by participants|Patient retention rate|Patient Primary Clinical Outcome Retention Rate|Change in acceptability from baseline|Number of unexpected adverse events|Number of participants with change in vital signs from baseline|Number of participants with changes in laboratory panels from baseline (CBC, CMP)|Change in number of participants with changes in radiological parameters|Change in annualized linear growth velocity|Change in fracture rate from baseline|Change in bone mineral density from baseline|Change in bone age|Change in Vertebral Compression Fractures (VCFs)|Number of participants with changes in bone metabolism markers|Change in Limb Deformity Modified EOS Questionnaire (LD-EOSQ-22) from baseline|Change in BAMF (Brief Assessment of Motor Function) from baseline|Change in Pediatric Orthopedic Data Collection Instrument (PODCI) from baseline","Emory University","All","3 Years to 10 Years   (Child)","Phase 1|Phase 2","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00003434","October 2022","October 2026","October 2026","September 29, 2022",,"September 29, 2022",,,"https://ClinicalTrials.gov/show/NCT05559801"
208,"NCT05078385","Safety of Mesenchymal Stem Cell Extracellular Vesicles (BM-MSC-EVs) for the Treatment of Burn Wounds",,"Not yet recruiting","No Results Available","Burns","Drug: AGLE-102","Primary Objective|Secondary Objective","Aegle Therapeutics|Congressionally Directed Medical Research Programs","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Industry|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AGLE-102-102","July 2022","April 2024","July 2024","October 14, 2021",,"October 14, 2021",,,"https://ClinicalTrials.gov/show/NCT05078385"
209,"NCT04544215","A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection",,"Recruiting","No Results Available","Drug-resistant","Biological: Dosage 1 of MPCs-derived exosomes|Biological: Dosage 2 of MPCs-derived exosomes|Biological: No MPCs-derived exosomes","Primary Outcome Measures:|1.Bacterial clearance rate on the 8th d;|2.Mortality on the 28th and 90th d;|3.Recurrence rate after cure within 28 d;|4.Secondary infection rate of other pathogenic bacteria after cure within 28 d;|5.Duration of mechanical ventilation within 28 d;|6.Length of ICU stay (d) within 28 d;|7.Incidence of adverse reactions at the end of treatment and 28 d after initial treatment.","Ruijin Hospital|Cellular Biomedicine Group Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MEXDR","July 1, 2020","May 2023","July 2023","September 10, 2020",,"September 10, 2020","Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04544215"
210,"NCT02962661","Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines",,"Recruiting","No Results Available","Cardiomyopathy|Heart Failure|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm","Other: Best Practice|Other: Laboratory Biomarker Analysis|Drug: Mesenchymal Stem Cell Transplantation","Incidence of adverse events|Change in left ventricular ejection fraction (LVEF)|Change in improvement of left ventricular (LV) systolic function as assessed by LVEF|LV end-systolic and end-diastolic volumes as determined by contrast-enhanced 2-dimensional(D)/3D echography|Cardiac death|Re-hospitalization after heart failure|Aborted death from an automatic implantable cardioverter defibrillator (AICD) firing|Nonfatal myocardial infarction|Revascularization","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","72","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0835|NCI-2016-01921","July 18, 2020","July 30, 2023","July 30, 2023","November 11, 2016",,"September 2, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02962661"
211,"NCT05176366","Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis",,"Not yet recruiting","No Results Available","Ulcerative Colitis","Drug: ExoFlo","Number of subjects who tolerate intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of adverse events in subjects who received intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improvement with intravenous ExoFlo in inducing clinical remission in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improvement with intravenous ExoFlo in inducing clinical response in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.|Number of subjects with improving disease-specific health-related quality of life after receiving intravenous ExoFlo.|Measurement of subject's C-reactive protein (CRP)|Measurement of subject fecal calprotectin|Measurement of subject fecal lactoferrin","Direct Biologics, LLC","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DB-EF-ULCERATIVE-0004","December 1, 2022","January 1, 2024","March 1, 2024","January 4, 2022",,"September 10, 2022",,,"https://ClinicalTrials.gov/show/NCT05176366"
212,"NCT05344157","A First-in-Human Study of XSTEM-OA in Patients With Knee Osteoarthritis",,"Recruiting","No Results Available","Osteoarthritis, Knee","Biological: XSTEM-OA","Safety and tolerability: Adverse events (AEs)|Safety and tolerability: 12-lead electrocardiogram (ECG)|Safety and tolerability: Laboratory examinations|Safety and tolerability: Physical examinations|Safety and tolerability: Vital signs|Preliminary efficacy: Changes in Visual Analogue Scale (VAS) for pain compared to baseline|Preliminary efficacy: Changes in Knee injury and Osteoarthritis Outcome Score (KOOS) compared to baseline|Preliminary efficacy: Change in EuroQoL 5 Dimension 5 Level test (EQ-5D-5L) compared to baseline|Preliminary efficacy: Change in 40 m fast paced walk test compared to baseline|Preliminary efficacy: Change in cartilage structure compared to baseline, based on MRI assessment of cartilage volume and composition|Preliminary efficacy: Change in whole knee health compared to baseline, based on MRI assessment by the MRI Osteoarthritis Knee Score (MOAKS)|Preliminary efficacy: Change in inflammatory activity compared to baseline, based on MRI assessment of synovial thickness and synovial blood flow|Preliminary efficacy: Changes in joint space narrowing based on x-ray compared to baseline","Xindu Pty Ltd|Xintela AB","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","54","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XIN-XSTEM-101","June 22, 2022","December 2024","December 2024","April 25, 2022",,"July 13, 2022","Emeritus Research, Camberwell, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT05344157"
213,"NCT00883727","Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI",,"Completed","No Results Available","Myocardial Infarction","Drug: Stem cell|Drug: Plasmalyte A","AE and ECG parameters|Regional myocardial perfusion and infarct size","Stempeutics Research Pvt Ltd","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SRPL/AMI/07-08/001","April 2009","May 2010","August 2012","April 20, 2009",,"March 5, 2013","Care Hospital, Hyderabad, Andhra Pradesh, India|SAL Hospital and Medical Institute, Ahmedabad, Gujarat, India|MS Ramaiah Memorial Hospital, Bangalore, Karnataka, India|Bhagawan Mahaveer Jain Heart Centre, Bangalore, Karnataka, India",,"https://ClinicalTrials.gov/show/NCT00883727"
214,"NCT00883870","Mesenchymal Stem Cells in Critical Limb Ischemia",,"Completed","No Results Available","Critical Limb Ischemia","Drug: mesenchymal stem cells|Drug: Plasmalyte A","AE and symptomatic relief|Increase in transcutaneous partial oxygen pressure (TcPO2) and Ankle brachial pressure index (ABPI) - measured by Doppler","Stempeutics Research Pvt Ltd","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SRPL/CLI/07-08/001","April 2009","February 2010","August 2012","April 20, 2009",,"March 5, 2013","M.S.Ramaiah Memorial Hospital, Bangalore, Karnataka, India|Bhagawan Mahaveer Jain Heart Centre, Bangalore, Karnataka, India|Amrita Institute of Medical Sciences, Kochi, Kerala, India|Sri Ganga Ram Hospital, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00883870"
215,"NCT00136903","Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)",,"Completed","No Results Available","Graft Vs Host Disease","Drug: Prochymal® - 2 Million cells/kg|Drug: Prochymal®- 8 Million cells/kg|Drug: Methylprednisolone|Drug: Prednisone|Drug: Cyclosporine|Drug: Tacrolimus|Drug: Mycophenolate Mofetil","Protocol 260 - Response by Day 28, also called Overall Response (OR). OR includes complete response (CR) and partial response (PR)|Protocol 261-The incidence rate of different adverse events among participants treated with either dose of Prochymal® in the preceding study (Protocol No. 260).|Protocol 260 - Partial Response or Improvement of GVHD by Day 28 in one or more organs involved with GVHD symptoms at Day 1,|Protocol 260 - Time to best response of GVHD|Protocol 260 - Time to improvement of GVHD in one or more organs|Protocol 261 - Survival through study day 90","Mesoblast, Inc.|Mesoblast, Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","260-261","April 27, 2005","July 28, 2006","July 14, 2008","August 29, 2005",,"January 31, 2022","St. Francis Hospital, Indianapolis, Indiana, United States|Kansas City Cancer Centers - BMT, Kansas City, Missouri, United States|The Cancer Center at Hackensack University, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Mt. Sinai Hospital, New York, New York, United States|University of Rochester, Rochester, New York, United States|New York Medical College, Valhalla, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States|Medical College of Wisconsin, FEC, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00136903"
216,"NCT03943576","Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (GXCPC1) for Knee Osteoarthritis",,"Recruiting","No Results Available","Knee Osteoarthritis","Drug: GXCPC1|Device: HA","WOMAC pain score|MRI|Visual Analogue Scale (VAS)|12-item Short Form (SF-12)","Gwo Xi Stem Cell Applied Technology Co., Ltd.","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","GXCPC1","December 1, 2019","December 31, 2021","October 31, 2022","May 9, 2019",,"March 17, 2020","GWOXI Stem Cell Applied Technology Co., Ltd., Hsinchu, Taiwan",,"https://ClinicalTrials.gov/show/NCT03943576"
217,"NCT04776538","Safety and Efficacy of Mesenchymal Stem Cell for Radiation-induced Hyposalivation and Xerostomia in Previous Head and Neck Cancer Patients","MESRIX-III","Recruiting","No Results Available","Xerostomia Following Radiotherapy","Biological: Stem cells|Biological: Placebo","Salivary gland function|Incidence of treatment-emergent adverse events|Patient-Reported Outcome of xerostomia|Salivary composition","Rigshospitalet, Denmark|Cardiology Stem Cell Centre, The Heart Centre, Rigshospitalet|The Cell Therapy Facility, The Blood bank, Dept. of Clinical Immunology, 2034, Rigshospitalet, Denmark|Department of Oncology, 3994, Rigshospitalet, Denmark|Department of Oncology Herlev Hospital, Denmark|Department of Dentistry and Oral Health, Aarhus, Denmark","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CVB2018-1","February 9, 2021","October 1, 2023","October 1, 2023","March 1, 2021",,"March 1, 2021","Christian von Buchwald, MD, DMSc, Professor, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04776538"
218,"NCT04758533","Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy","AloCELYVIR","Recruiting","No Results Available","Diffuse Intrinsic Pontine Glioma|Medulloblastoma, Childhood, Recurrent","Biological: AloCELYVIR","Dose-Limiting Toxicities rate (DLTs)|Objective response rate|Feasibility of the combination/monotherapy|Incidence of treatment-Emergent Adverse Event|Progression-free survival (PFS)|Overall Survival (OS)|Antiadenoviral humoral immune response in patients|Antiadenoviral tumoral immune response in patients|Replication kinetics of Icovir-5","Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Apices Soluciones S.L.","All","1 Year to 21 Years   (Child, Adult)","Phase 1|Phase 2","12","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIBHNJ-2020-01","April 19, 2021","October 2024","October 2024","February 17, 2021",,"August 26, 2021","Hospital Infantil Universitario Niño Jesús, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04758533"
219,"NCT01297972","Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia",,"Completed","No Results Available","Aplastic Anemia","Biological: Intravenous bone marrow mesenchymal stem cells infusion","Number of Participants with Adverse Events as a Measure of Safety and Tolerability of intravenous allogeneic unrelated mesenchymal stem cells infusion in patients with severe acquired aplastic anemia.|Level of cytopenias|Transfusional requirements|Incidence of infections and febrile neutropenia","University of Sao Paulo","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","9","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CONEP 16119","February 2011","November 2013","November 2013","February 17, 2011",,"February 4, 2014","Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT01297972"
220,"NCT05338099","Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)",,"Recruiting","No Results Available","Duchenne Muscular Dystrophy","Drug: EN001","Number of participants of any Adverse Events (AEs)/Serious Adverse Events (SAEs) related investigational product|Determination of Dose-limiting toxicity (DLT) levels of EN001|Determination of Maximum tolerated dose (MTD) levels of EN001|Number of participants with Vital Signs abnormalities|Number of participants with clinically significant abnormalities of Physical Examinations|Number of participants with abnormalities of Laboratory Parameters|Number of participants with abnormalities of 12-lead Electrocardiography (ECG)|Incidence of adverse events (AEs)|Number of participants with abnormalities of Vital Signs, Physical Findings, and Laboratory Parameters|Rate of change at the time of visit compared to baseline (percent [%]) in CK level|Change from baseline in Function tests","ENCell","Male","2 Years to 18 Years   (Child, Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENCell_2020_01","January 18, 2022","January 31, 2023","August 19, 2028","April 20, 2022",,"May 13, 2022","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05338099"
221,"NCT05333406","Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A",,"Recruiting","No Results Available","Charcot-Marie-Tooth Disease, Type IA","Drug: EN001","Number of participants of any Adverse Events (AEs)/Serious Adverse Events (SAEs) related investigational product|Determination of Dose-limiting toxicity (DLT) levels of EN001|Determination of Maximum tolerated dose (MTD) levels of EN001|Number of participants with Vital Signs abnormalities|Number of participants with clinically significant abnormalities of Physical Examinations|Number of participants with abnormalities of Laboratory Parameters|Number of participants with 12-lead Electrocardiography (ECG) abnormalities|Incidence of adverse events (AEs)|Number of participants with abnormalities of Vital Signs, Physical Findings, and Laboratory Parameters|Change from baseline in disease severity CMTNS-v2 score|Change from baseline in gait and balance functions|Change from baseline in the degree of muscle damage (%)|Change from baseline in nerve regeneration potential","ENCell","All","19 Years to 75 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENCell_2020_02","February 22, 2022","December 20, 2022","December 31, 2027","April 19, 2022",,"May 13, 2022","Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05333406"
222,"NCT03726255","Stem Cell Therapy: a Compassionate Use Program in Perianal Fistula","RESCeCUF","Completed","No Results Available","Perianal Fistula","Procedure: Mesenchymal Stem Cell injection","Number of patients with fistula healed|Number of adversus events","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","All","24 Years to 70 Years   (Adult, Older Adult)",,"52","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","EO166-18_FJD","April 1, 2014","January 26, 2018","July 26, 2018","October 31, 2018",,"November 13, 2018","Instituto Investigación Sanitario Fundación Jiménez Díaz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03726255"
223,"NCT04903327","Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress",,"Recruiting","No Results Available","Covid19","Biological: COVI-MSC|Drug: Placebo","All-cause mortality rate at Day 28|All-cause mortality rate at Day 60 and Day 90|Number of ventilator-free days through Day 28|Number of ICU days through Day 28|Change in clinical status|Change in oxygenation","Sorrento Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSC-COV-201BR","November 16, 2021","November 2022","March 2023","May 26, 2021",,"March 16, 2022","Hospital São Rafael S.A. - Instituto D'Or de Pesquisa e Ensino, Salvador, BA, Brazil|Santa Casa de Misericórdia da Bahia (Hospital Santa Izabel), Salvador, BA, Brazil|Saraiva & Berlinger Ltda. - EPP (IPECC), Campinas, SP, Brazil|CECIP JAU - Centro de Estudos Clínicos do Interior Paulista Ltda., Jaú, SP, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clínicos Ltda. - EPP, São Bernardo Do Campo, SP, Brazil|Impar Serviços Hospitalares S/A (Hospital Nove de Julho), São Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT04903327"
224,"NCT03169231","Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty",,"Completed","No Results Available","Aging Frailty","Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Other: Placebo","Change from baseline in 6 Minute Walk Test (6MWT) compared to placebo|Change in patient reported outcome of overall physical function capacity using the PROMIS-Physical Function-Short Form 20a compared to placebo|Change in TNF-alpha compared to placebo","Longeveron Inc.","All","70 Years to 85 Years   (Older Adult)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","001-03","July 6, 2017","September 30, 2021","September 30, 2021","May 30, 2017",,"March 7, 2022","Soffer Health Institute, Aventura, Florida, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Clinical Physiology Associates, Fort Myers, Florida, United States|Panax Clinical Research, Miami Lakes, Florida, United States|Miami VA Healthcare System, Miami, Florida, United States|Vista Health Research, Miami, Florida, United States|Advanced Research for Health Improvement, LLC, Naples, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03169231"
225,"NCT04670302","Mesenchymal Stem Cells and Amniotic Membrane Composite for Supraspinatus Tendon Repair Augmentation",,"Recruiting","No Results Available","Supraspinatus Tear","Procedure: Tendon repair procedure|Procedure: Tendon repair augmented with AAdMSC-HAM composite","Active range of motion (AROM) pre-surgery|Active range of motion (AROM) at 12 months follow-up|Pain pre-surgery|Pain at follow-up 12 months|Disabilities of the Arm, Shoulder, and Hand (DASH) score pre-surgery|Disabilities of the Arm, Shoulder, and Hand (DASH) score at follow-up 12 months|Constant-Murley Score (CS) pre-surgery|Constant-Murley Score (CS) at follow-up 12 months|Tear recurrence (re-tear)","Dr. Soetomo General Hospital","All","35 Years to 75 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","1208/KEPK/V/2019","October 17, 2019","December 31, 2021","December 31, 2022","December 17, 2020",,"December 17, 2020","Dr. Soetomo General Academic Hospital/ Department Orthopaedic & Traumatology Faculty of Medicine Universitas Airlangga, Surabaya, East Java, Indonesia",,"https://ClinicalTrials.gov/show/NCT04670302"
226,"NCT05549609","A Study of XSTEM-VLU in Patients With Difficult-to-heal Venous Leg Ulcers",,"Recruiting","No Results Available","Venous Leg Ulcer","Biological: XSTEM-VLU|Other: Vehicle","Safety and tolerability: Adverse events (AEs)|Safety and tolerability: Local tolerability|Safety and tolerability: Number of participants with abnormal 12-lead electrocardiogram (ECG)|Safety and tolerability: Number of participants with abnormal vital signs|Safety and tolerability: Number of participants with abnormal laboratory test results|Safety and tolerability: Number of participants with abnormal physical examination findings|Preliminary efficacy: Wound area reduction (absolute and percentage) compared to baseline|Preliminary efficacy: Proportion of patients with re-epithelialization of >=95% and >=50% of the wound area measured at baseline|Preliminary efficacy: Time to re-epithelialization of >=95% and >=50% of the wound area measured at baseline|Preliminary efficacy: Pain for target wound and the affected leg using Visual Analogue Scale (VAS)|Preliminary efficacy: Scar formation assessed by the Patient and Observer Scar Assessment Scale (POSAS)","Xintela AB|Vinnova","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","12","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","XIN-XSTEM-201","September 2022","June 2023","June 2023","September 22, 2022",,"September 23, 2022","Burn Centre, Linköping University Hospital, Linköping, Sweden",,"https://ClinicalTrials.gov/show/NCT05549609"
227,"NCT03525418","Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)","ELPIS","Completed","No Results Available","HLHS","Biological: Longeveron Mesenchymal Stem Cells","Safety: To evaluate the safety and feasibility of intramyocardial injection of LMSCs during the Stage II (BDCPA) operation for HLHS via incidence of Treatment-Emergent Serious Adverse Events.|Efficacy: Change from baseline in right ventricular ejection fraction (%).|Efficacy: Change from baseline in right ventricular end-systolic volume.|Efficacy: Change from baseline in right ventricular end-diastolic volume.|Efficacy: Change from baseline in right ventricular end-diastolic diameter.|Efficacy: Change from baseline tricuspid regurgitation.|Efficacy: Change in weight (in kilograms).|Efficacy: Change in height (in centimeters).|Efficacy: Change in head circumference (in centimeters).|Efficacy: Number of patients with Treatment-Emergent Adverse Events, and total number of occurrences of Treatment-Emergent Adverse Events, through-out participation in trial.","Longeveron Inc.","All","1 Day to 1 Year   (Child)","Phase 1|Phase 2","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","00-0000-05","February 21, 2018","December 31, 2021","December 31, 2021","May 15, 2018",,"March 7, 2022","Emory University/Childen's Healthcare of Atlanta, Atlanta, Georgia, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University Hospital, Baltimore, Maryland, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University of Utah/Heart Center-Primary Children's Hospital, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03525418"
228,"NCT00988338","Evaluation of Trinity Evolution in Patients Undergoing Foot and Ankle Fusion","TAF","Completed","No Results Available","Tibiotalar Arthrodesis|Subtalar Arthrodesis|Calcaneocuboid Arthrodesis|Talonavicular Arthrodesis|Double Arthrodesis (i.e. Calcaneocuboid and Talonavicular)|Triple Arthrodesis (i.e. Subtalar, Calcaneocuboid, and Talonavicular)","Biological: Trinity Evolution","Fusion Success|Improvement in scores: Ankle-Hindfoot Scale (AHS), Visual Analog Scale (VAS), and Health Survey (SF-36v2).","Orthofix Inc.","All","18 Years and older   (Adult, Older Adult)",,"106","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","TY01AF","September 2009","January 2013","January 2013","October 2, 2009",,"October 28, 2021","Orthopaedic Associates of South Broward, PA, Hollywood, Florida, United States|Sinai Hospital of Baltimore / Rubin Institute for Advanced Orthopedics, Baltimore, Maryland, United States|New Mexico Orthopedics, Albuquerque, New Mexico, United States|OrthoCarolina Research Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio Orthopedic Center of Excellence, Upper Arlington, Ohio, United States|The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|University Orthopedics Center, State College, Pennsylvania, United States|Central Tennessee Foot and Ankle Center, Sparta, Tennessee, United States|Franciscan Foot and Ankle Specialists, Burien, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00988338"
229,"NCT04527224","Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia",,"Not yet recruiting","No Results Available","Covid19 Pneumonia","Drug: AstroStem-V","Incidence of adverse events|Abnormalities of physical examination, vital signs, and laboratory test|SpO2|Mortality rate|Ventilator treatment status|Improvement of pneumonia assessed by radiologic examination(Chest X-ray or CT)|SOFA score (Sequential Organ Failure Assessment)|2019 nCOV nucleic acid test","Nature Cell Co. Ltd.","All","19 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASVP1N2A-US","October 1, 2022","November 1, 2023","December 1, 2023","August 26, 2020",,"September 28, 2022","Medical Advancement Center of Arizona, Phoenix, Arizona, United States|Epic Medical Research, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04527224"
230,"NCT00515307","Bone Marrow Stem Cells as a Source of Allogenic Hepatocyte Transplantation in Homozygous Familial Hypercholesterolemia",,"Completed","No Results Available","Hypercholesterolemia, Familial","Procedure: Cellular transplantation","Serum cholesterol and LDL levels|Tracking the infused cells","University of Tehran","Female","Child, Adult, Older Adult","Phase 1","1","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DDRC 85-15","June 2007","May 2008","June 2008","August 13, 2007",,"August 29, 2008","Digestive Disease Research Center, Shariati Hospital, North Kargar Ave., Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT00515307"
231,"NCT03389919","Intraosseous Administration of Mesenchymal Stromal Cells for Patients With Graft Failure After Allo-HSCT",,"Recruiting","No Results Available","Mesenchymal Stem Cell Transplantation","Biological: MSC administration (intraosseal)","Engraftment","National Research Center for Hematology, Russia","All","18 Years and older   (Adult, Older Adult)","Phase 3","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BM-MSC-01","January 1, 2017","December 31, 2020","December 31, 2022","January 4, 2018",,"January 4, 2018","BMT department, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03389919"
232,"NCT04434768","Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke",,"Recruiting","No Results Available","Acute Stroke","Biological: UMSC01","SAE incidences over the study period|SUSAR incidences over the study period|TEAE incidences over the study period|Changes of Glasgow Coma Scale (GCS; Score range: Max.15, Min. 3) from Baseline Visit (Visit 1) to subsequent scheduled visits|Changes in National Institute of Health Stroke Scale (NIHSS; Score Range: 0~42; the higher score the worsen outcome) from Baseline Visit (Visit 1) to subsequent scheduled visits|Changes in mRS from Baseline Visit (Visit 1) to subsequent scheduled visits.|Changes in FMT from Baseline Visit (Visit 1) to subsequent schedules visits|Changes in BI from Baseline Visit (Visit 1) to subsequent schedules visits|Change and ratios of MRI image from baseline to subsequent scheduled visits|Change and ratios of SPECT perfusion image from baseline to subsequent scheduled visits","Ever Supreme Bio Technology Co., Ltd.","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1","14","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ES-CMSC01-B1101","May 5, 2020","December 31, 2023","December 31, 2023","June 17, 2020",,"March 23, 2022","China Medical University Hospital, Taichung, Non-US, Taiwan|Tri-Service General Hospital, Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT04434768"
233,"NCT04194671","Clinical Trial of Mesenchymal Stem Cells in the Treatment of Severe Acute Kidney Injury",,"Not yet recruiting","No Results Available","Acute Kidney Injury|Mesenchymal Stem Cells","Biological: Mesenchymal stem cells|Other: Saline","The difference in the renal function between the two groups (MSC treatment group vs placebo control group) within 28 days after receiving MSC/ placebo treatment|Overall survival within 28 days after receiving MSC/ placebo treatment|Overall survival within 3 months after receiving MSC/ placebo treatment|Renal replacement therapy (RRT) dependent within 3 months after receiving MSC/ placebo treatment|Complete renal recovery within 3 months after receiving MSC/ placebo treatment|Partial renal recovery within 3 months after receiving MSC/ placebo treatment|ICU and hospitalization duration of stay among all AKI patients within 3 months after receiving MSC/ placebo treatment|Adverse events within 3 months after receiving MSC/ placebo treatment","Chinese PLA General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","MSC-001","December 31, 2021","October 31, 2022","December 31, 2022","December 11, 2019",,"October 25, 2021","Chinese PLA General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04194671"
234,"NCT00705120","Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation",,"Completed","No Results Available","Osteogenesis Imperfecta","Other: Bone Marrow Cell Transplantation|Radiation: Irradiation, Total Body|Drug: Cyclophosphamide|Drug: Cyclosporin|Procedure: Mesenchymal Stem Cell Transplantation|Drug: Busulfan","To investigate the safety and toxicity of allogeneic bone marrow transplantation (BMT) in children with severe Osteogenesis Imperfecta (OI)","St. Jude Children's Research Hospital","All","3 Years and older   (Child, Adult, Older Adult)","Phase 1","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TOIT","November 1995","July 2000","October 2007","June 25, 2008",,"June 25, 2008","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00705120"
235,"NCT04629833","Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy","IDUNN","Recruiting","No Results Available","Steroid-refractory Acute Graft-versus-host Disease","Biological: MC0518|Biological: BAT","Overall Response (OR)|Freedom from Treatment Failure (FFTF)|Overall Survival|Acute Graft-versus-host Disease (aGvHD) Response|Change from Baseline in aGvHD Grades|Time to Response|Duration of Response|Best Overall Response (OR)|Cumulative Dose of Steroids for SR-aGvHD per Kilogram (kg) of Body Weight|Number of Participants with Chronic Graft-versus-host Disease (cGvHD)|Time to Chronic Graft-versus-host Disease (cGvHD)|Number of Participants with Graft Failure (GF)|Number of Participants with Relapse or Progression in Participants with Underlying Malignant Disease|Time to Relapse or Progression in Participants with Underlying Malignant Disease|Event-free survival (EFS)|Non-relapse Mortality (NRM)|Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs)|Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs) by Severity|Change from Baseline in Performance score based on Karnofsky scale (recipient age >= 16 years)|Change from Baseline in Performance score based on Lansky Scale|Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Health Status Index (HSI)|Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Visual Analogue Scale (VAS)|Change from Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) Score","medac GmbH","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC-MSC.1/aGvHD","August 16, 2021","January 28, 2024","December 31, 2025","November 16, 2020",,"June 8, 2022","CHU de Grenoble Hopital Albert Michallon, Grenoble, France|CHRU Lille- Hopital Claude Huriez, Lille, France|CHU de Nice Hopital Archet 1, Nice, France|Centre Hospitalier Lyon Sud Pavillon Marcel Berard 1G, Pierre Benite Cedex, France|Rennes, Rennes, France|Centre Hospitalier Universitaire CHU de Toulouse, Toulouse, France|Hopitaux De Brabois, Vandoeuvre les Nancy, France|Klinikum rechts der Isar, Munich, Bavaria, Germany|Universitaetsklinikum Wuerzburg - Medizinische Klinik und Poliklinik II - Zentrum fuer Allogene Blutstammzelltransplantation, Würzburg, Bavaria, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet - Frankfurt am Main, Frankfurt am Main, Hessen, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Universitatsklinikum Muenster, Münster, Nordrhein-Westfalen, Germany|Universitaet Duisburg-Essen - Universitaetsklinikum Essen - Klinik fuer Knochenmarktransplantation (KMT), Essen, North Rhine-Westphalia, Germany|Uniklinik Koeln, Koeln, North Rhine-Westphalia, Germany|Universitatsklinikum Carl Gustav Carus Dresden, Dresden, Sachsen, Germany|Selbststandige Abteilung fur Hamatologie und Internistische Onkologie, Leipzig, Saxony, Germany|Universitaetsklinikum Jena, Jena, Thüringen, Germany|Universitatsklinikum Jena, Jena, Thüringen, Germany|Charit Universitaetsmedizin Berlin, Berlin, Germany|University Hospital Bonn, Medizinische Klinik III, Bonn, Germany|Universitaetsklinikum Essen, Essen, Germany|Klinikum der Johann Wolfgang Goethe, Frankfurt, Germany|Universitatklinikum Freiburg, Freiburg, Germany|University Medical Center Mainz, Mainz, Germany|UniversitÃ¤tsklinikum Mannheim, Mannheim, Germany|University Hospital Tuebingen Medical Center, Tuebingen, Germany|Department of Pediatric Hematology, Oncology and BMT, Wroclaw Medical University, Wrocław, Dolnoslaskie, Poland|Hospital Universitario Vall dHebron, Barcelona, Spain|Barcelona, Barcelona, Spain|Institut Catal dOncologia, Barcelona, Spain|Barcelona, Barcelona, Spain|Hospital Germans Trias i Pujol, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Puerta De Hierro, Madrid, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Center for Allogeneic Stem Cell Transplantation and Cell Therapy (CAST), Karolinska Universitetssjukhuset Huddinge, Huddinge, Sweden",,"https://ClinicalTrials.gov/show/NCT04629833"
236,"NCT03211793","Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis","MANUS","Recruiting","No Results Available","Systemic Sclerosis|Digital Ulcer","Drug: Mesenchymal stromal cells|Other: Placebo","Toxicity of the treatment|Serious adverse events|Change in perceived pain based on the Numerical Rating Scale|Change in perceived pain based on the digital ulcer visual analogue scale (part of the S-HAQ)|Change in perceived pain based on the pain VAS ( part of the S-HAQ)|Change in perceived pain based on the use of analgesics.|Quality of life - SF-36|Quality of life - Euroqol|Disability|Hand function|Number (and change in number) of digital ulcers|Healing of digital ulcers|Ulcer size|Time to healing of digital ulcers|Need to alter medication regime|Modified Rodnan Skin Score|Severity of Raynaud's symptoms|Changes in capillary morphology and architecture|Changes in laboratory parameters|Changes in circulating cell populations","UMC Utrecht|ZonMw: The Netherlands Organisation for Health Research and Development","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MANUS|2015-000168-32","October 6, 2021","November 1, 2023","November 1, 2023","July 7, 2017",,"March 22, 2022","Universitair Medisch Centrum Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT03211793"
237,"NCT02982915","Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty","HERA","Completed","No Results Available","Aging Frailty","Biological: Longeveron Mesenchymal Stem Cells (LMSCs)|Biological: Fluzone High Dose Vaccine","The incidence of any treatment-emergent serious adverse event (TE-SAE), defined as one or more of the following untoward medical occurrences within 30 days after infusion as assessed by the following:|The ability of Lomecel-B (LMSC) treatment to improve inactivation of influenza virus as assessed by validated hemagglutination inhibition (HAI) assays.|Changes from baseline between the LMSC and placebo cohorts as assessed by plasma cytokine levels:|Differences in rate of decline from Aging Frailty|Assessed by the Falls Efficacy Scale-International and Performance Oriented Mobility Assessment|PROMIS Short Form 20a questionnaire|PROMIS Mobility questionnaire|PROMIS Upper Extremity questionnaire|Short Form 36 questionnaire|IIEF questionnaire|SQOL-F questionnaire|Death from any cause|Falls Efficacy Scale-International (FES-I)|Changes from baseline between the LMSC and placebo cohorts as assessed by B & T cell levels:|Rate of decline in Aging Frailty status as assessed by the 6 minute walk test|Rate of decline in Aging Frailty status as assessed by the Short Physical Performance Battery (SPPB)|Rate of decline in Aging Frailty status as assessed by the Tinetti POMA Test|Rate of decline in Aging Frailty status as assessed by the Weight Loss|Rate of decline in Aging Frailty status as assessed by the Handgrip Test","Longeveron Inc.","All","65 Years to 90 Years   (Older Adult)","Phase 1|Phase 2","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","00-0000-03","November 2016","June 2021","June 2022","December 6, 2016",,"August 17, 2022","Clinical Research of South Florida, Coral Gables, Florida, United States|Clinical Physiology Associates, Fort Myers, Florida, United States|University of Miami, Miami, Florida, United States|Vista Health Research, Miami, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|Optimal Research LLC, Rockville, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02982915"
238,"NCT03378063","Stem Cells for Bronchopulmonary Dysplasia",,"Recruiting","No Results Available","Bronchopulmonary Dysplasia","Drug: transplantation of mesenchymal stem cell|Drug: no transplantation of mesenchymal stem cell","death|Bayley Scales of Infant Development","Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Children's Hospital of Chongqing Medical University|Chongqing Maternal and Child Health Hospital","All","1 Month to 3 Months   (Child)","Early Phase 1","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","stem cell for BPD","November 1, 2017","December 30, 2022","December 30, 2022","December 19, 2017",,"February 16, 2021","Department of Pediatrics, Daping Hospital, Research Institute of Surgery, Third Military Medical University, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT03378063"
239,"NCT01739777","Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy","RIMECARD","Completed","No Results Available","Dilated Cardiomyopathy","Biological: ucMSC|Other: Controls","• Change in global left ventricular ejection fraction|• Change in functional capacity measured in O2 consumption|• Occurrence of major adverse cardiac event|• Change in high sensitivity C-reactive protein (hs CRP)|• Reduction in level of B-type natriuretic peptide (BNP)","Universidad de los Andes, Chile","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","UANDES-C4C|CORFO-11IEI-9766","December 2012","June 2015","June 2015","December 3, 2012",,"June 4, 2015","Universidad de los Andes, Santiago de Chile, Chile",,"https://ClinicalTrials.gov/show/NCT01739777"
240,"NCT04315025","Safety Issues of Peribulbar Injection of UC-MSC in Patients With Retinitis Pigmentosa","RP","Completed","No Results Available","Retinitis Pigmentosa","Biological: Umbilical Cord Mesenchymal Stem Cell (UC-MSC)|Biological: Conditioned Medium (CM)","Visual Acuity Test|Visual Field Test|Funduscopy|Electrorectinography|Optical Coherence Tomography (OCT)|Angiography","PT. Prodia Stem Cell Indonesia","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CT/RP/02/2018","October 7, 2018","June 20, 2019","September 20, 2019","March 19, 2020",,"June 4, 2020","Jakarta Eye Center Hospital, Jakarta, DKI Jakarta, Indonesia|Sardjito Hospital, Yogyakarta, Special Region, Indonesia",,"https://ClinicalTrials.gov/show/NCT04315025"
241,"NCT05075811","Study of Ossium Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in the Setting of Crohn's Disease",,"Recruiting","No Results Available","Pouch, Ileal|Fistula","Drug: Ossium vBM-MSC|Other: Placebo","Treatment related adverse events|Complete clinical healing|Partial healing|Lack of response|Worsening disease","Amy Lightner|Ossium Health, Inc.|The Cleveland Clinic","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","21-860","February 1, 2022","November 15, 2024","November 15, 2024","October 13, 2021",,"April 5, 2022","Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT05075811"
242,"NCT03672825","REcycled CartiLage Auto/Allo IMplantation",,"Recruiting","No Results Available","Cartilage Defect","Drug: REcycled CartiLage Auto/Allo IMplantation","Nature, incidence and severity of adverse events (AEs)","Mayo Clinic","All","18 Years to 50 Years   (Adult)","Phase 1","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-000939","September 13, 2018","September 13, 2022","September 13, 2022","September 17, 2018",,"December 17, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03672825"
243,"NCT03173638","Safety Assessment of Intravitreal Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy","NEUROSTEM","Active, not recruiting","No Results Available","Non Arteritic Ischemic Optic Neuropathy","Procedure: intravitreal injection of MSV","Absence of inflammatory reaction - Slit lamp exploration - SUN (Standardization of Uveitis Nomenclature) scale|Adverse events procedure-related (intravitreal injection)","Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA|University of Valladolid","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IOBA01-2016|2016-003029-40","March 23, 2018","April 2022","December 2022","June 2, 2017",,"April 6, 2021","IOBA - Applied Ophthalmobiology Institute, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT03173638"
244,"NCT00951210","Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)",,"Completed","No Results Available","Peripheral Artery Disease|Peripheral Vascular Disease|Critical Limb Ischemia","Biological: PLX-PAD","Adverse events; Amputation incidence, Death incidence & Rehospitalization incidence|Immunological reaction","Pluristem Ltd.","All","40 Years to 81 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1202-2","August 2009","January 2011","October 2011","August 4, 2009",,"May 27, 2015","Cardiology PC, Birmingham, Alabama, United States|Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00951210"
245,"NCT05456243","Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients",,"Recruiting","No Results Available","Kidney Transplant","Biological: Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)|Biological: High dose adipose tissue derived mesenchymal stromal cells (A-MSC)","Worsening kidney allograft rejection|Adverse Events","Mayo Clinic","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","21-012522","October 2022","August 2025","August 2025","July 13, 2022",,"September 9, 2022","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT05456243"
246,"NCT04247945","Co-transplantation of MSC in the Setting of Allo-HSCT",,"Recruiting","No Results Available","Allogeneic Hematopoietic Stem Cell Transplantation","Biological: Cotransplant with MSCs","Survival Rate|Cumulative Incidence of Graft-versus Host Disease|Incidence of Systemic Infections|Mean Time to Engraftment|Transplant-Related Mortality|Rates of Relapse","Fujian Medical University","All","up to 65 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","MSC-SCT-03","February 1, 2020","December 1, 2023","December 1, 2025","January 30, 2020",,"January 30, 2020","Union Hospital,Fujian Medical University, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT04247945"
247,"NCT05407766","Mesenchymal Stem Cells (MSCs) for Perianal Fistula",,"Not yet recruiting","No Results Available","Rectal Fistula","Biological: OSSM-001|Other: Placebo","OSSM-001 (100M dose) related adverse events as assessed by CTCAE v5.0|OSSM-001 (300M dose) related adverse events as assessed by CTCAE v5.0|Fistula healing assessed by radiographic (MRI) assessments for OSSM-001 (100M dose)|Fistula healing assessed by clinical assessments for OSSM-001 (100M dose)|Fistula healing assessed by radiographic (MRI) assessments for OSSM-001 (300M dose)|Fistula healing assessed by clinical assessments for OSSM-001 (300M dose)","Ossium Health, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","OSSM-001-001-01","August 2022","April 2024","August 2024","June 7, 2022",,"June 7, 2022",,,"https://ClinicalTrials.gov/show/NCT05407766"
248,"NCT04961658","Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients","AMETHYST","Recruiting","No Results Available","Septic Shock","Biological: GEM00220","The safety of GEM00220 will be assessed by monitoring adverse events|Maximum Feasible Tolerated Dose","Northern Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 1","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT-GEM-001","August 11, 2021","September 2023","August 2024","July 14, 2021",,"June 21, 2022","Lakeridge Health, Oshawa, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04961658"
249,"NCT02923375","A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease",,"Completed","No Results Available","Graft vs Host Disease","Biological: Mesenchymoangioblast-derived mesenchymal stem cells","Incidence and severity of treatment emergent adverse events [safety and tolerability]|Incidence and severity of serious adverse events deemed possibly related to CYP-001 [safety and tolerability]|Complete Response by Day 28|Partial Response by Day 28|Overall Survival at Day 28|Complete Response by Day 100|Partial Response by Day 100|Overall Survival at Day 100","Cynata Therapeutics Limited","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CYP-GvHD-P1-01|2016-000070-38","March 1, 2017","August 28, 2018","June 30, 2020","October 4, 2016",,"August 11, 2020","Sydney Local Health District, Sydney, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|NHS Foundation Trust, Bristol, United Kingdom|NHS Trust, Leeds, United Kingdom|NHS Foundation Trust, Liverpool, United Kingdom|NHS Foundation Trust, Manchester, United Kingdom|NHS Foundation Trust, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02923375"
250,"NCT01541579","Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease","ADMIRE-CD","Completed","No Results Available","Crohn's Disease","Other: Cx601|Other: Saline solution","Combine remission of perianal fistulising Crohn's|Efficacy Assessment by week 24|Efficacy Assessment by week 52|Efficacy Assessment by week 104|Safety analysis throughout the study:","Tigenix S.A.U.|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 3","278","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Cx601-0302","July 2012","July 2015","November 2016","March 1, 2012",,"November 29, 2019","Univ.-Klinik Innsbruck, Innsbruck, Austria|Krankenhaus, St. Veit/Glan, Austria|Medizinische Universität, Wien, Austria|Hospital Oost-Limburg, Genk, Belgium|Gent University Hospital, Gent, Belgium|Leuven University Hospital, Leuven, Belgium|Hospital Hartziekenhuis, Roeselare, Belgium|CHU d'Amiens, Amiens, France|CHU de Bordeaux, Bordeaux, France|CHU de Caen, Caen, France|Hôpital Beaujon, Clichy, France|CHRU de Lille, Lille, France|CHU de Marseille, Marseille, France|CHU de Nice, Nice, France|Hôpital Saint-Louis, Paris, France|Charite, Berlin, Germany|Krakenhaus Walfriede, Berlin, Germany|Klinikum Braunscheweig, Braunschweig, Germany|Klinikum Frankfurt, Frankfurt/Main, Germany|Evangelisches Krankenhaus Kalk, Köln, Germany|Klinikum Lüneburg, Lüneburg, Germany|Rambam MC, Haifa, Israel|Sharee Zedek MC, Jerusalem, Israel|Rabin MC, Petah Tikva, Israel|Tel Aviv Sourasky MC, Tel Aviv, Israel|Sheba MC, Tel Hashomer, Israel|Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Instituto Clinico Humanitas IRCCS, Milano, Italy|Seconda Università degli Studi di Napoli, Napoli, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy|Università Cattolica del Sacro Cuore, Rome, Italy|AMC, Amsterdam, Netherlands|VUMC, Amsterdam, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|UMCU, Utrecht, Netherlands|Hospital de Manises, Manises, Valencia, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Juan Ramon Jimenez, Huelva, Spain|Hospital Ramón y Cajal, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital La Princesa, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Son Espases, Palma de Mallorca, Spain|Hospital de Montecelo, Pontevedra, Spain|Hospital Virgen del Rocio, Seville, Spain|Hospital de Sagunto, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01541579"
251,"NCT04896853","Treatment of Respiratory Complications Associated With COVID-19 Infection Using ProTrans®",,"Recruiting","No Results Available","COVID-19 Acute Respiratory Distress Syndrome","Biological: ProTrans®","Safety and tolerance of a single infusion of ProTrans®|Effect of ProTrans® -MSC on patient clinical status, including mortality|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 7|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 15|Effect of ProTrans® -MSC on patient clinical status, including mortality, at day 30|Time to clinical improvement after ProTrans® - MSC infusion|Effect of of ProTrans® -MSC on lung damage|Duration of hospitalization and Intensive Care Unit (ICU) stay|Kinetics of COVID-19 viral load after ProTrans® -MSC infusion","NextCell Pharma Ab|Karolinska Trial Alliance","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","9","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO TRANS 19+|2020-002078-29","May 18, 2021","September 30, 2024","December 31, 2024","May 21, 2021",,"May 21, 2021","Department of Cardiology, Respiratory medicine and Physiology, Örebro University Hospital, Örebro, Sweden",,"https://ClinicalTrials.gov/show/NCT04896853"
252,"NCT02580695","A Study to Assess Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells in Knee Osteoarthritis",,"Completed","No Results Available","Osteoarthritis","Biological: umbilical-cord mesenchymal stromal cells|Drug: Hyaluronic Acid","Proportion of patients who experience an adverse event|Physical function improvement measured by WOMAC OA index|Change in pain density measured by Visual analogue scale (VAS)|QoL improvement measured by SF-36|Changes in WORMS scale measured by knee MRI","Francisco Espinoza, MD|Universidad de los Andes, Chile","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C4COA01","December 2015","January 2017","April 2017","October 20, 2015",,"December 26, 2018","Clinica Universidad de los Andes, Santiago, Chile",,"https://ClinicalTrials.gov/show/NCT02580695"
253,"NCT01663116","Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients",,"Completed","No Results Available","Rheumatoid Arthritis Aggravated","Genetic: Stem cells|Genetic: Placebo","Number of Adverse Events and Severe Adverse Events|Proportion of ACR20 patients/ACR50 patients/ACR70 patients (swollen joints*, tender joints**, physician global assessment***, patient global assessment***, patient´s assessment of pain ***, ESR/CRP, HAQ score)","Tigenix S.A.U.|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","53","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Cx611-0101","March 2011","January 2013","January 2013","August 13, 2012",,"April 12, 2019","Hospital U. Central de Asturias, Oviedo, Asturias, Spain|Hospital General de Mérida, Mérida, Badajoz, Spain|Hospital U. de Canarias, La Laguna, Tenerife, Spain|Hospital de Cruces, Barakaldo, Vizcaya, Spain|Hospital de Basurto, Bilbao, Vizcaya, Spain|Complejo Hospitalario U. A Coruña, A Coruña, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital Clínico San Cecilio, Granada, Spain|Hospital U. Virgen de las Nieves, Granada, Spain|Hospital U. de Guadalajara, Guadalajara, Spain|Hospital de La Princesa, Madrid, Spain|Hospital U. Gregorio Marañon, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital U. La Paz, Madrid, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital U. Marques de Valdecilla, Santander, Spain|Hospital Ntra. Sª de Valme, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital La Fe, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01663116"
254,"NCT00919958","Safety of Intramuscular Injection of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia",,"Completed","No Results Available","Peripheral Artery Disease|Peripheral Vascular Disease|Critical Limb Ischemia","Biological: PLX-PAD IM injection","Adverse events, Safety laboratory values and ECG findings|Immunological reaction|Tumorigenesis","Pluristem Ltd.","All","40 Years to 81 Years   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PLX-PAD 1202-1","June 2009","June 2012","June 2012","June 12, 2009",,"June 19, 2012","Franziskus-Krankenhaus, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT00919958"
255,"NCT04276987","A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia",,"Completed","No Results Available","Coronavirus","Biological: MSCs-derived exosomes","Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality","Ruijin Hospital|Shanghai Public Health Clinical Center|Wuhan Jinyintan Hospital, Wuhan, China|Cellular Biomedicine Group Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEXCOVID","February 15, 2020","May 31, 2020","July 31, 2020","February 19, 2020",,"September 7, 2020","Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04276987"
256,"NCT03920397","Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus",,"Completed","No Results Available","Type 1 Diabetes Mellitus","Biological: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation","Pancreatic β-cell function after an adipose tissue-derived stem/stromal cells infusion|Glycemic control after an adipose tissue-derived stem/stromal cells|Oral cholecalciferol 2000UI/day supplementation","Universidade Federal do Rio de Janeiro","All","16 Years to 35 Years   (Child, Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Nutro_MesenchymalStemCells_DM1","March 1, 2015","March 1, 2021","May 1, 2021","April 18, 2019",,"May 26, 2021","Clementino Fraga Filho University Hospital of Rio de Janeiro, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT03920397"
257,"NCT04623606","Boost to Brittle Bones - Stem Cell Transplantation for Treatment of Brittle Bones","BOOST2B","Recruiting","No Results Available","Osteogenesis Imperfecta","Biological: BOOST cells","Safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events (AEs)|Number of fractures [ Time Frame: From baseline to 16 months follow-up ]|Time (days) to first fracture after each stem cell administration. [ Time Frame: From each dose of stem cells to the time point of the first fracture.|Change in bone-marrow density (g/cm2). [ Time Frame: From baseline to the primary follow-up (From baseline to 16 months follow up)|Growth (cm). [ Time Frame: From baseline to16 months follow up]|Weight (kg). [ Time Frame: From baseline to 16 months follow up]|Change in clinical status of OI. [ Time Frame: From baseline to 16 months follow up]|Assessment of biochemical bone turnover by analysis of the markers P-Calcium (mg %) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers P-Phosphate (mg %) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers P-Albumin (g/dL)|Assessment of biochemical bone turnover by analysis of the markers S-ALP (IU/L) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers S-CTx (mg %) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers fP-PTH (pg/mL)in blood samples.|Assessment of biochemical bone turnover by analysis of the markers Vitamin D (nmol/L) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers Bone specific S-ALP (μg/L) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers S-Osteocalcin (ng/mL) in blood samples.|Assessment of biochemical bone turnover by analysis of the markers U-DPD/Krea and U-NTx/Krea (mg %) in blood samples.","Christian Medical College, Vellore, India|Ministry of Science and Technology, India|Vinnova|Karolinska Institutet","All","1 Year to 8 Years   (Child)","Phase 1|Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMCB2B0X","May 20, 2019","November 2021","December 2021","November 10, 2020",,"November 10, 2020","Christian Medical College, Vellore, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT04623606"
258,"NCT05182034","Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis",,"Recruiting","No Results Available","Knee Osteoarthritis","Biological: SMUP-IA-01(low dose)|Biological: SMUP-IA-01(mid dose)|Drug: Active Control Group Sodium chloride","Change in the WOMAC(Western Ontario and McMaster University Osteoarthritis Index) total score at post-dose 52 weeks from baseline|Change amount of WOMAC total score at post-dose 24 weeks from the baseline|Chage amount of WOMAC score by item (pain, stiffness, physical function) at post-dose 24 weeks and 52 weeks from the baseline|Chage amount of 100-mm VAS((Visual Analogue Scale) at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks from the baseline|Chage amount of IKDC(International Knee Documentation Committee) at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks from the baseline|Change in the WOMAS(whole-organ magnetic resonance imaging score) at post-dose 52 weeks from the baseline|Change in T2 mapping at post-dose 52 weeks from the baseline|Change in K&L grade, joint space width, mechanical axis, and anatomical axis at post-dose 52 weeks from the baseline|Change amount of biomarkers at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks against the baseline; serum CTX-I, Serum HA, Serum MMP-3, Urine CTX-I, Urine CTX-II.|Percentage of patients who took the rescue drugs and dosage at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks","Medipost Co Ltd.","All","19 Years and older   (Adult, Older Adult)","Phase 2","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MP-SMUP-IA-01-P02","February 24, 2022","August 30, 2023","August 30, 2023","January 10, 2022",,"September 1, 2022","Seoul Nation University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Korea University Anam Hospita, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05182034"
259,"NCT03706482","Boost Brittle Bones Before Birth","BOOSTB4","Recruiting","No Results Available","Osteogenesis Imperfecta","Biological: BOOST cells","Safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events.|Number of fractures.|Time (days) to first fracture after each stem cell administration.|Numbers of fractures at birth.|Change in bone-marrow density (g/cm2).|Growth (cm).|Growth (kg).|Change in clinical status of OI.|Assessment of biochemical bone turnover by analysis of the markers P-Calcium, P-Phosphate, P-Albumin, S-ALP, fP-PTH, S-25-OH Vitamin D, Bone specific S-ALP, S-CTx, S-Osteocalcin and U-DPD/Krea and U-NTx/Krea in blood and urine samples.","Karolinska Institutet|Karolinska University Hospital|Great Ormond Street Hospital for Children NHS Foundation Trust|University College, London|Universitätsklinikum Köln|UMC Utrecht|Leiden University Medical Center|Lund University","All","up to 18 Months   (Child)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KIBB01","August 12, 2019","August 12, 2023","August 12, 2033","October 16, 2018",,"October 14, 2021","Karolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03706482"
260,"NCT04590118","Allogeneic Mesenchymal Stem Cells for the Survivors of Ischemic Stroke Trial (ASSIST)",,"Recruiting","No Results Available","Ischemic Stroke","Drug: it-hMSC|Drug: Placebo","Incidence and severity of adverse events assessed by CTCAE V5.0 during the twelve-month study period after it-hMSC infusion.|Modified Rankin Scale|National Institute of Health stroke scale|Mini-mental State Examination|Barthel Index|Geriatric Depression Scale","Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.|Beijing Tiantan Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","STCMSC-CT-001","April 26, 2021","April 1, 2023","August 1, 2023","October 19, 2020",,"March 31, 2022","Beijing Tiantan Hospital, Capital Medical University, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04590118"
261,"NCT04089579","hCT-MSC in Children With Autism Spectrum Disorder","IMPACT","Recruiting","No Results Available","Autism|Autism Spectrum Disorder","Biological: Cord Tissue Mesenchymal Stromal Cells|Other: Placebo Infusion","Change on the Socialization and Communication Subscale Standard Scores on the Vineland Behavior Scales|Change in VABS-3 Socialization Standard Score|Change in VABS-3 Communication Standard Score|Change in CGI-Severity score|CGI-Intervention score|Change in the Pediatric Quality of Life Scale","Joanne Kurtzberg, MD|The Marcus Foundation|Duke University","All","4 Years to 11 Years   (Child)","Phase 2","164","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00102894","October 12, 2020","February 1, 2023","August 1, 2023","September 13, 2019",,"February 18, 2022","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04089579"
262,"NCT01733186","Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects",,"Completed","Has Results","Degeneration Articular Cartilage Knee","Biological: CARTISTEM®","IKDC Score|VAS|Lysholm Score|KOOS Score","Medipost Co Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-0201-01","January 7, 2013","June 2, 2017","August 29, 2017","November 26, 2012","July 30, 2021","July 30, 2021","Cartilage Restoration Center; RUSH University Medical Center, Chicago, Illinois, United States|Cartilage Repair Center; Brigham and Women's Hospital, Chestnut Hill, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT01733186/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01733186"
263,"NCT03003364","Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury",,"Completed","No Results Available","Spinal Cord Injury, Chronic","Drug: XCEL-UMC-BETA|Drug: Placebo","Incidence of treatment-emergent adverse events|Extent and severity of a patient's spinal cord injury|Motor electrophysiology assessment|Somatosensory electrophysiology assessment|Electrical nerve stimulation on pain perception|Mictional dysfunction|Anal sphincter integrity|Neuropathic pain|Spasticity|Functionality|Quality of life (individual overall perception of quality of life, individual overall perception of their health, Physical health, Psychological, Social relationships, Environment)|Urinary disorder|Size injury|Presence of allogeneic cells|Immunology","Banc de Sang i Teixits|Hospital de Neurorehabilitació Institut Guttmann|Recerca Clínica S.L.|Syntax for Science, S.L","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","XCEL-SCI-01","December 27, 2016","July 25, 2019","February 11, 2020","December 28, 2016",,"February 17, 2020","Hospital de Neurorehabilitació Institut Guttmann, Badalona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03003364"
264,"NCT04377334","Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)",,"Not yet recruiting","No Results Available","ARDS|COVID-19","Biological: MSC","lung injury score|D-dimers|phenotype|pro-resolving lipid mediators|cytokines|chemokines|Survival|extubation|lymphocyte subpopulations|SARS-CoV-2-specific antibody titers|complement molecules (C5-C9)","University Hospital Tuebingen","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RESCOVID","May 2022","November 2022","February 2023","May 6, 2020",,"January 27, 2022","University Hospital Tuebingen, Tuebingen, Germany",,"https://ClinicalTrials.gov/show/NCT04377334"
265,"NCT00603330","Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function",,"Recruiting","No Results Available","Graft-versus-host Disease|Poor Graft Function|Low Donor T-cell Chimerism","Biological: Mesenchymal stem cells","Arm 1. Efficacy of MSC infusion as treatment for steroid-resistant grade II - IV acute GVHD.|Arm 2. Efficacy of MSC infusion as treatment for poor graft function|Arm 3. Efficacy of MSC infusion followed by donor lymphocyte infusion for preventing graft rejection in patients with low or failing donor T-cell chimerism after allogeneic HCT|Toxicity of MSC infusion","University of Liege|KU Leuven|Maastricht University Medical Center|Ziekenhuis Netwerk Antwerpen (ZNA)|University Hospital, Antwerp|University Hospital, Ghent|AZ-VUB|AZ Sint-Jan AV|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|University Hospital of Mont-Godinne|Jolimont Hospital Haine Saint Paul|Queen Fabiola Children's University Hospital","All","Child, Adult, Older Adult","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TJB0703P1","January 2008","August 2024","August 2024","January 29, 2008",,"September 21, 2022","UZA, Edeghem, Antwerpen, Belgium|Hôpital des enfants Reine Fabiola, Brussels, Brabant, Belgium|AZ VUB Jette, Brussels, Brabant, Belgium|Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Brussels, Brabant, Belgium|AZ Gasthuisberg Leuven, Leuven, Flamish Brabant, Belgium|UZ Gent, Gent, Flanders Ost, Belgium|Hôpital de Jolimont, Haine St Paul, Hainaut, Belgium|Cliniques Universitaires Mont-Godinne, Yvoir, Namur, Belgium|AZ St Jan, Brugge, West Flanders, Belgium|Hôpital Stuyvenberg, Antwerpen, Belgium|CHU Sart Tilman, Liege, Belgium|University Hospital Maastricht, Maastricht, Limburg, Netherlands",,"https://ClinicalTrials.gov/show/NCT00603330"
266,"NCT03257098","Allogeneic ABCB5-positive Stem Cells for Treatment of CVU",,"Completed","No Results Available","Skin Ulcer Venous Stasis Chronic","Biological: allo-APZ2-CVU","Percentage of wound size reduction|Assessment of adverse event (AE) occurrence|Absolute wound size reduction|Proportion of patients achieving complete wound closure|Time to first complete wound closure|Proportion of patients achieving 30% wound closure|Time to first 30% wound closure|Epithelialization|Assessment of further wound healing parameters: formation of granulation tissue and wound exudation|Pain assessment as per numerical rating scale (NRS)|Assessment of quality of life (QoL) using the short form 36 (SF-36) questionnaire|Assessment of dermatology-specific quality of life based on the Dermatology Life Quality Index (DLQI) questionnaire|Physical examination and vital signs at Week 6.1 and Week 12","RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Ticeba GmbH|Granzer Regulatory Consulting & Services","All","35 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","31","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","allo-APZ2-CVU-II-01","November 16, 2017","June 25, 2020","June 25, 2020","August 22, 2017",,"September 10, 2020","Venenzentrum der Dermatologischen und Gefäßchirurgischen Kliniken, Kliniken der Ruhr-Universität Bochum im St. Maria Hilf Krankenhaus, Bochum, Germany|Universitätsklinikum Erlangen, Hautklinik, Erlangen, Germany|Klinik und Poliklinik für Hautkrankheiten, Universitätsmedizin Greifswald, Greifswald, Germany|Klinische Forschung Hamburg GmbH, Dermatologie / Allergologie, Hamburg, Germany|pro scientia med im Mare Klinikum; Department Klinische Forschung und Entwicklung, Kiel, Germany|Universitätsklinikum Münster, Klinik für Hautkrankheiten, Allgemeine Dermatologie und Venerologie, Münster, Germany|Klinische Forschung Schwerin GmbH, Schwerin, Germany|Universitätsklinikum Ulm, Klinik für Dermatologie und Allergologie, Ulm, Germany|Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT03257098"
267,"NCT02582775","MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs",,"Recruiting","No Results Available","Epidermolysis Bullosa","Drug: Thymoglobulin|Drug: Cyclophosphamide|Drug: Fludarabine|Radiation: Total Body Irradiation|Procedure: Bone marrow infusion|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Biological: Donor mesenchymal stem cell infusions|Drug: Busulfan","Event-free survival|Percentage change of a patient's iscorEB|Transplant-related mortality|Quality of life|Lymphoid Chimerism|Myeloid Chimerism","Masonic Cancer Center, University of Minnesota","All","up to 25 Years   (Child, Adult)","Phase 2","84","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015LS076","March 2016","December 2024","December 2024","October 21, 2015",,"January 24, 2022","University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02582775"
268,"NCT03267784","Allogeneic ABCB5-positive Stem Cells for Treatment of DFU ""Malum Perforans""",,"Completed","No Results Available","Diabetic Neuropathic Ulcer","Biological: allo-APZ2-DFU","Percentage of wound surface area reduction|Assessment of adverse event (AE) occurrence|Percentage of invisible and visible wound surface area reduction|Absolute wound surface area reduction|Absolute invisible and visible wound surface area reduction|Assessment of wound infection|Time to first complete wound closure|Proportion of patients achieving complete wound closure|Time to first 30% reduction of wound surface area|Proportion of patients achieving 30% reduction of wound surface area|Assessment of wound exudation, epithelialization and formation of granulation tissue|Time to amputation at target leg until Week 12|Pain assessment as per numerical rating scale (NRS)|Assessment of Quality of life (QoL) using the short form 36 (SF-36) questionnaire|Assessment of Dermatology-specific QoL based on the Dermatology Life Quality Index (DLQI) questionnaire|Physical examination and vital signs|Time to amputation of target leg until month 12","RHEACELL GmbH & Co. KG|FGK Clinical Research GmbH|Ticeba GmbH|Granzer Regulatory Consulting & Services","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","23","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","allo-APZ2-DFU-II-01","November 21, 2017","June 29, 2020","June 29, 2020","August 30, 2017",,"September 10, 2020","Universitätsmedizin Greifswald; Klinik und Poliklinik für Hautkrankheiten, Greifswald, Germany|St. Josefskrankenhaus Heidelberg GmbH; Klinische Studienabteilung, Heidelberg, Germany|Diabetologikum Raab, Privatärztliche Facharztpraxis, Kassel, Germany|pro scientia med im Mare Klinikum, Department Klinische Forschung und Entwicklung, Kronshagen, Germany|Studienambulanz Leipzig, medamed GmbH, Leipzig, Germany|Diabetologikum Ludwigshafen, Gemeinschaftspraxis, Ludwigshafen, Germany|Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT03267784"
269,"NCT05019287","Menstrual Blood Stem Cells in Severe Covid-19",,"Completed","No Results Available","Covid19|Cytokine Storm","Biological: Allogeneic human menstrual blood stem cells secretome|Other: Intravenous saline injection","Adverse reactions incidence|Time to clinical improvement|Assessment of serum CRP (mg/L) levels|Assessment of serum LDH (U/L) levels|Assessment of serum Ferritin (ng/ml) levels|Assessment of serum D-dimer (microgr/ml) levels|Immunological changes on CD4+ T and CD8+ T|Lung Involvement|Changes in Inflammatory cytokine IL 6|Changes in anti-Inflammatory cytokine IL10","Avicenna Research Institute|Tehran University of Medical Sciences","All","25 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","990308-026|99/3436","April 17, 2021","May 21, 2021","June 9, 2021","August 24, 2021",,"September 2, 2021","Avicenna Research Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT05019287"
270,"NCT05443464","Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD)",,"Not yet recruiting","No Results Available","GVHD,Acute","Biological: OSSM-001","Safety events|Maximum tolerated dose (MTD)","Ossium Health, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSSM-001-006-01","June 5, 2023","June 10, 2024","October 14, 2024","July 5, 2022",,"July 5, 2022",,,"https://ClinicalTrials.gov/show/NCT05443464"
271,"NCT04281797","Intestinal Microbiome Dynamics in Solid Organ and Stem Cell Transplant Recipients",,"Enrolling by invitation","No Results Available","Transplantation Infection|Kidney Transplant; Complications|Stem Cell Transplant Complications|Liver Transplant; Complications|Microbial Colonization","Diagnostic Test: Intestinal microbiome new generation sequencing","Gut microbiome composition|Infectious complications after transplantation|Organ or tissue rejection","Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology","All","Child, Adult, Older Adult",,"90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Microbiome Minsk_1","January 1, 2020","December 31, 2022","June 30, 2023","February 24, 2020",,"August 31, 2022","Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04281797"
272,"NCT02635464","Human Umbilical Cord-derived Mesenchymal Stem Cells With Injectable Collagen Scaffold Transplantation for Chronic Ischemic Cardiomyopathy",,"Completed","No Results Available","Chronic Ischemic Cardiomyopathy","Biological: hUC-MSCs+Injectable collagen scaffold+CABG|Biological: hUC-MSCs+CABG|Procedure: CABG","Incidence of treatment-emergent adverse events|Myocardial blood flow|Left ventricle ejection fraction (LVEF)|Infarct size|New York Heart Association (NYHA) Functional Classification|Canadian Cardiovascular Society (CCS) Angina Grading Scale","Chinese Academy of Sciences|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","All","35 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CAS-XDA-CIC/IGDB","October 2015","August 2019","August 2019","December 18, 2015",,"December 23, 2020","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT02635464"
273,"NCT05497401","A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With COVID-related Pneumonia",,"Not yet recruiting","No Results Available","Covid-related Pneumonia","Biological: MesenCure|Other: Placebo","Mortality|CRP reduction|Invasive ventilation","BonusBio Group Ltd","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MCS-03","October 2022","December 31, 2023","July 2024","August 11, 2022",,"August 11, 2022",,,"https://ClinicalTrials.gov/show/NCT05497401"
274,"NCT01033552","Biochemical Correction of Severe EB by Allo HSCT and ""Off-the-shelf"" MSCs",,"Active, not recruiting","No Results Available","Epidermolysis Bullosa","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Anti-thymocyte globulin|Drug: Cyclosporine A|Drug: Mycophenolate mofetil|Procedure: Mesenchymal stem cell transplantation|Radiation: Total body irradiation|Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation","Event-free survival rate|Transplant-related mortality (TRM)|Pattern of biochemical improvement|Measure patients Quality of Life using a questionnaire|Durability of HSC and third party MSC engraftment in the skin|Probability of Survival|Number of participants experiencing Acute GVHD","Masonic Cancer Center, University of Minnesota","All","up to 25 Years   (Child, Adult)","Phase 1|Phase 2","32","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MT2009-09|0911M74035","January 2010","November 12, 2022","December 12, 2022","December 16, 2009",,"September 29, 2022","University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01033552"
275,"NCT04445220","A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy",,"Active, not recruiting","No Results Available","COVID-19|Acute Kidney Injury|Sepsis","Biological: SBI-101","Safety and tolerability as measured by incidence of IP-related serious adverse events","Sentien Biotechnologies, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SBI-101-02","November 19, 2020","March 2022","September 2022","June 24, 2020",,"January 14, 2022","University of New Mexico School of Medicine, Albuquerque, New Mexico, United States|Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04445220"
276,"NCT02917291","Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury","SPINE","Recruiting","No Results Available","Acute Traumatic Spinal Cord Injury","Drug: FAB117-HC|Other: Control group","Number of adverse events as a measure of safety and tolerability of a single dose of FAB117-HC when administered by intramedullary injection into the injured spinal cord|Changes in neurological function using the International Standards for Neurological Classification of SCI (ISNCSCI) scale, examinations at 24h, 72h, 7d, 14d, 28d, 90d and 360 days after injection of FAB117-HC|Changes in the functional assessment of Spinal Cord Independence Measure (SCIM III)|Changes in Somatosensory-Evoked Potentials (SSEP) electrophysiological assessment test.|Changes in Motor-Evoked Potentials (MEP) electrophysiological assessment test","Ferrer Internacional S.A.|Histocell, S.L.","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","FAB117-CT-01","December 2016","July 2022","July 2023","September 28, 2016",,"September 16, 2021","Complexo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Complejo Hospitalario de Toledo (HNP y VS), Toledo, Spain|Hospital Universitari La Fe, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT02917291"
277,"NCT04976140","Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis",,"Enrolling by invitation","No Results Available","Polymyositis|Dermatomyositis","Biological: PN-101","Dose Limiting Toxicity(DLT)|International Myositis And Clinical Studies group-Total Improvement Score(IMACS-TIS)|Response rate of IMACS-TIS|Changes of Core Set Activity Measures(CSAM)|Changes of Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)|Changes of Peak Pruritus Numeral Rating Scale(PPNRS)","Paean Biotechnology Inc.","All","19 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PN-101-101","December 15, 2021","April 2023","April 2023","July 26, 2021",,"June 13, 2022","Seoul National University Hospital, Seoul, Korea, Republic of|Soonchunhyang University Seoul Hospital, Seoul, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04976140"
278,"NCT04825730","Follow-up Study for Participants of Jointstem Investigator Initiated Trial by Arthroscopy",,"Not yet recruiting","No Results Available","Degenerative Arthritis|Knee Arthritis","Drug: JOINTSTEM","Adverse Events|Adverse Events (Special Attention Target)","R-Bio","All","20 Years and older   (Adult, Older Adult)","Not Applicable","14","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BS-JS-IIT1-FU","December 1, 2023","December 1, 2028","December 31, 2029","April 1, 2021",,"September 28, 2022",,,"https://ClinicalTrials.gov/show/NCT04825730"
279,"NCT03896568","MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma",,"Recruiting","No Results Available","IDH1 wt Allele|Recurrent Anaplastic Astrocytoma|Recurrent Glioblastoma|Recurrent Gliosarcoma|Recurrent Malignant Glioma","Biological: Oncolytic Adenovirus Ad5-DNX-2401|Procedure: Therapeutic Conventional Surgery","Maximum-tolerated dose (MTD)|Incidence of adverse events (AEs)|Tumor response|Time to progression|Virus replication in tumor|Virus shedding|Immunogenicity based on adenoviral (AdV) antibodies","M.D. Anderson Cancer Center|DNAtrix, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","36","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0953|NCI-2019-01195","February 12, 2019","September 30, 2023","September 30, 2023","April 1, 2019",,"August 15, 2022","M D Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03896568"
280,"NCT04953663","Clinical Plan of Ischemic Stroke",,"Recruiting","No Results Available","Stroke","Biological: it-hMSC","Adverse events and serious adverse events rate|Rate of clinical significant changes in laboratory|Rate of abnormal neurological physical examination results|Rate of imaging changes|Change of NIHSS scores|Change of BI scores|Change of mRS scores|Change of MMSE scores|Change of GDS scores","Peking University Third Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D2020093","January 1, 2021","January 1, 2022","January 1, 2023","July 8, 2021",,"July 8, 2021","Peking University Third Hospital, Beijin, China",,"https://ClinicalTrials.gov/show/NCT04953663"
281,"NCT03015623","A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy",,"Active, not recruiting","No Results Available","Acute Kidney Injury","Biological: SBI-101|Device: Sham","Safety and tolerability as measured by incidence of IP-related serious adverse events","Sentien Biotechnologies, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SBI-101-01","June 20, 2017","December 2021","December 2021","January 10, 2017",,"March 16, 2021","Lehigh Valley Hospital, Allentown, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03015623"
282,"NCT03509025","Follow-up Study for Participants Jointstem Clinical Trial",,"Completed","No Results Available","Knee Osteoarthritis","Drug: Jointstem","Adverse Events|WOMAC score|WOMAC 3 subscale score|X-ray","R-Bio","All","18 Years and older   (Adult, Older Adult)","Phase 2","11","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JM2b-FU","February 8, 2017","December 9, 2020","December 9, 2020","April 26, 2018",,"September 28, 2022","KyungHee University Gangdong Hospital, Seoul, Korea, Republic of|GangNam Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03509025"
283,"NCT02483364","A Clinical Trial to Assess the Effect of HC-SVT-1001 and HC-SVT-1002 in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones (Bonecure)","Bonecure","Completed","No Results Available","Pseudoarthrosis","Other: HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment)","Safety of HC-SVT-1001 and HC-SVT-1002 in the surgical treatment of atrophic nonunion in long bones by recording of adverse events.|Effectiveness by mean of radiological methods on the appearance of signs of osseous setting formation.|Comparative statistical analysis","Salvat","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STEMQUIRI/12ES01","November 10, 2015","May 18, 2020","October 20, 2020","June 26, 2015",,"March 17, 2021","Laboratorios Salvat, S.A., Esplugues de Llobregat, Barcelone, Spain",,"https://ClinicalTrials.gov/show/NCT02483364"
284,"NCT03635450","Study of hCT-MSC in Newborn Infants With Moderate or Severe HIE",,"Completed","No Results Available","Moderate to Severe Hypoxic-ischemic Encephalopathy","Biological: Infusion of hCT-MSC","Incidence of infusion reactions|Incidence of Infections post-infusion|Survival|Neurodevelopmental Assessments","Joanne Kurtzberg, MD|Duke Clinical and Translational Science Institute (CTSI), part of the NIH Clinical and Translational Science Awards (CTSA)|Duke University","All","0 Hours to 48 Hours   (Child)","Phase 1","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00100253","December 27, 2018","July 28, 2019","December 28, 2020","August 17, 2018",,"March 22, 2021","Duke University, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03635450"
285,"NCT01041001","Study to Compare Efficacy and Safety of Cartistem and Microfracture in Patients With Knee Articular Cartilage Injury",,"Completed","No Results Available","Cartilage Injury|Osteoarthritis","Biological: Cartistem|Procedure: Microfracture treatment","ICRS Cartilage Repair Assessment will follow to determine the appropriate grade. The treatment will be considered efficacious if the ICRS grade drops by at least 1 grade or more from baseline to week 48.|Degree of improvement in the grade of joint pain measured on a 100-mm VAS (Visual Analogue Scale)|Grade of cartilage regeneration in patients who agreed to a biopsy during arthroscopy at week 48|Changes in WOMAC scores|Changes in IKDC Subjective Score|ICRS scores","Medipost Co Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-CRP-005","February 2009","December 2010","January 2011","December 30, 2009",,"April 20, 2017","Gachon University Gil Hospital, Incheon, Gyunggido, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Hanyang University Medical Center, Seoul, Korea, Republic of|Seoul Veterans Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01041001"
